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Abstract 
Hematopoietic diseases such as leukaemia can be treated by a haematopoietic stem cell transplant, 
but suitable donors are in short supply. Hematopoietic cells derived from pluripotent stem cells 
have been suggested as a possible alternative, however hematopoietic progenitors made this way 
have so far been unable to either engraft in sufficient numbers or differentiate into all mature blood 
lineage types in vivo.  
Recent published evidence suggests this may be due to a failure to down-regulate key miRNAs. 
Microarray data comparing hematopoietic progenitors derived from bone marrow or from 
pluripotent stem cells was studied and key miRNAs were selected for validation.  
This combined analysis showed that several miRNAs fail to down-regulate in pluripotent cell 
derived progenitors, unlike the equivalent cells in bone marrow. These miRNAs play a role in 
suppressing epithelial-mesenchymal transition and their high expression may be a cause of the 
observed failure to engraft. 
 Five of these miRNAs were chosen as candidates for inhibition (miR-200b, miR-200c, miR-148a, 
miR-205, and miR-424). Methods of miRNA inhibition were investigated, and the effects of the 
inhibition of the chosen miRNAs on hematopoietic development from hESCs and hiPSCs were 
assessed using gene expression, marker expression and colony assay techniques.  
Although miRNAs were successfully inhibited using lipofection both individually and in multiplex 
these experiments did not significantly improve the efficiency of hematopoietic development, 
possibly due to high levels of redundancy among tumour suppressors. The limitations of the 
inhibition technique, i.e. the short timeframe of inhibition and inability to down-regulate more than 
5 miRNA at once may be insufficient to overcome this problem.  
Differentiation in hypoxic conditions was tried in the hope of making more global changes to 
miRNA expression, and these experiments yielded an increase in CFU-GEMMs and cells 
expressing HSC markers, which may be helpful in future attempts at hematopoietic stem cell 
generation. 
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1. Introduction 
1.1 Brief introduction into hematopoietic stem cell transplantation 
Bone marrow transplants are a lifesaving treatment for leukaemias and bone marrow 
deficiencies [11]. The cells which are transplanted are called hematopoietic stem cells 
(HSCs), which produce all the blood cell types found in adults including erythrocytes, which 
carry oxygen around the body, and the white blood cells which make up the immune system. 
HSC are extracted from donors’ bone marrow or from banks of frozen umbilical cord blood 
and transferred to the patient, where they migrate to the bone marrow and engraft, 
reconstituting the hematopoietic system with healthy cells. Because the transplant produces 
immune cells the donor and recipient must be genetically matched for histocompatibility 
antigens, or the transplanted immune system will recognise the patients’ own cells as foreign, 
and attack them. This phenomenon is known as graft vs. host disease (GVHD) and it can be 
chronic or deadly. Unfortunately perfect genetic matches are rare and can take months to find. 
Umbilical cord blood cells are immunologically naive so they have a lower risk of GVHD, 
but multiple donors are required because a single umbilical cord does not have enough HSCs 
to treat a patient [12], and it is extremely difficult to expand HSCs in culture. Due to these 
problems alternative sources of HSC are being sought; one of the most promising of these is 
to generate them from pluripotent stem cells. 
1.2 Pluripotent stem cells 
Pluripotency: Pluripotent stem cell (PSC) is the term used to describe both embryonic and 
induced pluripotent stem cells (ESC and iPSC respectively). These cells resemble those found 
in the pre-implantation (blastocyst stage) embryo, they are uniquely useful due to their ability 
to proliferate indefinitely in culture and their capacity to give rise to any adult cell type, a 
quality known as ‘pluripotency’. PSCs have many potential uses in both basic research and in 
medicine. For example differentiation of PSCs in vitro can shed light on early development, 
studying the behaviour of differentiating stem cells from patients with genetic diseases can 
illuminate their mechanisms, and drug discovery can be aided by in vitro testing on key cell 
types derived from pluripotent cells. Finally, the use of PSCs opens up the field of 
regenerative medicine, where replacement tissues, including HSCs, may be grown to replace 
damaged ones. 
Derivation and culture of pluripotent stem cells: Embryonic stem cells are derived from 
the inner cell mass of blastocysts [13] (see Figure 1.1). Cells in this early embryonic stage are 
unique, as at any later stage the cells will be limited in the number of times that they can 
divide and committed to a particular lineage. Once differentiated, cells are unable to change to 
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another cell type. However, in 2007 Shinya Yamanaka [14] and Jamie Thomson [15] showed 
that human adult cells can be reprogrammed back into the pluripotent state by expressing 4 
key pluripotency factors (OCT4, SOX2 KLF4 and c-MYC) introduced into the cell as viral 
transgenes. These cells are called iPSCs and have similar morphology and gene expression to 
ESCs as well as indefinite ability for self-renewal. Since 2007 techniques for reprogramming 
have progressed, using non-viral or non-integrating techniques with the aim of increased 
efficiency and reduced risk of mutagenesis. It has also been discovered that other factors can 
be substituted for the original ‘Yamanaka factors’ and in some cases some factors can be 
eliminated entirely.  These techniques are described in Table 1.1. 
 
Table 1.1: Techniques for reprogramming 
Type of vector 
Factors (O-OCT4, K-KLF4, S-SOX2, N-NANOG, L-LIN28 
and M -c-MYC References 
Integrating virus 
Retroviral 
OKSM 
Established technique, good efficiency, 
random integration of genes, incomplete  [16] 
Figure 1.1 
                   
Figure 1.1: Schematic diagram showing derivation and potential of ESCs (adapted 
from Ref. [4]). A fertilised oocyte is allowed to develop to the blastocyst stage and then 
the ICM is removed and cultured. These pluripotent cells can be induced to 
differentiate into many cell types including neurons, cardiac cells and blood cells. 
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silencing 
Lentiviral 
OSNL 
Higher efficiency than retroviral 
vectors, allows reprogramming of non-
dividing cells, random integration of 
genes, incomplete silencing  [15, 16] 
Adenoviral OKSM 
Low likelihood of integration, low 
efficiency  [17] 
Non-integrating virus 
Sendai virus OKSM Good efficiency, non-integrating  [18] 
Non-viral methods 
Episomal 
plasmids OSKMNL Very low efficiency  [19] 
piggyBac 
transposon OKSM 
Medium efficiency, precise transgene 
deletion, labour intensive  [20] 
miRNA 
miR-200c, miR-
302 family Very low efficiency  [21] 
Synthetic 
mRNA OKSML 
Medium efficiency, no antiviral 
response, time and labour intensive  [22] 
Protein  OKSM 
No risk of immune response associated 
with RNA or DNA, low efficiency, 
expensive  [23, 24] 
Small 
molecules 
CHIR,  FSK, 
PD0325901, 
VPA, 
Tranylcypromine, 
TTNP, B616452,  
DZNep,  
Low cost, no immune response, not yet 
proved in human cells  [25] 
 
Both types of hPSCs will spontaneously differentiate unless carefully cultured. Human PSCs 
(hPSCs) form round, flat colonies which were originally kept on a feeder layer of mouse 
embryonic fibroblasts alongside media supplemented with serum and bFGF. More recently 
feeder cells and serum have been replaced by chemically defined animal free equivalents, 
which reduces variation and allows the cells to be used clinically. 
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Once a line of PSCs is established researchers can differentiate the cells into the lineage or 
cell type that they wish to study. This is done by mimicking the conditions which promote 
differentiation to a particular tissue in the developing embryo, usually by exposing the cells to 
various combinations of cytokines. 
 
PSC could be used to make HSC for transplant: If an efficient technique for deriving HSC 
from PSC was developed the proliferative capacity of PSC would allow unlimited numbers of 
HSC to be generated, solving the problem of limited HSC numbers. The PSC would still need 
to be genetically matched to the patient, but any cells produced this way would be completely 
immunologically naive, reducing the need for a perfect match. It would also be possible to 
bank large numbers of PSC lines with many combinations of histocompatibility antigens. 
Finally, as reprogramming techniques improve in safety and efficiency it may eventually be 
possible to derive iPSC from a patient’s own cells, which would completely remove the risk 
of GVHD. 
 
Challenges must be overcome before PSCs can be used clinically:  PSC derived treatments 
have considerable clinical potential, but there are barriers to their use in regenerative 
medicine. The most concerning is the possibility of transplanted cells giving rise to tumours. 
The constant proliferation of PSCs in culture can lead to genetic [26] and epigenetic [27] 
mutations which are potentially tumorigenic [28]. Undifferentiated PSCs are themselves 
tumorigenic; their proliferative capacity and undifferentiated state means they form teratomas 
in vivo, so any PSC derived graft with cells which are not fully differentiated is at risk of 
creating tumours. Another risk is that an imperfect differentiation protocol may produce cells 
which appear to be the correct cell type but which are aberrant in some way which causes 
them to behave unpredictably in vivo.  
The use of hESCs for regenerative medicine is complicated by ethical and political obstacles 
as they can only be made by destroying a human foetus, and also by the possibility of immune 
rejection of the transplant, as it is likely to be difficult to find a perfect genetic match for 
every patient. 
hiPSCs have been suggested as a solution to the ethical problem, as they can be made from 
cells derived from adult volunteer donors, and also to the problem of immune rejection as 
they could theoretically be derived from the patient’s own cells. However reprogramming 
techniques are imperfect, and the reprogramming techniques with the highest efficiency use 
integrating viruses (see Table 1.1) which carry a risk of insertional mutagenesis. The stress of 
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reprogramming itself can also introduce mutations [29]. iPSCs also retain epigenetic markers 
from their tissue of origin after reprogramming, which can have unpredictable effects on gene 
expression [30, 31]. Any PSC derived cells will have to be carefully screened for mutations 
and gene expression before they can be used for transplant. 
 
PSC derived treatments have clinical potential: In spite of these problems stem cell 
research has progressed to the point that it is possible to conduct clinical trials. The first of 
these trials was performed by Geron Corporation, using hESC derived oligodendrocytes for 
spinal cord repair. Although the initial results were positive, showing no adverse effects on the 
patients even after immune suppression was withdrawn, there was no clear improvement in 
the patients’ condition and the trial was ended for financial reasons [32]. The trial has recently 
been picked up by another company, Asterias, and is ongoing [33]. 
The most successful trials of PSC treatments so far have used hiPSC derived retinal pigment 
epithelium to treat macular degeneration. A phase I trial showed excellent results, with no 
immune rejection and an improvement in vision for the majority of the patients [34]. Further 
trials, including a phase II trial are ongoing and of the 13 current clinical trials involving 
PSCs, 9 of them are treating macular degeneration [35].  
A report of a case where hESC derived cardiac progenitors were used to treat heart failure 
showed positive results [36], and other trials, including one using hESC derived insulin-
producing β-cells [33] are due to begin soon. For many of these studies it is too early to say if 
the treatment is effective but the lack of adverse effects and immune rejection suggests that 
pluripotent stem cells can be used safely, which means that if an effective protocol for 
differentiating hPSC to HSC was developed it could be translated to the clinic. 
 
1.3 Hematopoietic differentiation from pluripotent cells 
1.3.1 HSCs are at the top of the hematopoietic hierarchy and reside in the bone marrow 
niche 
Several types of hematopoietic cells can be differentiated from PSC. HSC are cells at the very 
top of the hematopoietic hierarchy and they differentiate through various stages before 
committing to a particular hematopoietic lineage. ‘Long-term repopulating’ HSCs (LT-HSCs) 
are defined by their ability to repopulate transplanted bone marrow and reconstitute 
haematopoiesis indefinitely. These cells reside in the endosteal part of the bone marrow niche 
and are quiescent throughout the lifetime of the organism. The niche is complex and many 
factors are required in order to maintain a HSC population. Some of these are illustrated in 
Figure 1.2. LT-HSCs give rise to ‘short term repopulating’ HSCs (ST-HSCs), which are 
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proliferative but have more limited self renewal potential, and are capable of reconstituting 
haematopoiesis in a transplant recipient for 8-12 weeks [7]. The cells migrate, towards the 
perivascular bone marrow niche and become multi-potent progenitors (MPs/MPPs) which are 
capable of differentiating into all cell types but have no self-renewal capacity. Collectively, 
this group of CD34+ cells are termed hematopoietic stem and progenitor cells or HSPCs. 
They can differentiate towards any of the hematopoietic lineages and eventually give rise to 
all mature hematopoietic cells. Combinations of cell surface markers have been developed to 
distinguish hematopoietic precursors at each stage of differentiation, some of which are 
shown on Figure 1.3, and which are described in more detail in results section 3.2.5. 
 
Figure 1.2 
 
Figure 1.2: Schematic of bone marrow niche derived from Morrison et al review [7]. 
HSCs are found between the trabecular bone and the blood vessels of the bone marrow 
and are maintained by signals from osteoclasts, endothelial cells, mesenchymal stromal 
cells, lymphoid cells, myeloid cells and the sympathetic nervous system. Many factors 
which control the maintenance and differentiation of HSCs have yet to be elucidated 
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Figure 1.3 
 
Figure 1.3: Schematic of differentiation from long term hematopoietic stem cells 
including some of the cell surface markers which can be used to distinguish cell types. 
LT-HSC= long term repopulating HSC (indefinite self-renewal); ST-HSC= short term 
repopulating HSC; MPP= multipotent hematopoietic stem cell (non-self-renewing); 
CLP=common lymphoid progenitor; CMP=common myeloid progenitor; 
GMP=granulocyte-macrophage progenitor; EMP=erythrocyte macrophage progenitor. 
LMPP= lympho-myeloid progenitor. 
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Researchers have attempted to derive HSC from PSC for some time, but without much 
success. Attempts to make HSC from PSC have followed one of two methods: either the cells 
are co-cultured with stromal cells which provide an in vitro niche and generate signalling 
molecules which promote hematopoietic differentiation, or cells are allowed to form round 
aggregates of cells called embryoid bodies (EBs), which differentiate into hematopoietic cells 
due to exposure to particular combinations of cytokines (methods that have been used to make 
hematopoietic progenitors are shown in Table 1.2). These techniques have been successful in 
producing hematopoietic progenitors of various kinds, however none have been able to 
produce HSC, defined as cells able to engraft in a recipient animal and reconstitute its 
hematopoietic system (see results section 3.2.1) without resorting to genetic manipulation 
[3]. Although it is possible to produce adult hematopoietic cell types in vitro, most attempts 
have produced cells which are foetal in character, and there is typically very low engraftment, 
which is due to a failure of these cells to migrate to the bone marrow niche. What little 
engraftment there is appears to be short term and mostly myeloid, rather than multi-lineage 
production of blood cells [37-42]. For example, hESCs differentiated by co-culture with S17 
stromal bone marrow cells engrafted at only 0.16-1.44%, and the cells which did engraft were 
mostly myeloid [43]. Better engraftment resulted from mimicking the foetal hematopoietic 
niche by co-culture with stromal cells derived from the aorta-gonad-mesonephros (AGM) [39] 
which is where HSC arise (see below section 1.3.2 Definitive hematopoiesis), although 
engraftment was still below the level required for clinical transplantations. Experiments where 
PSC derived hematopoietic progenitors were transplanted into foetal sheep showed higher 
engraftment and the capability for secondary engraftment, suggesting that there are factors 
present in foetal tissues (possibly the AGM and foetal liver in particular [39, 44]) which 
promote the development of engraftment capacity in hematopoietic progenitor cells derived 
from pluripotent stem cells (here called P-HPCs). 
Table 1.2 : Methods of in vitro hematopoietic differentiation  
Co-culture 
Co-culture with mouse stromal cell 
lines OP9 or S17 
 [44-
47] 
Co-culture with stromal cells from 
mouse Aorta-Gonad-Mesonephros 
(the foetal tissue from which HSCs 
arise –see section 1.3.1) and foetal 
 [48] 
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liver 
Co-culture with FH-B-hTERT, a 
human foetal liver-derived cell line, 
and S17 
 [48] 
Embryoid bodies with a combination of hematopoietic 
cytokines 
 [2, 49-
57] 
Embryoid bodies and mesodermal cytokines, then culture on 
OP9 stromal cells 
 [58] 
Monolayer 
Monolayer culture with 
hematopoietic cytokines 
 [61] 
Transplant 
Transplant of hESCs differentiated 
on S17 stromal cells into foetal sheep [45] 
Transplant of  hESC derived 
haemangioblasts into mice [46] 
Direct transplant of hESCs with 
hematopoietic cytokines into mice [47] 
Direct transplant of hESCs with OP9 
cells into mice [48] 
 
 
Several reasons have been speculated for the difficulty in deriving HSC from PSC: As 
described above, early attempts to create P-HPCs gave hematopoietic cells with foetal or 
embryonic characteristics indicating that the cells produced were derived from primitive 
hematopoietic progenitors rather than HSCs (see below section 1.3.2 Primitive 
Hematopoiesis), leading some to suggest that the protocols used could only produce primitive 
cells. Fluorescent marker tracking studies have shown that some of these cells form 
endothelial cells upon engraftment rather than contributing to blood lineages [41]. However 
more recent protocols are able to produce definitive hematopoietic cells of the same types 
found in adults in vitro or in vivo [8, 49] although they still don’t engraft in acceptable 
numbers. It has also been suggested that these protocols do produce HSCs but that these cells 
immediately differentiate to non-self-renewing progenitors due to the high concentrations of 
hematopoietic cytokines and the lack of an appropriate niche in culture. This would explain 
both the ability of these protocols to produce adult hematopoietic cell types but not long-term 
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engraftment. A further theory suggests that HSC are produced in these experiments but that 
they are defective in some way, particularly in their ability to home-to and engraft-in the bone 
marrow niche. This is supported by the fact that experiments where the cells are injected into 
the blood stream are much less successful than those where they are injected directly into the 
bone marrow [37, 46] and in these experiments there is very little colonisation of 
hematopoietic organs other than the one that the cells are injected into [37].  
 
P-HPCs derived by ectopic gene expression: Hematopoietic development is controlled by 
transcription factors, and enforcing expression of the correct factors promotes HSC formation. 
Ectopically expressing Hoxb4 encouraged mESCs to differentiate into definitive rather than 
primitive progenitors (see embryonic haematopoiesis section 1.3.2) and allowed them to 
repopulate the hematopoietic system of irradiated mice [50]. Unfortunately HOXB4 
expression did not confer engraftment when it was tried with human cells, although it did 
increase the yield of hematopoietic progenitors [38]. Other groups have attempted to directly 
convert other cell types into HSCs using multiple transcription factors; these methods have 
met with some success (see discussion section 7.1) but as they require the introduction of 
ectopically expressed transcription factors into the genome they are not suitable for clinical 
use. 
To understand the failure of P-HPC to reconstitute the hematopoietic system in vivo it is 
necessary to understand the process of hematopoietic development in the embryo, as 
differentiation of pluripotent stem cells into hematopoietic lineages closely resembles 
haematopoietic development in vivo. 
1.3.2 Embryonic hematopoiesis 
Hematopoiesis follows a similar pattern in all vertebrates: Most of what we know about 
embryonic hematopoiesis comes from studies done in mice or zebrafish, although studies in 
differentiating hESCs show that a similar pattern is followed in human development. 
Embryonic hematopoiesis is a complex process, and there are several types of hematopoietic 
progenitors which arise at different times in different anatomical locations. Briefly, there are 
three ‘waves’ of hematopoiesis; primitive hematopoietic progenitors are the first to arise, in 
the yolk sac blood-islands, followed by and erythro-myeloid progenitors and finally definitive 
hematopoietic progenitors (which includes all HSCs) which arise in the foetal aorta (see 
Figure 1.4). 
Hematopoietic ontogeny: All hematopoietic precursors derive from the posterior primitive 
streak mesoderm in response to Ihh signalling [51, 52]. Some of these cells colonise the yolk 
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sac and form ‘blood islands’. Early experiments on mouse and chick embryos showed that 
these clusters are made from cells with both endothelial and hematopoietic potential, which 
were therefore named ‘haemangioblasts’ [53, 54] which are responsible for the first 
hematopoietic cells to arise in the embryo. The same cell type can be made using 
differentiation of PSCs as a model for hematopoiesis [55, 56]. Later in development 
hematopoietic cells arise from an endothelial tissue called the hemogenic endothelium (HE) 
[9] via a process called endothelial-hematopoietic transition (EHT) [57, 58]. The cells have 
endothelial morphology and gene expression and are part of the blood vessel wall, but then 
begin to express hematopoietic markers before partially detaching and rounding up, forming 
clusters of cells attached to the blood vessel wall. Eventually they lose contact with the 
endothelium and join the bloodstream. Wang et al have shown that it is possible to specify HE 
from hESCs [59]. HE cells with hematopoietic potential are distinct from the rest of the 
endothelium and are fated to become hematopoietic [60, 61], rather than being bipotential 
haemangioblasts, so the term hemogenic endothelium has come to replace the term 
haemangioblast. The hematopoietic ontogeny is shown in Figure 1.5. 
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Figure 1.4 
 
Figure 1.4: Schematic showing the location and timing of hematopoiesis in humans, mice 
and zebrafish. Figure from Rowe et al review [3]. Human development is shown in blue, 
mouse in red and zebrafish in green. Each species goes through the same developmental 
stages of hematopoiesis in the same order: first primitive hematopoiesis, arising in the 
yolk sac or ICM just prior to the start of circulation, then definitive hematopoiesis, 
originally in the AGM but later migrating to other hematopoietic organs. The timing of 
these progressions is different between species and this is shown in the schematic.  
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Primitive Hematopoiesis: The first hematopoietic cells arise from the blood islands in the 
yolk sac between mouse embryonic day 7.5 (E 7.5) and E 8.5 and are called ‘primitive’ 
hematopoietic progenitors [62]. These cells give rise to macrophages and primitive 
erythrocytes [63], which are larger than erythrocytes found in adults, retain their nucleus, and 
express embryonic haemoglobins. Primitive hematopoietic cells don’t self-renew; they arise 
transiently to allow oxygenation of rapidly growing foetal tissues.  
Primitive hematopoiesis is recapitulated in hESC differentiation models, which show an early 
wave of primitive erythroid and megakaryocyte and macrophage progenitors [8, 49, 64]. 
Although primitive and definitive hematopoietic cells are separated both temporally and by 
anatomical location in the embryo, in PSC models there is considerable overlap so a 
combination of cell surface markers has been developed to allow them to be distinguished [8, 
54, 65] (see Figure 1.3).  
Figure 1.5 
            
 
Figure 1.5: Schematic of cell types in embryonic haematopoiesis, showing differentiation 
from mesoderm to hemogenic endothelium and then definitive and primitive 
hematopoietic progenitors [9]. Markers for definitive and primitive hematopoietic cells are 
as shown in Kennedy et al [8] 
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Erythro-Myeloid Progenitors: The second wave of hematopoiesis also arises in the blood 
islands, overlapping with primitive hematopoiesis starting at E 8.25 [66]. It is distinguished 
from primitive haematopoiesis because it produces erythroid and myeloid cells with adult-like 
morphology [67] which are therefore called erythro-myeloid progenitors (EMPs) [68]. These 
progenitors are proliferative but they are not capable of self renewal [66]. They continue to 
arise from vascular tissues throughout the embryo, temporally overlapping with HSC 
emergence, and like HSCs they migrate to the foetal liver to develop.  
EMPs are relatively recently discovered and as yet there are few known markers for 
distinguishing them from definitive hematopoetic cells. It has been suggested that protocols 
for generating HSCs are instead generating EMPs, as they produce hematopoietic cells with 
adult morphology but they produce only a temporary wave of erythroid and myeloid cells 
when transplanted in vivo [39, 40]. They are distinguishable from definitive HSCs because 
they cannot self renew, and they are unable to produce lymphoid cells. 
Definitive hematopoiesis: Definitive hematopoietic progenitors give rise to all blood cells 
found in the adult, and the definitive wave is the source of all HSCs. HSC development is 
restricted to a single anatomical location and a narrow time-frame. Experiments where 
hematopoietic cells from different locations in the foetus showed that cells capable of 
hematopoietic reconstitution emerge in the aorta-gonad-mesonephros (AGM) between E 10.5 
and E 11.5 [69, 70] in mice and at around five weeks in humans [71].  Specifically they arise 
in the ventral wall of the dorsal aorta [72].  Once they have undergone EHT they form clusters 
of cells attached to the aortic wall, and then migrate to the foetal liver, where they proliferate 
and mature. At birth they migrate again to the adult niche in the bone marrow. 
Limiting dilution experiments show that there are only around 3 HSCs capable of 
hematopoietic reconstitution in the embryo at E 11, but by the following day there are more 
than 60 [73]. This expansion is too rapid to be cell division, which means HSCs are specified 
at an earlier stage but take time to mature. The immature cells are called ‘pre’-HCSs and are 
believed to arise between E 8.5 and E 9.5 as shown by Cre-inducible labelling experiments 
[74, 75]. Taking cells from the AGM  and culturing them  in vitro provides a model system 
allowing study of the maturation of cells from HE to pre-HSCs to HSCs [76-78]. 
The narrow time frame and specific location of definitive haematopoiesis, as well as the 
multi-step process of specification and maturation demonstrate why it is so challenging to 
derive P-HPCs capable of engraftment and hematopoietic reconstitution. To successfully do 
so one would have to drive differentiation along the definitive pathway while avoiding 
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causing primitive and EMP development instead, and allow pre-HSC to mature in vitro in 
spite of the tendency of HSC to spontaneously differentiate outside of their niche. 
It is important to be able to recognise HSC in vitro and distinguish them from the other cell 
types. Markers for this purpose are being developed (see results section 3.2) but it has been 
established that only definitive cells are capable of lymphopoiesis [8]. A recent paper suggests 
that a small number of cells with lymphoid potential arise independently of HSC formation 
[79], however significant lymphoid potential is still associated with HSCs and still provides a 
valuable in vitro assay for the presence of HSCs 
 
1.3.3 Hematopoiesis from pluripotent cells 
A great deal of progress towards the generation of transplantable P-HPCs has been made but 
the process is still incompletely understood. There are several credible theories for the 
ineffectiveness of P-HPC at engrafting, but a recent study of miRNA expression suggests that 
a failure to correctly regulate key miRNAs blocks differentiation and the ability of the cells to 
home to their niche [37]. 
In 2012, Risueño et al [37] injected P-HPCs and HSCs derived from volunteer bone marrow 
into the femurs of immune compromised mice. They found that the HSC would transplant 
into the femur and engraft, and could later be found in the contra-lateral femur and the spleen, 
and produced mature hematopoietic cells. In contrast hESC derived cells failed to engraft in 
significant numbers and the hiPSC derived cells were found only in the femur into which they 
had originally been injected, indicating a failure to migrate to and colonise other 
hematopoietic organs, and they failed to differentiate into mature hematopoietic cells. 
Interestingly they were able to differentiate in vitro when removed from the mice, meaning 
they had hematopoietic potential but that they were blocked from differentiation in vivo. The 
authors examined the expression of a panel of miRNAs, which are key regulators in both 
pluripotent stem cell biology and hematopoietic differentiation, and found that a number of 
miRNAs were differentially regulated between bone marrow derived cells and P-HPCs. 
Therefore it was decided that miRNA expression in hiPSC and hESC derived hematopoietic 
progenitors should be further investigated in this project. 
 
1.4 miRNAs 
Micro-RNAs or miRNAs are a relatively recently discovered group of short non-coding RNA 
molecules 20-22 nucleotides long, which inhibit gene expression by targeting mRNA 
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molecules, and an individual miRNA can be used to control whole networks of genes, which 
makes them particularly important for processes which require a large number of different 
genes to be controlled at the same time. Multiple studies have shown that miRNAs are 
expressed in a development- or tissue-specific manner and participate in determination of cell 
fate, pattern formation during embryonic development, cell cycle control, cell proliferation 
and apoptosis, regulation of cell signalling and differentiation [1, 80, 81]. This means that 
manipulating their expression can be useful for controlling cell fate and behaviour. 
 
1.4.1 Biogenesis and mechanism of miRNAs 
miRNAs are complimentary to a region of a gene’s mRNA transcript, usually the 3’UTR 
region. They bind to and silence any mRNA to which they are complementary.  miRNA 
biogenesis is shown in Figure 1.6. miRNAs are usually transcribed from the genome as part 
of a longer RNA molecule called a pri-miRNA.  They are processed by DROSHA into shorter 
strands, called pre-miRNA, which are about 70 nucleotides long and form a hairpin loop 
structure. These are exported into the cytoplasm, where they are further processed by DICER 
into 20-22 nucleotide double stranded molecules. One of these strands is loaded into the RISC 
complex, the other is degraded [1]. The RISC-miRNA complex uses several mechanisms to 
silence target genes (reviewed by Eulialio et al in 2008 [81]); it causes degradation of both 
mRNA and translated polypeptides and inhibits translation initiation and elongation as well as 
encouraging ribosome dissociation. 
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1.4.2 miRNA terminology and nomenclature.  
miRBase, the principal database of known miRNAs lists over 2500 human miRNAs, although 
many of these have not been validated and are believed not to be real [82]. miRNAs have 
been named numerically, i.e. miR-1, miR-2 etc, with the exception of some of the very first 
miRNAs discovered, for example let-7 or lin-4. Duplications of miRNA genes have created 
miRNA ‘families’. miRNAs from the same family with the same seed sequence are 
distinguished by letters, e.g. miR-200b and miR-200c. miRNAs can be made from both 
strands of the short stem loop pre-miRNA, but in general only one of them will have a 
functional role and this one will be the one which is predominant in the cytoplasm, with the 
other having been immediately degraded. The convention has been to mark the other strand 
with an asterisk. For example mir-150 is expressed in many hematopoietic cells and the 
complimentary strand is called mir-150*. In many cases it is not known which of the strands 
Figure 1.6 
                     
Figure 1.6: Schematic diagram of miRNA biogenesis derived from Mallana et al review 
[1]. The process of biogenesis is shown from top to bottom: the pri-RNA is transcribed 
from the genome and forms a stem-loop, and is then processed by DROSHA and DGCR8. 
It is then transported from the nucleus and further processed by Dicer into a short two 
stranded RNA molecule which is taken up by RISC and used to guide the degradation of 
complimentary mRNA. 
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is functional and in some both appear to have some mRNA inhibitory function so the more 
precise nomenclature of naming the strands as -3p or -5p has been adopted [83]. For example 
mir-150 is called mir-150-5p and mir-150* is called 150-3p [84].  
1.4.3 miRNAs in reprogramming 
miRNAs are a useful target for reprogramming because many genes in a pathway can be 
controlled by a single miRNA, which can potentially avoid issues of redundancy, and because 
they can be introduced to cells without genomic integration, avoiding mutagenesis. Ectopic 
miRNA expression has been explored as a method of reprogramming cells to pluripotency:  
miR-302 can improve the efficiency of four factor reprogramming [85], and inhibition of 
miR-145 promotes reprogramming [86].  Fibroblasts can be reprogrammed into iPSCs using 
miRNAs alone (miR-302, -369 and -200c), although efficiency is low [87]. miRNAs have 
also been used for direct reprogramming of one mature cell type to another (see discussion 
section 7.1). 
1.4.4 miRNAs in hematopoiesis 
The process of differentiation from HSCs involves several steps: cells must leave the 
quiescent self-renewing state of HSCs, then they become very proliferative and undergo a 
series of progressive specialisations while maintaining their proliferative state. Once their 
final cell type is determined they undergo maturation and eventually become terminally 
differentiated and lose their proliferative capacity. All of these steps involve miRNA. 
miRNA maintain stemness in HSCs. Knocking out DICER in HSC results in the loss of HSC 
maintenance as well as loss of erythroid commitment [88]. miRNAs target genes involved in 
differentiation, maintaining the cells in a less differentiated state [89] and it has been 
suggested that miRNAs help to balance HSC in a state of multi-lineage potential by 
preventing the expression of genes which promote a particular lineage. miRNAs also regulate 
the self-renewal of HSC, for example increasing the expression of miR-125a causes 
expansion of HSCs [90] and miR-126 maintains HSCs by preventing their entry into the cell 
cycle [91]. miR-29a promotes self-renewal of HSCs [92]. Increased expression of miR-34a, a 
miRNA which promotes apoptosis, is associated with myelodysplastic syndrome, a condition 
in which there is a severe depletion of the HSC population [90, 93-95], as is an increase in 
miRNAs associated with hematopoietic differentiation such as miR-223 and miR-181 [90, 
96]. 
miRNA are differentially expressed in different hematopoietic lineages and are responsible 
for the small changes in concentration of cellular factors which control lineage fate decisions 
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in differentiating hematopoietic cells [97]. miR-181a promotes T-cell development [98]. The 
miR-23-27 cluster increases myeloid progenitor numbers at the expense of lymphoid 
progenitors [99], miR-299 promotes granulocyte formation and decreases erythrocyte 
colonies [100], miR-424 controls the monocyte/macrophage fate decision by targeting NF1A 
[101] and the megakaryocyte/erythroid fate decision is controlled by miR-150 and miR-223 
[102, 103]. These miRNAs ensure that appropriate numbers of each hematopoietic cell type 
are produced. 
Other miRNAs are responsible for regulating the maturation process of hematopoietic cells to 
the point where they are terminally differentiated and no longer proliferative. The greatest 
changes in miRNA expression occur when the cells are switching from a proliferative 
committed progenitor to a terminally differentiated non dividing cell [104]. There is a 
hierarchy of miRNAs which regulate different stages in this process [105-107]. miRNAs 
targeting mitophagy must be down-regulated before erythrocytes can undergo terminal 
differentiation [108] and miR-144 and miR-451, although not required for erythroblast 
formation are essential for the terminal differentiation of erythrocytes [109]. The final stage of 
granulocyte maturation requires miR-21 and miR-196b [110], myeloid terminal 
differentiation requires the down-regulation of miRNAs which promote proliferation [104], 
and excess miR-34a causes the accumulation of immature B-cells [111].  
miRNA are key players at every stage of adult haematopoiesis, but less is known of their role 
in embryonic haematopoiesis. Experiments in zebrafish have shown that the switch from 
embryonic to adult erythropoiesis is regulated by miR-144 [112], miR-451 [113] (and miR-
223 [114] and miR-126 controls the onset of definitive haematopoiesis via the targeting of c-
MYB [115]. Few studies of in vivo miRNA expression in emerging hematopoietic cells have 
been done, so little is known about this subject. 
miRNAs in hematopoietic differentiation from pluripotent cells: In transplant experiments 
HSCs can be injected directly into the bone marrow of the femur or introduced instead into 
the bloodstream, from where they will home to the bone marrow and make their way through 
the blood vessel wall into the niche. HSC are mobile and will eventually grow to colonise the 
marrow of bones other than those which they are directly injected into and will produce cells 
which colonise other hematopoietic organs such as the spleen and thymus. Risueño et al. [37] 
transplanted hematopoietic progenitors derived from pluripotent cells into mice and found that 
the hiPSC derived cells could engraft only when directly injected into the femur, and that they 
would not colonise the contra-lateral femur or the other hematopoietic organs.  This is 
consistent with other published experiments in which P-HPCs have been transplanted into 
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animals. The same cells showed multipotent hematopoietic potential in vitro which suggests 
that there is a defect in migration or chemotaxis which prevents the cells from reaching their 
niche. Risueño et al. discovered a possible mechanism for this failure to acquire a motile 
phenotype when they studied the molecular/genetic profiles of engrafted and in vitro P-HPCs 
compared to HSCs derived from adult bone marrow: they found that there were a number of 
miRNAs which fail to down-regulate during in vitro differentiation, and which are therefore 
expressed at unusually high levels compared with HSC derived from bone marrow. miRNAs 
are key regulators of embryonic differentiation and have well documented roles in regulating 
motility and migration (see results 4.2.1). It is therefore reasonable to hypothesise that 
ectopic expression or inhibition of miRNAs may be helpful in generating functional P-HPCs. 
 
1.5 Aims 
The broad aim of this project was to improve the process of generation of human HSCs from 
PSCs, specifically by altering the levels of key miRNAs.  
Hypothesis: the production of functional P-HPCs is impaired due to mis-regulation of 
miRNAs; genetic manipulation of these key miRNAs could lead to improvements in the yield 
and functionality of definitive hematopoietic progenitors. The aims of this study were to:  
1. Investigate techniques for hematopoietic differentiation, choosing the most effective 
chemically defined, feeder free method and improve upon differentiation protocols by 
adjusting differentiation conditions, for example oxygen levels. 
2. Identify candidate miRNAs which are differentially regulated in P-HPCs compared to 
hematopoietic progenitors found in bone marrow and cord blood, by analysis of 
microarray data and validate these candidates by qPCR. 
3. Develop efficient techniques for manipulating miRNA expression in hPSC derived 
hematopoietic progenitors. 
4. Investigate if genetic manipulation of miRNAs improves the efficiency and 
functionality of hematopoietic differentiation from human pluripotent stem cells as, as 
measured by colony assays, gene expression and cell surface markers. 
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2. Materials and methods 
2.1 Tissue culture 
2.1.1 Culture of human pluripotent stem cells 
This project used two cell lines: H9, a hESC line bought form WICell. Inc. and SB-Ad3, a 
hiPSC line made from adult dermal fibroblasts using Yamanaka factors encoded in a Sendai 
virus which had been derived by Lako’s group. Both of these cell lines have been extensively 
characterised and validated by Lako’s group. 
The cells were cultured in STEMPRO® hESC medium (see Tables 2.1 and 2.2) on 
vitronectin coated 6 well plates after being adapted from mTeSR™1 and Matrigel coated 
plates. Cells were incubated at 37°C in a humidified atmosphere with 5% CO2. Media was 
replaced daily. Differentiated cells were removed by scraping the thicker, more opaque, and 
irregularly shaped differentiated areas of the colonies away using a pipette tip. Typical hESC 
colonies are shown in Figure 2.1. The cells were passaged at a ratio of 1:3 every 4-5 days or 
when they reached 75% confluence.  Prior to passaging each well of a fresh 6 well plate was 
coated with 1ml of vitronectin solution diluted in PBS to a concentration of 10µg per ml. The 
plate was then incubated for 1hr at room temperature (20-25
o
C), and the solution was 
aspirated immediately before cells were passaged onto the plate. Cells were passaged 
manually using a StemPro® EZPassage roller to cut the colonies into squares as shown in 
Figure 2.2, which were lifted by flushing and then transferred into the new plates.  
 
 
 
 
  
Table 2.2: Products for culture of pluripotent stem cells 
Product name Product number Manufacturer 
TPP® 6 well plates 92006T Sigma-Aldrich 
StemPro® hESC SF Media A1000701 Thermo Fisher Scientific 
StemPro® EZPassage roller 23181010 Thermo Fisher Scientific 
Vitronectin 7190 Stem cell technologies 
Stemline® II S0912 Sigma-Aldrich 
Corning® Ultra-low attachment culture dish CLS3262 Sigma-Aldrich 
TrypLE™Express 12604039 Thermo Fisher Scientific 
Human FGF-basic PHG0023 Thermo Fisher Scientific 
 
Table 2.1: StemPro® hESC media 
DMEM-F12 454ml 
StemPro® hESC supplement 10ml 
BSA25% 36ml 
FGF-β 400µl (final conc. 8 ng/ml) 
β-mercaptoethanol (55mM) 909µl 
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2.1.2 Hematopoietic differentiation 
Several methods of hematopoietic differentiation were used in this project. The microarray 
data is derived from a population of cells made using the protocol described in Kennedy et al. 
in 2006 [64], these experiments were done before the start of the project; see methods section 
2.2 for further details. 
Figure 2.2 
  
Figure 2.2: Manufacturers schematic of a StemPro® EZPassage roller [5], showing how 
colonies of pluripotent cells can be divided into evenly sized squares of cells by running 
the ridged roller over the surface of the plate. These squares of cells can then be lifted by 
flushing the plate with a pipette and transferred onto a fresh plate. 
Figure 2.1 
 
Figure 2.1: Representative micrographs of H9 colonies grown on STEMPRO®. Bar 
on the left-hand picture represents 200 µm, bar on the right-hand picture represents 
100 µm. 
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Some of the preliminary work on this project was done using the more recent Kennedy 2012 
protocol [8], a method involving embryoid body formation and exposure to hematopoietic 
cytokines (see Figure 2.3 for schematic of the process). However the majority of the 
experiments were done using a protocol developed and provided to us by Dr Jo Mountford 
and Dr Scott Cowan working at the University of Glasgow [2]. Their protocol was developed 
to produce large numbers of definitive mature erythroid cells and was modified in our lab to 
produce hematopoietic progenitors by using only the first 12 days of the protocol, stopping 
before the cytokines for erythroid specific differentiation are added.  
Glasgow protocol: 
Day 0, embryoid body (EB) formation: Medium was replaced with StemlineII™ medium 
with day 0 haematopoietic cytokines (Table 2.3).  Colonies were cut into squares using the 
STEMPRO® EZPassage™ Tool, and lifted from the surface of the plate by flushing with a 
5ml pipette. They were then transferred to Co-star ultra low attachment 6 well plates at a ratio 
of 2:1. More cytokine-media mix was added to make the media up to 3ml/well. 
Day 2, feeding cells: ½ ml of media was added to each well with cytokines at 6x 
concentration shown in Table 2.3; bringing the total amount of media in each well back to 
3ml (this assumes that approx. ½ ml is lost to evaporation). 
Figure 2.3 
 
Figure 2.3: Schematic of protocol found in Kennedy et al 2012 [8]. Schematic shows 
combinations and timing of cytokines used to induce hematopoiesis from human pluripotent 
stem cell derived EBs. Activin or an Activin inhibitor (SB) can be added between days 2 and 4 
to promote primitive or definitive hematopoiesis respectively. 
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Day 3, dissociation and plating: Day three EBs were dissociated with TrypLE Express for 
approximately 15 minutes. TrypLE Express was removed by diluting in a falcon tube with 
15ml of PBS, centrifuging and removing the supernatant. A small amount of medium was 
added to allow the cells to be counted with a standard haemocytometer, they were then plated 
onto uncoated 6 well plates at a density of 300k cells/well in 3ml/well StemlineII media with 
cytokines shown in Table 2.3.  
Day 5, feeding cells: ½ ml of fresh media and cytokines (Table 2.3) at 6x concentration were 
added to each well. 
Day 7, feeding cells: Medium was replaced by removing cells and medium from wells, 
centrifuging and aspirating the supernatant, and then resuspending the cells in fresh media-
cytokine mix and returning it to the wells. ½ ml of media cytokine mix (Table 2.3) was added 
to the wells during the centrifugation to prevent the adherent cells from drying out. Media in 
each well totalled 3ml once suspended cells were replaced. 
Day 9, feeding cells: ½ ml of fresh media-cytokine mix (Table 2.3) at 6x concentration was 
added to each well. 
 
Table 2.3: Cytokines used in hematopoietic differentiation 
Factor Manufacturer 
Product 
number 
Final concentration 
Day 0 Day 2 
Days 3 
and 5 
Days 7 
and 9 
BMP4 
R and D 
Systems 314-BP 10ng/ml 20ng/ml 20ng/ml 20ng/ml 
VEGF Peprotech 100-20 10ng/ml 30ng/ml 30ng/ml 30ng/ml 
Wnt3a 
R and D 
Systems 
5036-WN-
010 10ng/ml 10ng/ml - - 
Activin A Peprotech 120-14E 5ng/ml 5ng/ml - - 
GSK-3b 
Inhibitor 
VIII Calbiochem 361549 2mM 2mM - - 
FGFα Peprotech 100-17A - 10ng/ml 10ng/ml 10ng/ml 
SCF Invitrogen PHC2113 - 20ng/ml 30ng/ml 30ng/ml 
β-estradiol 
Sigma-
Aldrich E2758 - 0.4ng/ml 0.4ng/ml 0.4ng/ml 
IGF2 Peprotech 100-12 - - 10ng/ml 10ng/ml 
TPO Peprotech 300-18 - - 10ng/ml 10ng/ml 
Heparin 
Sigma-
Aldrich H0878 - - 5ng/ml 2.5ng/ml 
IBMX 
Sigma-
Aldrich 15879 - - 50uM 50uM 
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2.2 Microarray 
 Microarray analysis was done prior to the start of the project, by Lako’s group, in 
collaboration with Dr David Blesa. Two replicates of undifferentiated H9  hESC line and 
CD31+CD34+KDR+CD45- subpopulation from day 4 of differentiation were subjected to 
RNA extraction and hybridisation to an Agilent G4470C-021827 array containing 866 human 
and 89 human viral miRNAs using the Agilent protocol ‘miRNA Microarray System with 
miRNA Complete Labelling and Hyb Kit', Version 2.1. Human placenta cells were used as an 
internal control. This data was compared to the expression profile of human CD34+ bone 
marrow cells which were hybridised to the same array. The data from this array was obtained 
from Gene Expression Omnibus (GEO), accession number GSM595699. 
Bioinformatic analysis of this data was done by David Montaner at Centro de Investigacion 
Principe Felipe in Valencia (Spain). In brief, the expression data was normalised using 
quantile normalisation [116] and differential miRNA expression was estimated using Limma 
package [117] from Bioconductor. Statistical significance (adjusted p values) was used to 
select the miRNAs that were differentially expressed during human pluripotent stem cell 
differentiation and adult bone marrow hematopoietic progenitors. The significantly changed 
miRNAs were organized into patterns, for example “flat-down” which means that miRNA is 
expressed at the same level from human pluripotent stem cells to hematopoietic progenitors 
arising at day 4 of differentiation, but is under-expressed in adult bone marrow hematopoietic 
progenitor cells (see results section 4.2 for further explanation). 
A number of miRNAs were chosen for validation by qRT-PCR on the basis that their target 
genes might have a function in hematopoiesis. This was determined by analysis of all the mis-
regulated miRNAs with information from databases such as Targetscan [118] and miRbase 
[82] and a literature search on the NCBI database. 
 
2.3 Quantitative RT- PCR (qPCR) 
2.3.1 miRNA expression analysis. 
The Taqman system of using primers specific to the miRNA of interest was chosen for reverse 
transcription. See results section 4.1 for an in-depth explanation of this system and why it is 
necessary to use it. The primer sequences used in these experiments are proprietary and have 
not been released in spite of several requests, but the sequences of the miRNAs tested are 
shown in Table 2.4. Small nuclear RNAs RNU44 and RNU48 were chosen as internal 
controls as they are known to be stably and abundantly expressed across different cell types 
[119-121]  
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CD34+ human adult bone marrow and CD34+ cord blood cells purchased from AllCells were 
used as positive controls for qPCR analysis. 
 
RNA was extracted using the Reliaprep
TM
 RNA cell miniprep system.  miRNA was amplified 
using the TaqMan Micro-RNA Reverse Transcription (RT) Kit with a specific TaqMan Micro-
RNA primer. Components of the RT reaction are shown in Table 2.5 and the PCR program is 
shown in Table 2.6. 
Table 2.4: Sequences of miRNAs studied by qPCR 
  Mature miRNA sequence 
miR-9 UCUUUGGUUAUCUAGCUGUAUGA 
miR-18b UAAGGUGCAUCUAGUGCAGUUAG 
miR-134 UGUGACUGGUUGACCAGAGGGG 
miR-150 UCUCCCAACCCUUGUACCAGUG 
miR-150* CUGGUACAGGCCUGGGGGACAG 
miR-148a UCAGUGCACUACAGAACUUUGU 
miR-200b UAAUACUGCCUGGUAAUGAUGA 
miR-200c UAAUACUGCCGGGUAAUGAUGGA 
miR-205 UCCUUCAUUCCACCGGAGUCUG 
miR-302a UAAGUGCUUCCAUGUUUUGGUGA 
miR-302a* ACUUAAACGUGGAUGUACUUGCU 
miR-367 AAUUGCACUUUAGCAAUGGUGA 
miR-424 CAGCAGCAAUUCAUGUUUUGAA 
miR-142 CAUAAAGUAGAAAGCACUACU 
miR-146 UGAGAACUGAAUUCCAUGGGUU 
miR-223 UGUCAGUUUGUCAAAUACCCCA 
miR-181b AACAUUCAUUGCUGUCGGUGGGU 
RNU44 CCTGGATGATGATAGCAAATGCTGACTGA 
  ACATGAAGGTCTTAATTAGCTCTAACTGACT 
RNU48 GATGACCCCAGGTAACTCTGAGTGTGTCG 
  CTGATGCCATCACCGCAGCGCTCTGACC 
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TaqMan Universal PCR Mastermix II and TaqMan MicroRNA Assays were used for the 
qPCR, components of the reaction shown in Table 2.7. 10µl qRT-PCR reactions were done in 
triplicate on a 386 well plate in a TaqMan 7900 or a QuantStudio
™
 7 machine, using the 
programme shown in Table 2.8. 
 
Table 2.7: Summary of components for qPCR 
Components Volume per 30-µl reaction 
  Triplicates 
TaqMan® Small RNA Assay (20 X) 1.8 µl 
Product of RT reaction 2.4 µl 
TaqMan® Universal PCR Master Mix II (2X), no UNG 18.0 µl 
Nuclease-free water 13.8 µl 
Total volume 36.0 µl 
 
Table 2.6: PCR Programme for reverse transcription 
Step Time Temperature 
Hold 30 minutes 16 °C 
Hold 30 minutes 42 °C 
Hold 5 minutes 85 °C 
Hold ∞ 4 °C 
 
Table 2.5: Summary of components for reverse transcription 
Components 
Master mix volume (per 
15-µl reaction) 
Final concentration 
 100 mM dNTPs (with dTTP) 0.15 µl  10^5 mM 
MultiScribe™ Reverse Transcriptase, 
50 units/µl 1.00 µl  3.33 units 
10X Reverse Transcription Buffer 1.50 µl 
 RNase Inhibitor, 20 units/µl 0.19 µl 0.25units/µL 
Nuclease-free water 4.16 µl 
 Cell lysate 5.00 µl 0.333 
RT Primer 3.00 µl 0.2 
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2.3.2 Gene expression analysis 
For the analysis of gene expression by qPCR RNA was extracted in the same way and 1μg of 
RNA was used in a 20μl GoScript™ reverse transcription reaction, according to the 
manufacturer’s instructions. The RNA was mixed with oligo(dT) and random primers  as 
Table 2.9: qPCR reagents 
 
Product number Manufacturer 
TaqMan® MicroRNA Reverse Transcription Kit 4366597 Thermo Fisher Scientific 
ReliaPrep™ Z6012 Promega 
TaqMan® MicroRNA Reverse Transcription Kit 4366597 Thermo Fisher Scientific 
RNU44 TaqMan® miR assay 4427975/001094  Thermo Fisher Scientific 
RNU48 TaqMan® miR assay 4427975/001006 Thermo Fisher Scientific 
miR-200c TaqMan® miR assay 4427975/002300 Thermo Fisher Scientific 
miR-200b TaqMan® miR assay 4427975/002251 Thermo Fisher Scientific 
miR-424 TaqMan® miR assay 4427975/000604 Thermo Fisher Scientific 
miR-205 TaqMan® miR assay 4427975/000509  Thermo Fisher Scientific 
miR-148a TaqMan® miR assay 4427975/000470  Thermo Fisher Scientific 
miR-9 TaqMan® miR assay 4427975/000853 Thermo Fisher Scientific 
miR-18b TaqMan® miR assay 4427975/002217 Thermo Fisher Scientific 
miR-134 TaqMan® miR assay 4427975/000459  Thermo Fisher Scientific 
miR-150 TaqMan® miR assay 4427975/000473 Thermo Fisher Scientific 
miR-150* TaqMan® miR assay 4427975/002637 Thermo Fisher Scientific 
miR-302a TaqMan® miR assay 4427975/000529 Thermo Fisher Scientific 
miR-302a* TaqMan® miR assay 4427975/002381 Thermo Fisher Scientific 
miR-367 TaqMan® miR assay 4427975/000555 Thermo Fisher Scientific 
miR-142 TaqMan® miR assay 4427975/000464 Thermo Fisher Scientific 
miR-146 TaqMan® miR assay 4427975/000468 Thermo Fisher Scientific 
miR-223 TaqMan® miR assay 4427975/000526 Thermo Fisher Scientific 
miR-181b TaqMan® miR assay 4427975/001098 Thermo Fisher Scientific 
TaqMan® Universal mastermix II 4440044 Thermo Fisher Scientific 
MicroAmp® Optical 384-Well Reaction Plate 4309849 Thermo Fisher Scientific 
GoScript™ reverse transcription kit A5000 Promega 
SYBR™ Green qPCR kit 11762500 Life technologies 
 
Table 2.8: programme for qPCR 
Steps 
Enzyme Activation PCR Amplification 
HOLD 
CYCLE (40 cycles) 
Denature  Anneal/extend 
Temperature 95°C 95°C 60°C 
Time 10 minutes 15 seconds  60 seconds 
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shown in Table 2.10(i), then heated at 70
o
C for 5 minutes, cooled on ice for 5 minutes, then 
mixed with the reagents for reverse transcription shown in Table 2.10(ii). The program for 
reverse transcription is shown in Table 2.11. Information on the reagents used for this and the 
qPCR reactions are shown in Table 2.9. 
 
 
 
qPCR was then performed on the cDNA using components shown in Table 2.12 and primers 
shown in Table 2.13. Controls without cDNA were used to exclude results from wells with 
contamination. 10µl qRT-PCR reactions were done in triplicate on a 386 well plate in a 
TaqMan 7900 or a QuantStudio
™
 7 machine, using the programme shown in Table 2.8. 
Primers were designed using the NCBI Primer-BLAST tool [122]. Parameters for qPCR 
primers are that the primers were 18-22 nucleotides long,  specific to the gene of interest, 
PCR product size was 70-200 base pairs and melting temperature was between 58-62
o
C. 
Where possible, primers were designed so that the PCR product spans an intron to reduce the 
likelihood of genomic DNA contamination. The primers were analysed for primer dimers and 
secondary structure formation using Thermo fisher’s multiple primer analyser software [123]. 
The efficiency of the primers was determined by melt curve analysis. 
 Table 2.11: Programme for reverse transcription 
Step Time Temperature 
Anneal 5 minutes 25 °C 
Extend 60 minutes 42 °C 
Inactivate RT 15 minutes 70 °C 
  ∞ 4 °C 
 
Table 2.10(i): components for reverse transcription 
Component  Volume 
Experimental RNA  Xμl(1μg/reaction)  
Primer Oligo(dT) /random primer 1μl(0.5μg/reaction) 
Nuclease-Free Water  Xμl 
Final volume  5μl 
  Table 2.10(ii) 
Component  Volume 
GoScript™ 5X Reaction Buffer  4.0μl 
MgCl2  1 1.2–6.4μl (final concentration 1.5–5.0mM) 
PCR Nucleotide Mix 2 1.0μl  (final concentration 0.5mM each dNTP) 
GoScript™ Reverse Transcriptase  1.0μl 
Nuclease-Free Water Xμl  (to a final volume of 15μl)  
Final volume  15μl 
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All qPCR Results were analysed with SDS 4.2 and DataAssist Software v3.01. Significance 
was determined by one way ANOVA with three replicates. Information about the reagents 
used is shown in Table 2.9. 
 
2.4 Flow cytometry and cell sorting 
Cells were prepared for flow cytometry by dissociating them with TypLE
TM
 Express at 37
o
C 
for 15 minutes. The TypLE
TM
 Express was then diluted with PBS and the cells were pelleted 
by centrifugation, and the supernatant was aspirated. The cells were then re-suspended in 2% 
BSA-PBS, filtered through a 40µm filter and stained with fluorescent-conjugated antibodies 
in darkness for 1 hour to avoid photo-bleaching. The cells were then washed and stained with 
DAPI to eliminate dead cells before being analysed. Unstained populations of cells were used 
 
Table 2.13: Primers for qPCR 
Gene Forward primer Reverse primer 
GATA1 CAGGCCAGGGAACTCCA ATCACACTGAGCTTGCCACA 
SCL AGCCGGATGCCTTCCCTAT CCGCACAACTTTGGTGTGG 
HOXB4 GTCGTCTACCCCTGGATGC CGTGTCAGGTAGCGGTTGTA 
GATA2 GGGGACCCTGTCTGCAACGC GGCAGCTGCACTGAAGGGGG 
cMYB GACAGCAGGTGCTACCAACA GCTGCATGTGTGGTTCTGTG 
HOXA9 CCGAGAGGCAGGTCAAGATC  AAATAAGCCCAAATGGCATCA 
RORA GCACCGCGGCTTAAATGATGT CTTCTCCTGAAAAAGCCCTTGC 
SOX4 ACCACCACTCGCTGTACAAG AGGTAGACGCGCTTCACCTT 
ERG TCTGTCTTAGCCAGGTGTGG CGCATTATGGCCAGCACTAT 
SOX17 TCTGCCTCCTCCACGAAG CAGAATCCAGACCTGCACAA 
RUNX1 CAATGGATCCCAGGTATTGG CACTGCCTTTAACCCTCAGC 
ZEB1 GCGGAAGACAGAAAATGGAA GATTCCACACTCATGAGGTC 
ZEB2 AATGAAGCAGCCGATCATGG CAGAACCTGTGTCCACTAC 
PU.1 CACAGCGAGTTCGAGAGCTT GATGGGTACTGGAGGCACAT 
 
Table 2.12: SYBR Green components 
Component Volume 
2x master mix buffer  5μl 
Template cDNA 0.4-0.8μl 
Primers (F/R )  0.4~0.6μl 
Nuclease free water  Xμl 
CXR 0.1μl 
Final volume 20μl 
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to control for auto-fluorescence. Consumables used for preparation of flow cytometry 
experiments are shown in Table 2.14, and all antibodies used are in Table 2.15. 
In the experiments for results section 3.3 cells were sorted on the BD FACS Aria machine at 
days 4, 7 and 12 of differentiation, using the combinations of markers shown in Table 2.16 
(fluorescent conjugated antibodies used are shown in Table 2.15). FACS was repeated at least 
three times for each time-point. Multi-colour flow cytometric analysis set-up, colour 
compensation and cell sorting were done by Ian Dimmik. 
Cells were also analysed after miRNA inhibition on the LSRII flow cytometry machine using 
the combinations of markers shown in Table 2.16. Results were analysed using BD FACS 
DIVA software. 
 
 
 
Table 2.15 Antibodies used in flow cytometry 
Marker Flourophore Product number Manufacturer 
‘Kennedy’ Antibodies 
CD34 APC 555824 BD Biosciences 
CD43 FITC MHCD4301 Life Technologies 
CD41a APC-H7 561422 BD Biosciences 
CD235a BV421 562938 BD Biosciences 
CD45 PercP-Cy5.5 564105 BD Biosciences 
‘Notta’ Antibodies 
CD34 Percp-cy5.5 343522 Cambridge biosciences 
CD45RA APC (660) 550855 BD biosciences 
CD38 BV 421 562444 BD biosciences 
CD90 PE-Cy7 561558 BD biosciences 
CD49f PE 555736 BD biosciences 
‘Vodyanik’ antibodies 
CD90 PE-Cy7 561558 BD biosciences 
CD73 BV 421 562431 BD biosciences 
CD34 APC 555824 BD Biosciences 
CD43 FITC MHCD4301 Life Technologies 
CD45 PercP-Cy5.5 564105 BD Biosciences 
 
Table 2.14: Products for preparation of Flow cytometry samples 
Consumables Product number Manufacturer 
40μm nylon cell strainers 32540 Corning 
DAPI 50-5005 Sysmex 
5μl round bottom tubes 352054 Corning 
Comp Beads 51-90-9001229/9001291 BD Biosciences 
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2.5 Colony forming unit (CFU) assays 
Hematopoietic progenitors were dissociated with TrypLE
TM
 Express and counted. 60000 cells 
were then filtered through a 40μm cell strainer and transferred to a 3ml aliquot of 
MethoCult
TM
 media. A syringe with a blunt ended needle was used to mix the cells into the 
media and transfer it into two 10mm cell culture dishes scored with 2mm grids. See Table 
2.17 for information about the products used in this experiment. These dishes were placed 
into a larger cell culture dish along with a small tissue culture dish filled with sterilised water 
as shown in Figure 2.4. This was then incubated at 37
o
C and 5% CO2. After 14 days colonies 
in each dish were counted under a light microscope. Numbers were averaged between the two 
dishes. Representative images of CFU-M, CFU-G, CFU-E, and BFU-E are shown in Figure 
2.5. 
 
Table 2.17: Components for colony forming unit assay 
Product Product number Manufacturer 
MethoCult™ 4034 Stem cell technology 
40μm nylon cell strainers 32540 Corning 
Blunt-end Needles 28110/28120 Stem cell technology 
3 cc Syringe 28230/28240 Stem cell technology 
60 mm Gridded Scoring Dishes 27500 Stem cell technology 
 
Table 2.16: Markers used in cell sorting 
Time points Day 4 Day 7 Day12 
Markers used 
CD31 CD34 
KDR CD45 CD34 CD41a CD43 CD235a CD45 
P
o
p
u
la
ti
o
n
s 
so
rt
ed
 Negative 
CD31- CD34-
KDR- CD45- CD34- CD41a- CD43- CD235a- CD45- 
Haemangioblast 
CD31+  CD34+ 
KDR+  CD45- - - 
Primitive - CD43+ CD34+/- CD41a+ CD235a+ CD45- 
Definitive - - 
CD43+ CD34+/- 
CD41a- CD235a- 
CD45+  
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2.6 CAFC assays  
Figure 2.5 
 
 
Figure 2.5: Representative micrographs showing typical morphology of the different types of 
colony forming unit. Top left: CFU-E (hemoglobinised colonies of 8-200 cells), top right 
BFU-E (hemoglobinised colonies of >200 cells), bottom left: CFU-M (diffuse colonies with 
large round cells), bottom right CFU-G (colonies made of small cells, sometimes with a dark 
‘core’). The bars on the images represent 200um. 
 
Figure 2.4 
 
Figure 2.4: Schematic of CFU setup 
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OP9-DL4 cells were cultured at 37
o
C and 5% CO2 in T75 flasks in OP9 medium (see Table 
2.18) which was replaced every three days. The OP9-DL4cells were passaged every 5-7 days 
to prevent them from becoming confluent, which causes them to become adipogenic. Cells 
were passaged into 96 well plates approximately 3 days before co-culture, at a density 
allowing them to achieve 80-90% confluence at the start of the experiment. At day 12 of 
differentiation hematopoietic progenitors were dissociated using TrypLE
TM
 Express and 
plated onto the 96 well plate of OP9-DL4 cells in 3x dilutions starting at 5 x 10
4
 cells per ml 
in OP9 medium supplemented with 5ng/ml Flt-3L and 1ng/ml IL-7. They were incubated for 
7 days, with ½ of the supplemented medium replaced after 3 days, and then analysed under 
phase contrast microscopy for cobblestone colonies. 
 
 
2.7 Lentiviral transfection 
NHDF fibroblasts or differentiating H9 cells were transfected either using Genecopoiea
TM’s 
lentiviral particles containing a plasmid with a mir-200c inhibitor, mCherry reporter and 
hygromycin resistance gene, or with MISSION
®
 Lenti microRNA Inhibitors (Sigma-Aldrich 
HLTUD0001) containing a plasmid with a miR-200c inhibitor and a puromycin resistance 
gene.  
NHDF or H9 cells were passaged into 12 well plates 24hrs before transduction. Cells must be 
in the exponential growth phase so they were plated at a density allowing them to be no more 
than 80% confluent. The media was aspirated and replaced with fresh media with 8μg/ml of 
polybrene. Lentiviral particles were thawed on ice and added to the cells at a range of MOIs 
(see results section 5.1). Wells were transfected in triplicate for each MOI and for the 
negative scramble-control. Media was changed after 24hrs to remove the polybrene. Cells 
were analysed after 48 hrs. 
For experiments with Genecopoiea
TM’s lentiviral particles, the percentage of cells expressing 
mCherry was calculated either by flow cytometry or by counting the percentage of fluorescent 
Table 2.18: OP9 medium and cytokines for CAFC 
Recombinant human Flt-3 ligand 308-FK R&D Systems 
Recombinant IL-7  217-17 Peprotech  
OP9 medium 
α-MEM 500ml 
FBS 126ml 
Penicillin-streptomycin 5ml 
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cells photographed using a Zeiss fluorescent microscope. For experiments with Sigma 
lentiviral particles the cells were treated with 0.5μg/ml puromycin 24hr after transfection. 
Multiplicity of infection (MOI) was calculated using the formula MOI = number of viral 
particles/number of cells. The number of viral particles used in a particular experiment was 
calculated based on information about the number of viral particles per micro-litre provided 
on the manufacturer’s datasheet. 
2.8 Lipofection  
Lipofectamine™-RNAi complexes were prepared by diluting 20pmol of mirVanaTM miRNA 
inhibitor or control (mirVana
TM
 miRNA inhibitor negative control or Santa Cruz 
biotechnology Flourescein conjugate control, see Table 2.19) in 50ul Opti-MEM® I Medium 
and 6μl of Lipofectamine RNAiMax™ in 50ul Opti-MEM® I Medium. Both were incubated 
at room temperature for 5 minutes, then mixed and incubated at room temperature for a 
further 20 minutes. For Multiplex reactions 20pmol of each inhibitor was used, while 
increasing the quantity of lipofectamine to maintain the miRNA-inhibitor to lipofectmine 
ratio. 
The complexes were added to one well of a 12 well plate with 1ml of differentiation medium 
at day 10 of differentiation, the plate was spun at approx 300g for 10 minutes and then 
returned to the incubator. Cells were analysed after 48 hours.  
 
2.9 CytoSNP 
CytoSNP analysis was performed by Dr Simon Zwolinski (Northern Genetics Service) and Dr 
David Lee. 1μg of sample DNA was processed on the CytoChip oligo SNP microarray and 
analysed using BlueFuse Multi software. 
Table 2.19: Components for lipofection 
  Manufacturer Product number 
Opti-MEM® Reduced Serum Medium Life technologies 31985062 
Control siRNA (FITC Conjugate)-A Santa Cruz sc-36869 
lipofectamine® RNAiMAX Life technologies 13778075 
miR-424 mirVana® miRNA inhibitor Life technologies 4464084/MH10306 
miR-205 mirVana® miRNA inhibitor Life technologies 4464084/MH11015  
miR-148a mirVana® miRNA inhibitor Life technologies 4464084/MH10263  
miR-200c mirVana® miRNA inhibitor Life technologies 4464084/MH11714 
miR-200b mirVana® miRNA inhibitor Life technologies 4464084/MH10492 
mirVana™ miRNA Inhibitor, Negative Control #1 Life technologies 4464076 
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2.10 Statistical analysis 
The original experimental design in this project intended to use ANOVA to determine the 
significance of the difference between the control and treated cells. However it is necessary to 
take into account the effect of passage number on hematopoietic differentiation (see results 
section 3.4). Since this did not become clear until the project was almost completed it was not 
possible to do all the experiments at the same passage. ANCOVA (analysis of covariance) 
was used to determine significance instead. 
ANCOVA is a generalised linear model which combines ANOVA and linear regression. The 
control is compared to the treatment while statistically adjusting for the variation caused by 
the covariate, which in this case is the effect of passage number. 
This technique for statistical analysis allows the data to be presented in the form of ‘estimated 
marginal means’ (EMMs), the means of each factor adjusted for the covariate. This 
effectively shows an estimate of what the results would look like if all the experiments were 
done at the same passage. 
The figures and the majority of statistics were calculated in GraphPad Prism®, however this 
software cannot do ANCOVA so the ANCOVA and EMM were done in SPSS statistics. 
Inhibitions were compared to control data using univariate one-way ANCOVA, p values are 
calculated as Sidak corrected bootstrapped significance. 
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3. Results: hematopoietic differentiation 
3.1 Differentiation of pluripotent cells into hematopoietic progenitors 
This project requires an efficient method for differentiating pluripotent cells into 
hematopoietic progenitors. Several methods have been used to differentiate pluripotent cells 
into hematopoietic cells; the main types being co-culture and EB formation with various 
combinations of cytokines (see introduction section 1.3). In order to compare the 
effectiveness of these methods we need to cover the techniques which can be used to assess 
the quantities and types of hematopoietic cells which they produce. 
3.2 Methods for assessing the effectiveness of differentiation protocols 
3.2.1 Transplantation assay 
 The gold-standard for testing for the presence of HSCs is functional transplantation: that is, 
hematopoietic cells injected into an animal which home to the bone marrow niche, engraft 
there and produce all blood lineages, and continue to do so on a permanent basis or over 
multiple transplantations. Performing this test on human cells presents a challenge, as the 
animal’s immune system will react to the presence of foreign cells. To overcome this 
researchers have used mice with various types of immune deficiencies. It is essential to use 
the most immune-deficient mouse possible as any immune response can cause the transplant 
to be rejected and interfere with the results of the experiment. 
‘SCID’ (severe combined immune deficiency) mice were discovered in 1983 by Bosma et al. 
[124] They have a mutation in Prkdc, the gene responsible for repairing DNA after V(D) J 
recombination, which means very few T-cells can survive to maturity [125]. Human bone 
marrow has been transplanted into SCID mice since 1992 [126].   
SCID mutations have been made in mice with a NOD (non-obese diabetic) genetic 
background, which means they are almost without B-cells, T-cells and NK-cells and have 
impaired innate immunity due to abnormal myelopoiesis and deficiencies in the haemolytic 
complement system [127-129]. NOD-SCID mice have up to 10-fold more engraftment of 
human cells compared to mice with the SCID mutation alone [127], but they can still 
sometimes achieve an immune reaction. This is due to a phenomenon called ‘leakiness’; a 
fraction of lymphocytes spontaneously repair their DNA after V(D) J recombination without 
Prkdc, and these viable NK cells accumulate in the mouse with age, allowing it to reject 
foreign cells [130]. 
Ito et al. induced a null mutation in the gene encoding IL2Rγ, which completely blocks the 
formation of NK-cells, further improving engraftment [131]. These NSG (NOD-SCID-
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Gamma chain null) mice are the most immune-deficient mice that have been developed [132] 
and are now commonly used to assess human HSC potential. 
Although transplantation into immune compromised mice remains the gold standard for 
testing for the presence of HSCs, the ethical issues around animal use and the cost, technical 
challenges, and time consuming nature of the transplantation assay have meant that in vitro 
assays for hematopoietic cells’ potential have been developed. The most informative of these 
are colony assays, cell surface marker expression and gene expression. 
 
3.2.2 Cobblestone Area Forming Cells (CAFC ) 
 CAFC assays can inform us about the presence of cells with lymphocyte potential, which is 
used as a stand-in for HSC potential. The bone marrow niche is mimicked using defined 
mouse stromal cell lines. The stromal cells form a monolayer, which the hematopoietic 
progenitors migrate underneath, forming ‘cobblestone-like’ areas of cells which can be 
distinguished from mature hematopoietic cells because they are non-refractile, appearing dark 
under phase contrast microscopy [133]. The co-cultures are assayed at different time points 
after seeding with hematopoietic progenitors, as the cells will differentiate according to their 
stage of differentiation/position on the hematopoietic hierarchy. At 7-10 days cobblestone 
areas indicate committed lymphoid progenitors, and cobblestone areas which persist at 5-8 
weeks are less mature leukocytes. The presence of these colonies correlates with long term 
repopulating cells [134], although there is insufficient evidence to say that they actually 
represent LT-HSC. 
The most commonly used stromal cell line is OP9 cells, which are a from a mouse line 
deficient for M-CSF, making them unable to support macrophage development which allows 
other hematopoietic cell types to develop. OP9s can be used to support both B and T 
lymphocytes [135]. OP9s have also been used to support hematopoiesis from pluripotent cells 
(see introduction section 1.3). Notch signalling is critical for T cell development [136] so 
OP9 cells modified to express delta ligands DL1 or DL4 have been used to support the 
differentiation of T cells [137]. In co-culture with human cells they are also supplemented 
with IL7 and FLt3l. This assay is particularly important for this project as T cells are 
considered to only arise from definitive HSCs and have been used as evidence for HSC 
presence by Kennedy et al [8], although a recent paper has shown that T-cells may be able to 
arise independently  [79], and long term T-lymphocyte regenerating cells have to been 
demonstrated to exist in P-HPC experiments. T cells can be tested for with a set of markers 
including CD4 and CD8. 
42 
 
This technique can be quantitative with the use of limiting dilutions, however the use of 
animal cell lines which can behave very differently in at different times and in different hands 
severely limits the reliability of this assay. 
 
3.2.3 Colony forming unit (CFU) assays 
 CFU assays are the most commonly used in vitro assay for determining the numbers of 
hematopoietic progenitors in a sample. They are used both in basic research and in diagnosis 
of haematological malignancies and diseases of the bone marrow [138]. The assay is done by 
plating hematopoietic progenitor cells in methylcellulose supplemented with hematopoietic 
cytokines. The methylcellulose is viscous enough to prevent colonies from dispersing, 
allowing them to be easily counted. Cytokines, including EPO, SCF, GM-CSF and IL3 are 
used to encourage the cells to differentiate. The test can distinguish several types of 
hematopoietic colony on the basis of morphology; The most common are lineage restricted 
colonies such as colony forming unit granulocytes (CFU-G), colony forming unit 
monocytes/macrophages (CFU-M), colony forming unit erythrocytes (CFU-E) and the larger, 
less mature burst forming unit erythrocytes (BFU-E), but there are also multi-lineage colony 
forming units, colony forming unit granulocyte-monocyte (CFU-GM) and colony forming 
unit granulocyte erythroid monocyte (CFU-GEMM) derived from more primitive multi-
lineage precursors [133]. CFU-GEMM colonies are the rarest but the most important for this 
project as they have multipotent potential and are therefore the ones most similar to HSCs. 
However CFU assays cannot measure HSC potential directly, as a CFU-GEMM could also be 
produced by multipotent progenitors or common myeloid progenitors. Although there is some 
subjectivity in the way the colonies can be scored they are morphologically distinct enough 
that this is considered a quantitative method. 
In the absence of supporting stromal cells the hematopoietic progenitors can’t differentiate 
into lymphocytes, so this assay can only test for erythroid, myeloid and megakaryocyte 
lineages. Although this assay is limited in that it does not measure lymphoid potential or long 
term potential it is useful in that it is relatively quick and simple to run, requires far fewer man 
hours and less technical expertise than CAFCs or transplant assays, and the lack of animal cell 
lines make it relatively reproducible. 
 
3.2.4 Gene expression 
 Hematopoietic cells of different types express specific genes. The expression of a particular 
gene in a sample can be measured by qPCR, allowing a determination to be made about 
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whether or not it is possible that they are HSCs. In murine embryos gene expression of 
emerging HSCs has been studied at the single cell level [139]. However, demonstrating the 
expression of any one gene is not enough to prove that HSCs are present because there are no 
known genes which are specific to only HSCs; many of the hematopoietic genes are expressed 
at even higher level in more differentiated hematopoietic cells, and other genes reduce in 
expression as HSC differentiate, so low expression may mean that the cells are terminally 
differentiated or that they are not hematopoietic at all. It is possible to make comparisons of 
the level of gene expression for these key hematopoietic genes between P-HPCs and 
hematopoietic progenitors which are derived from bone marrow or cord blood. 
There are several key transcription factors which a HSC must express. HSC are specified in a 
stepwise manner in the embryo, and this is achieved by the carefully timed switching on of 
particular genes: Brachyury is used to specify mesoderm [140], which is further specialised 
into hemogenic mesoderm by KDR [52, 65], and later into hemogenic endothelium by the 
expression of SCL [9, 141-144] and TGFβ [145]. SCL and GATA2 are responsible for 
promoting the expression of RUNX1, which allows EHT to occur and thereby promotes 
definitive HSC formation in the AGM [71, 146-148].  
HOX genes are also essential for specifying hematopoietic cells, there are several involved in 
hematopoiesis [50, 149, 150], and in general they are highly expressed in HSC but expression 
decreases as the cells differentiate. HOXB4’s role in hematopoiesis has been extensively 
studied as ectopic expression has been shown to enhance engraftment [151] and can even 
reprogram mESC derived primitive hematopoietic progenitors into LT-HSCs [50]. HOXA9 is 
also a key hematopoietic gene and has been shown to be one of the most differentially 
regulated genes in HSC compared to P-HPC [150]. 
There are also several master transcription factors which control hematopoietic cell fate and 
lineage specification. For example GATA1 promotes erythroid cell fate [109, 152], CEBPA is 
required for granulocyte/macrophage development [153] and PU.1 is necessary for 
macrophages and B-cells [99, 101, 154]. 
3.2.5 Cell surface markers and flow cytometry 
The methods described so far have been retrospective, by the time the test produces 
meaningful results the cell types being tested for are gone, but cells of different types can be 
distinguished from one another by the proteins or ‘markers’ which are expressed on their 
surfaces. Fluorescent conjugated antibodies of different colours bind to the markers on the 
cells and the combination of the antibodies is used to determine cell type. This can be done in 
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fixed tissues using immunostaining or in live or fixed single cells using flow cytometry. Blood 
cells are usually found in suspension and it is often clinically useful to be able to analyse and 
sort live blood cells so blood is usually analysed using flow cytometry. Fortunately the study 
of normal and pathogenic blood cell types by flow cytometry is well established, markers for 
all the blood cell types found in adults have been extensively studies and validated and 
antibodies for many different blood markers with different fluorescence spectra are available 
commercially, allowing us considerable flexibility in these experiments. 
 
Markers for LT-HSC: CD34 has long been used to isolate hematopoietic progenitors for 
transplant but this population, although it contains LT-HSC, is mostly made of more 
differentiated progenitors. CD45RA [155, 156] and CD38 [157] were found to exclude the 
CD34+ population with hematopoietic reconstitution potential  and the CD90+ population 
was found to contain all LT-HSCs. This combination of markers alone still cannot isolate LT-
HSCs at the single cell level [158], this was only achieved by Notta et al [159] when they 
discovered that CD49f is exclusively expressed on LT-HSCs within the CD34+CD38-
CD45RA-CD90+ population. This combination of markers can isolate single cells capable of 
reconstituting long term multi-lineage hematopoiesis from bone marrow, although it has not 
been demonstrated that pluripotent derived cells bearing these markers are capable of the 
same. 
Markers for embryonic hematopoiesis:  Markers for human embryonic hematopoiesis are 
less well studied than those for adult hematopoiesis. In mice the SLAM markers 
CD150+CD48- represent HSCs [160]. However, although there is some similarity and 
overlap between the markers on mouse and human hematopoietic cells there are enough 
known differences as to make it impossible for us to conclude that a combination of markers 
which are found on one cell type in mice are the same as in human cells [161].  
Studies in human foetal tissue are rare and few of them have been done at the time point 
which is most useful for us, i.e. approx. 6 weeks, when definitive cells start to appear in the 
AGM. Almost all of our knowledge of the markers for embryonic development hematopoietic 
cells comes from in vitro studies of differentiating PSCs. This presents a problem in that 
although cells made in vitro to those found in vivo are comparable in terms of morphology 
and gene expression they don’t necessarily form in exactly the same way. It is also impossible 
to study the very first markers of HSCs this way, even though it is in these markers we are 
most interested, since it has not yet been demonstrated that HSCs can be made in vitro at all. 
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Historically, the two most important markers for studying hematopoietic stem cells were 
CD34 and CD45. CD45 is a ‘pan-hematopoietic’ marker which is expressed on all 
hematopoietic cells except mature erythrocytes and can be used to distinguish blood cells 
from any other type of cell [162, 163]. CD34 is a marker for hematopoietic progenitors, and is 
expressed on LT-HSCs as well as ST-HSCs, MPPs and some more differentiated 
hematopoietic progenitors [54]. However when analysing cells differentiated from PSCs it is 
necessary to use other markers as CD34 is also expressed on endothelial cells and haemogenic 
endothelium [54] and CD45 does not appear on the very earliest hematopoietic population to 
arise [65].  
The primitive streak mesoderm from which hematopoietic cells eventually arise expresses 
Brachyury, the subset of cells which will eventually give rise to hematopoietic cells also 
express endothelial marker KDR [164]. Other endothelial markers such as CD34 and CD31a 
are expressed on both endothelial cells and the haemogenic endothelium [54, 165]; the earliest 
markers which can distinguish hematopoietic potential are CD43 [65] and CD41a [148, 166], 
cells begin to express CD45 as they undergo EHT [167, 168], and lose expression of 
endothelial markers such as CD31a and VE-Cadherin at the same time. Hematopoietic cells 
express both CD34 and CD45 for a time and lose CD34 expression as they develop. All CFU-
GEMMs develop from the CD34+ population [65]. 
Experiments by Vodyanik et al [65] where differentiating PSCs were sorted for these cell 
surface markers and then analysed for their colony forming potential showed that the 
CD34+CD43+CD235a+CD41a+CD45– cells represented megakaryocyte-erythroid primitive 
progenitors.  The same  paper shows that CD34+CD43+CD41a–CD235a–CD45– cells were 
multipotent myeloid progenitors and Kennedy et al [8] confirmed these results and 
demonstrated that CD34+/-CD43+CD235a-CD41a-CD45+ cells are definitive progenitors 
capable of lymphopoiesis.  
3.3 Choosing a protocol for hematopoietic differentiation 
Protocols for hematopoietic differentiation from pluripotent stem cells have been developed 
for some time (see introduction section 1.3), with progressive improvement in yield and the 
ability to make more of the different definitive and primitive cell types. Although co-culture 
methods have proven successful in many ways it is more useful to use an EB protocol with 
defined factors as this is more reliable than using animal cells and it has more translational 
potential. Initially the protocol described by Kennedy et al in 2012 [8] (see methods section 
2.1.2) was chosen, as it a) makes use of defined factors and medium, b) is similar to the one 
used to generate the microarray data, since it was developed by the same group and c) because 
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it was shown to produce T-lymphocytes, considered a stand-in for HSC potential, as well as 
all other hematopoietic lineages. 
Unfortunately the protocol proved challenging in our hands, requiring very high numbers of 
pluripotent stem cells to produce very small numbers of EBs and frequently failing to produce 
any EBs entirely. This was a serious limiting factor in the early part of the project, making it 
difficult to produce enough hematopoietic progenitors to experimentally analyse (see Figure 
3.1).  
Fortunately our collaborators Dr Joanne Mountford and Dr Scott Cowan at the University of 
Glasgow had developed a protocol for the differentiation of erythroid cells [2]. Our lab 
modified this protocol by differentiating only up to the progenitor stage (a schematic for this 
protocol is shown in Figure 3.2, a more detailed description of the protocol is in methods 
section 2.1.2). This protocol was far more efficient and reliable than the previous one. It can 
reliably produce hundreds of EBs from a single well of pluripotent stem cells which, once 
formed can produce hematopoietic cells of all the same types as the Kennedy protocol with at 
least equivalent efficiency (see Figure 3.1). The Kennedy protocol was abandoned early in 
the project in favour of the one from the Glasgow group, and all the experiments in this 
project were done using cells made with the Glasgow protocol unless otherwise stated. 
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Figure 3.1a 
 
Figure 3.1b 
 
Figure 3.1a: Graph showing mean+SD for the number of embryoid bodies per well of H9 cells at 
day 3 for each protocol. n = 3  
Figure 3.1b; Graph showing comparison between the number of primitive or definitive 
hematopoietic progenitors produced by each protocol at day 12. Mean+SD n=3. 
Primitive=CD34low/-CD43+ CD235a+CD41a+, Definitive=CD34low/-CD43+CD45+. 
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The major difference between the protocols is in the way EBs are formed, with the Kennedy 
protocol dissociating the pluripotent cells into single cells and then re-aggregating them. The 
advantage of this method is that it allows precise control over the size of the embryoid body 
using Aggrewell
TM
 plates, which is important because 500-1000 cell EBs are optimal for 
hematopoietic development [169]. However human stem cells are not able to survive as single 
cells, and rapidly undergo anoikis when dissociated. This problem can be overcome using 
Figure 3.2 
 
Figure 3.2: Schematic of Glasgow protocol as used in this project, adapted from figure in Olivier 
et al [2] 
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ROCK inhibitor [170], but inhibiting the ROCK pathway inhibits hematopoiesis [171]. 
Without ROCK inhibitor the cells failed to form reasonable numbers of EBs. In contrast,  the 
Glasgow protocol uses the EZ-roller to cut out uniformly sized squares of cells in the correct 
size for EBs (see methods section 2.1.2) , and as the cells are not split into individual cells it 
avoids the problem of anoikis.  
The Glasgow protocol also used a slightly different combination of cytokines so there was a 
question of whether the Glasgow or Kennedy cytokines should be used after using the 
Glasgow method for EB formation. Work by my colleague Dr Jarmila Spegarova showed that 
the Glasgow cytokines produced a slightly higher yield of progenitors (data not shown). 
The Glasgow protocol is able to produce all the major blood lineages: lymphocytes, as 
shown by our CAFC results (see Figure 3.3), and granulocytes, monocytes and erythroid 
cells, as shown by our CFU data (see Figure 3.5). Use of the cell surface markers described 
by Kennedy et al (see results section 3.2.5) shows that their protocol can produce both 
primitive and definitive hematopoietic progenitors. There is also a small population of cells 
which express CD34+CD38-CD45RA-CD49f+CD90+ (see results section 3.2.5) at day 12 
(see Figure 5.7). Although it is assumed that the hematopoietic progenitors produced by these 
cells are foetal in character and it is not known what combination of markers the earliest 
HSCs that arise in the human embryo express, and this combination of markers cannot 
unambiguously be said to represent HSCs in this context, it is encouraging that this 
population exists in our cultures. The efficiency, defined nature, and success at producing 
diverse hematopoietic progenitors makes this protocol ideal for assessing the effect of miRNA 
expression on HSC potential. 
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The Glasgow protocol recapitulates embryonic hematopoietic development: First, 
mesoderm is formed, then endothelial cells (KDR+CD31a+CD34+CD45-), followed by 
primitive hematopoietic cells (CD43+CD34+/-CD41a+CD235a+CD45-), and finally 
definitive cells (CD43+CD34+/-CD41a-CD235a-CD45+) (see results section 4.2). The 
dissociation and plating of the progenitors at day three allows colonies of endothelial-
hematopoietic progenitors to grow, and clusters of rounded hematopoietic cells can be seen 
arising from the adherent endothelial colonies –the same morphological progression which 
has been observed in developing hematopoietic cells in the foetal aorta [58] (see introduction 
section 1.3), which provides an immediate visual confirmation of hematopoietic development 
(see Figure 3.4). 
In this project both a hESC line and a hiPSC line have been used (H9 and SB-Ad3 
respectively). This is important because several papers have shown differences in the 
effectiveness of hematopoietic differentiation between ESCs and iPSCs [37, 38]. The H9 and 
SB-Ad3 lines in particular were chosen because they are established, well-characterised lines 
Figure 3.3 
            
Figure 3.3: Representative micrograph of CAFC assay. Colonies with cobblestone 
morphology can be seen (green arrows). Bar represents 200 µm. 
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which are known to be easy to culture and can be reliably differentiated into many cell types 
(see methods section 2.1.1). 
52 
 
 
Figure 3.4a 
 
Figure 3.4b 
 
Figure 3.4a: Representative micrograph of day 3 H9 EBs. Bar represents 500 µm 3.4b: 
Representative micrograph of day 4 colonies. This image is of SB-Ad3 derived cells but 
both H9 and SB-Ad3 show the same morphology. Small colonies of endothelial-like 
cells can be seen (green arrows). Bar represents 100 µm 
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Figure 3.4c 
 
Figure 3.4d 
 
Figure 3.4c: Representative micrographs of day 6 H9 derived hematopoietic colonies. 
SB-Ad3 colonies have the same morphology. The bar on 3.4c  represents 200 µm, 3.4d 
represents 100 µm. Colonies at day 6 are larger; cells with endothelial morphology can be 
seen around the edges of the colonies (green arrows) and some cells are beginning to 
round up and ‘bud off’ the colonies (red arrows), similar to in vivo hematopoietic cluster 
formation. 
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3.4 The effect of passage number on hematopoietic differentiation 
CFU assays: During the course of this project, in spite of using an improved protocol it 
became clear that the results of many of our experiments were inconsistent, giving variable 
results from one repeat to another. While searching for an explanation for this problem a 
pattern in the colony forming assay results became clear; fewer hematopoietic colonies are 
formed from pluripotent stem cells at later passages (see Figure 3.5). The trend is clear in 
both the H9 and SB-Ad3 cell lines, numbers of all colony types are reduced at later passage, 
although not all of them have statistical significance. The trend is particularly obvious in the 
erythroid colony potential as day 12 hematopoietic progenitors can produce up to several 
hundred per plate at passage <40 but consistently none or almost none at passage >60.  
Although there are is not enough data to show significance for all of the different colony types 
there is a clear downward trend in the number of cells with any type of hematopoietic 
potential.
 
Figure 3.4e: Representative micrograph of day 12 hESC derived haematopoietic cells. 
The majority of cells are in suspension at this point, in both the H9 and SB-Ad3 
experiments. Bar represents 200 µm. 
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Figure 3.5a 
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Figure 3.5b 
                        
Figure 3.5: Scatterplots showing colony numbers of hematopoietic cell types (per 30000 live cells) vs. passage number for a: H9 cells and b: SB-Ad3 cells. Red 
lines indicate that the line of best fit deviates significantly from horizontal. 
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Flow cytometry assays: Having observed this pattern in the CFU data it became important to 
re-analyse the flow cytometry data which had been gathered throughout this project. The cells 
were analysed using the Kennedy 2012 markers (see results section 3.2), and using these 
were divided into Definitive hematopoietic cells, Megakaryocyte erythroid progenitors 
(MkEps), and multilineage myeloid progenitors (MMps).The data show a weaker trend than is 
seen in the CFU data (see Figure 3.6). There may be a small decrease in MkEps and a small 
increase in definitive cells at late passage, but the change is not significant. 
 
Importance of passage number to the project: It is clear that there is a decrease in 
hematopoietic potential as passage number increases, and that this loss of potential does not 
affect all hematopoietic cell types equally. It is essential to recognise the importance of this 
discovery to the project, as failing to do so leads to misinterpretation of the results. For 
example it had appeared earlier in the project that the hiPSC line, SB-Ad3 had greater 
Figure 3.6 
 
Figure 3.6: Scatterplots numbers of hematopoietic cell types (as a percentage of live cells) vs. passage 
number for H9 cells and SB-Ad3 cells. None of the results are statistically significant. 
MkEp = Megakaryocyte erythroid progenitors CD43+CD34+CD235a+CD41a+CD45-, 
MMp = multilineage myeloid progenitors CD43+CD34+CD235a-CD41a-CD45- 
Definitive = CD43+CD34+/-CD235-CD41a-CD45+ 
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hematopoietic potential than the H9 hESC line, however this apparent difference was due to 
the lower passage number of the more recently derived hiPSC line rather than a biological 
difference between ESCs and iPSCs. It also complicates the interpretation of results published 
by other groups, as some papers have reported better results with hiPSC lines than hESC lines 
[37], but different results between different cell lines may be due either to the biology of those 
lines or passage number. Information about passage number is almost never reported in these 
papers. Attempts to transplant PSC derived hematopoietic cells have almost always been done 
using well established and well characterised lines, for the same reasons as they have been 
used in this project, but this means that the cells used would likely not have been very early 
passage, which may be optimal for avoiding the loss of hematopoietic potential described 
here. Unfortunately it has not been possible to acquire very early passage (< 30) H9 or SB-
Ad3 cells for analysis of their hematopoietic potential so it is not clear if hematopoietic 
potential would continue to improve at increasingly lower passages.  It's important to note that 
although little has been published on the effects of very high passage number on 
differentiation potential of pluripotent stem cells it is well known in the field that yields of 
many different desired cell types can decrease at high passage number, and few of my 
colleagues continue to grow their cells after passage 60. The biological explanation for this is 
not definitively known, and my results suggest that the effect of passage number can be seen 
before the passage 60 cut off point, so this phenomenon is worth further study, both for this 
project and the field as a whole. 
 
Identifying the unknown cell type: The flow cytometry results are given as a 'percentage of 
live cells', and the colony assay results are from a starting point of 30,000 live cells per well, 
so the differentiating cells are not disappearing or dying; they are becoming a non-
hematopoietic cell type. Whatever the effect of passage on the cells it caused them to 
differentiate along another differentiation pathway in spite of the hematopoietic cytokines that 
they were being exposed to. 
 
Flow cytometry of mesenchymal markers: The morphology of the cells is important in 
determining what cell type that these late passage cells become. Colonies of large adherent 
cells were seen in the colony assays at late passage, in contrast to the small round suspended 
hematopoietic cells produced in earlier passage experiments. These adherent cells are either 
polarised or have multiple processes (see Figure 3.7a). As it was not unusual to see 
occasional colonies of endothelial cells in CFU experiments from earlier passages the initial 
assumption was that these were also endothelial cells, which had been prevented by an 
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unknown mechanism from transitioning into hematopoietic cells. The cells seen at late 
passage do not form the 'spider web'-like structures which are typical of HUVEC (human 
umbilical vein endothelial cells) and which are seen in the endothelial colonies at early 
passages (see Figure 3.7b), however the colonies are more confluent so this might account 
for the differences in morphology. In order to confirm this, late and early passage cells were 
analysed by flow cytometry using a combination of markers designed by Vodyanik et al [172] 
to separate endothelial, mesenchymal and hematopoietic precursors made from hESCs. The 
results of this experiment confirm that the endothelial population is not increasing but do not 
prove that the mesenchymal population is increasing at late passage (Figure 3.7c). 
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Figure 3.7a                                                    Figure 3.7b 
   
Figure 3.7c 
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Figure 3.7d 
 
 
Figure 3.7a: Micrograph of cells found in late-passage CFU cultures. Large flat cells 
with multiple processes can be observed. Bar = 200 μm. 
Figure 3.7b: Micrograph of adherent cells typically found in earlier-passage CFU cultures. 
Morphology is typical of foetal endothelial cells: ‘lacy’ or ‘spiderweb’ shaped colonies. Bar = 
200 μm. 
Figure 3.7c: Graph of flow cytometry data showing change in cell types found in day 12 SB-Ad3 
cultures from early and late passage experiments. ‘Hematopoetic cells’ =CD43+CD34+/-, 
Mesenchymal cells= CD43-CD90+CD73+, Endothelial cells = CD34+CD43-. 
Figure 3.7d: Representative flow cytometry plots for high and low passage differentiated cells 
showing H: hematopoietic cells CD34+/-CD43+, E endothelial cells CD34+CD43-, and M: 
mesenchymal cells CD43-CD90+CD73+ 
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 Gene expression results: In parallel to these experiments the change in gene expression 
from day 12 cells made at late passage compared to early passage was analysed. Since there is 
a possible change in the lineage bias, genes involved in lineage specification (GATA1, PU.1, 
CEBPA, ERG) were analysed as were genes associated with HSCs (SCL, TGFB, GATA2, 
RUNX1a) and genes involved in epigenetic changes (EZH1 TET1, TET3), as it is possible that 
there is some gradual epigenetic change which is responsible for the differences in lineage 
commitment at late passage (see Figure 3.8). 
 The qPCR results show very little change in most of the genes, the only gene which is 
significantly changed in both cell lines is CEBPA, which was analysed because it is a gene for 
myeloid lineage specification. However, it is also a gene which is highly expressed in MSCs 
[173], which is consistent with the morphology of the cells seen in CFU cultures at late 
passage but not with the flow cytometry results, although an increase in CEBPA could also 
explain the changes in which colonies are most frequent in the CFU assays as CEBPA pushes 
hematopoietic progenitors towards the monocyte lineage and away from the erythrocyte 
lineage [153]. There is little change in the expression of the epigenetic regulator genes but it is 
possible that epigenetic markers could shift slowly over time in culture without showing a 
major change in the regulatory genes which would fit with the slow and gradual change in 
hematopoietic potential, so this result does not conclusively rule out an epigenetic cause. 
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Figure 3.8a: Genes associated with HSCs 
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Figure 3.8b: Genes associated with hematopoietic lineage commitment 
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Changes in miRNA expression: miRNA mis-expression has been suggested as the cause of 
the failure of P-HPC to thrive in vivo (see section 1.4.4). This mis-expression could be due to 
the use of later-passage, more established PSC lines so miRNA identified as mis-expressed in 
results section 4.2 were analysed at late and early passage derived hematopoietic progenitors. 
The expression of several key miRNAs was analysed at late and early passage, only a few of 
the changes are significant and there is little in the way of a clear pattern which runs across 
both cell lines. However the down-regulation of miR-148 is consistent with the results 
showing fewer hematopoietic cells as this miRNA is hematopoietic specific. The increase in 
the other miRNAs at late passage in SB-Ad3 derived cells (see Figure 3.9) is consistent with 
an increased adhesion phenotype as these miRNAs are EMT suppressors (see results section 
4.2). 
Figure 3.8c: Genes controlling epigenetic changes 
 
 
Figure 3.8: Graphs of qPCR data for H9 and SB-Ad3 cells showing ΔΔCT of high and low 
passage cells at day 12 of hematopoietic differentiation. a: genes associated with HSCs, b: genes 
associated with differentiation towards specific lineages, c: genes associated with epigenetic 
changes. Graphs show mean±SEM, n=3, significant results (p<0.05) are shown with a *. 
Housekeeping gene = GAPDH 
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CytoSNP results: established stem cell lines are expected to be genomically stable, however 
the medium that is used for this project, STEMPRO is not typical and is not as commonly 
used as feeders or mTESR. The protocol has been tried by my colleague Dr Jarmila 
Spegarova using mTESR rather than STEMPRO but this was found to be ineffective. Both 
mediums use mercaptoethanol which protects against mutations caused by free radicals. 
CytoSNP was used to analyse both cell lines and to compare earlier passage cells of each line 
to later ones. The cytoSNP results are striking, showing duplications in chromosome 12 in 
both cell lines at later passage (see Figure 3.10). The SB-Ad3 cell line also shows a 
duplication of a large section of chromosome 1 at late passage and a duplication of part of 
chromosome 9 at early passage which does not appear in the later passage cells. 
The literature about chromosomal abnormalities in pluripotent stem cells mostly focuses on 
the mutations which arise during reprogramming or early passages, but there are a few papers 
which focus on the effect of extended passaging [174-177].  
Figure 3.9 
 
Figure 3.9: Graph showing qPCR data of key miRNAs at high and low passages at day 12 of 
differentiation. Calculated using ΔΔCT method. P = Passage number. Data is shown as mean±SEM, 
n=3, significant results (p<0.05) are shown with a *. 
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3.4.1 Mutations in PSC lines 
Origin of mutations: Mutations found in iPSCs can originate in several ways. Some are 
amplified from mutations found at low levels in the original tissue from which they are 
derived [178], some are caused by the stress of reprogramming [179], and others arise 
spontaneously during long term culture of the cells [174]. Most of these mutations are caused 
by oxidative stress, which is a particularly acute problem in pluripotent stem cells because of 
their constant proliferation. Pluripotent stem cells compensate for this problem by repairing 
Figure 3.10c H9 early passage                      Figure 3.10d H9 late passage 
  
Figure 3.10: Schematic of CytoSNP data comparing mutations in late and early passage 
cells. Green = duplication, Red = deletion. 3.10a = passage 45, 3.10b = passage 64, 3.10c 
= passage 47, 3.10d = passage 75. 
Figure 3.10a SB-Ad3 early passage                Figure 3.10b SB-Ad3 late passage 
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their DNA using homologous recombination or NHEJ, although they are more likely to use 
the more accurate homologous recombination, which means they have a base rate of mutation 
around 10 times lower than somatic cells in culture [174, 180]. They are also sensitive to 
DNA damage which they can’t repair and will activate the G1/S checkpoint and stop 
proliferating [181].  However, in the long term, and with hundreds of thousands of cells 
dividing constantly, some mutations are eventually inevitable. 
Selection for advantageous mutations: All pluripotent stem cells which have been studied 
appear to have at least a low level of mosaicism within the culture. According to Laurent et al 
[182] this mosaicism undergoes ‘dynamic shifts’, with populations of a specific mutation 
growing and shrinking over time due to a drift effect, which explains the duplication in 
chromosome 9 in the early passage SB-Ad3 cells which does not appear at later passage. 
However there are a few mutations which are selected for in pluripotent stem cell culture. 
Deletion of chromosome 17 and duplications of all or part of chromosome 20 and 
chromosome 12 are the most common mutations found in PSC culture [175-177]. All three 
mutations have the effect of maintaining stemness and preventing apoptosis. The region of 
chromosome 12 which is commonly duplicated contains the gene NANOG, a pluripotency 
factor. High expression of this gene protects the cells from apoptosis via the p53 pathway 
[183]. Assuming the chromosome 12 duplication impairs hematopoiesis, the results can be 
explained by a duplication arising in each of the H9 and SB-Ad3 cultures and gradually 
coming to form a larger percentage of the culture due to the survival advantage it confers. 
Mutations which maintain stemness impair hematopoietic differentiation: Chromosome 
12 contains many other genes aside from NANOG, including a HOX gene cluster, but it does 
not contain CEBPA, so the increased expression of CEBPA cannot be directly explained by the 
duplication although it may be indirectly controlled by any of the transcription factors on 
chromosome 12. Many of the genes on chromosome 12 might have a negative impact on 
hematopoiesis if incorrectly expressed, however a study of a chromosome 20 duplication in 
another iPSC line showed a similar phenotype upon differentiation in EBs: no hematopoietic 
cells were formed, and the EBs were made of mostly immature mesenchymal cells [184]. This 
suggests that it is not any particular gene on chromosome 12 which impairs hematopoiesis, 
but rather an effect of the high expression of pluripotency factors. Some of my colleagues 
have observed a similar effect in late passage cells on the differentiation of other highly 
specialised cell types such as RPE. In EBs which have these mutations OCT4 and other 
pluripotency markers are expressed for longer [184, 185]. It seems that these mutations have 
the effect of slowing or stopping the specialisation process, leaving the cells in an immature 
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or undifferentiated state. This may explain the greater changes seen in the CFU results 
compared to the flow cytometry data: the colony forming cells have been cultured for a 
further 14 days to a terminally differentiated state, the mutations may be blocking this final 
stage of differentiation rather than the earlier stages. No studies have specifically analysed 
hematopoietic differentiation in these mutated cells as they are more concerned with the 
potential tumorgenicity of the mutated cells. 
The flow cytometry results show a much weaker downward trend compared to the CFU 
assays.  This is unexpected as a loss of hematopoietic potential should lead to fewer cells 
expressing hematopoietic markers. However the cells are analysed by flow at day 12 of 
differentiation and the antibodies used are for markers of hematopoietic progenitors. On the 
other hand the colonies are assessed 14 days after that and are testing for terminally 
differentiated hematopoietic cells so it is consistent with the theory that the duplication of the 
pluripotency gene, in this case NANOG, prevents the cells from fully maturing. 
It may be impossible to entirely avoid this problem, however culture conditions which reduce 
the amount of stress on the cells, such as passaging them mechanically rather than 
enzymatically have been shown to reduce the number of mutations which arise [183, 186]. 
Although the tissue culture methods used in this project involved mechanical passaging and 
mercaptoethanol in the medium to reduce the number of free radicals, the cells were also 
cultured in feeder free conditions, which has been shown to have a higher rate of mutations 
than cells grown on feeders [175, 183]. This is a problem that will need to be overcome before 
stem cells can be widely used in a clinical setting. 
 
3.5 Statistics 
The results shown in this chapter were gathered and analysed at a late stage in the project, 
from controls which had been done for experiments on miRNA analysis and inhibition (see 
results sections 4 and 5).  As this trend did not become obvious early on, many of the 
experiments done on this project have been repeated at very different passage numbers, which 
caused them to have a large amount of inter-repeat variability, making effective statistical 
analysis difficult. The original intention for these experiments was to perform ANOVA to 
assess the significance of the difference between the controls and the various miRNA 
inhibited cells, but this will not give meaningful results as there is too much variation. The 
most useful solution was to use ANCOVA instead, a variation of ANOVA which takes into 
account a confounding variable, in this case passage number. See methods section 2.10 for 
details of how this analysis was performed. Passage number variability also creates a 
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challenge in visualising the data: bar charts can't take into account the covariate and scatter 
plots quickly become unreadable when more than one experimental condition is plotted. 
Fortunately the ANCOVA analysis can provide a solution, in the form of 'Estimated Marginal 
Means' (EMMs) which, as the name suggests, are estimates of the mean adjusted for the 
covariate, allowing us to plot, for example, estimates of the number of CFU-G colonies for all 
experimental conditions, if all the experiments had been done at passage 50. The CFU and 
flow cytometry results in later chapters are given in this form. Although some of the results in 
this chapter are from cells as late as passage 70+, all of the data shown in the later chapters 
was calculated from cells at passage <56, which allowed more meaningful results to be 
obtained. 
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4. Results: miRNA expression analysis 
 
4.1 Methods for expression analysis 
Novel miRNAs are discovered via cloning, and northern blot is used to confirm their 
existence [187]. miRNAs can also be predicted by algorithms which search the genome for 
conserved sequences with structure similar to known miRNAs. 
Since their discovery, various techniques have been developed which can allow us to analyse 
the localisation and quantity of miRNA transcripts being expressed in a particular cell line, 
tissue or organism. There are several challenges in determining miRNA expression: it is 
difficult to design specific probes or primers for miRNAS as their GC content varies widely 
leading to very different melting temperatures, and they are small and have high levels of 
homology within miRNA families. This is further complicated by the multiple stages of 
processing miRNAs go through; probes and primers must be specific to the mature miRNA 
and not one of the earlier stages, as pri- and pre- miRNAs are often expressed at drastically 
different levels than the corresponding mature miRNA. The mechanisms which control the 
amount of precursor molecules which are processed into active miRNAs are not well 
understood but they produce important functional effects [188]. The various methods which 
have been used to overcome these technical challenges are discussed below. 
Microarrays are a useful way of quickly assessing hundreds of miRNAs:  A slide is 
printed with 1000s of oligos homologous to miRNAs and the RNA from the sample is 
conjugated to a fluorescent dye and allowed to hybridise to the oligos on the slide. 
The accuracy of microarray analysis is limited because of the short length and varying 
melting temperatures of the miRNA but this problem can be ameliorated in several ways. 
Altering the length of the probes can solve the problem of the differences in melting 
temperature [189], but it can further reduce the specificity of probes which are already very 
short. Another solution is to chemically alter the probes to increase hybridisation stability, for 
example using locked-nucleic acids (LNAs) which allow hybridisation over a wider range of 
temperatures [190].  
Probes are also printed multiple times in different places on the slide as this allows the 
researchers to take an average which is more accurate, and reduces the problems caused if the 
slide gets scratched or contaminated with dust. 
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In spite of these efforts, microarrays are still limited in their accuracy and are often poor at 
distinguishing between mature miRNAs and their precursors. However they are still 
frequently used as a first step in studying the role of miRNAs in disease, because they allow 
rapid screening of thousands of candidates. In these experiments a panel of thousands of 
miRNAs is used to compare diseased and healthy tissue and this comparison is used to 
suggest which miRNAs should be validated by other methods and further studied for their 
role in pathogenesis. 
qPCR can accurately analyse the expression level of a miRNA: qPCR is often used to 
validate specific miRNAs which have been identified as being of interest by microarray data. 
In qPCR the RNA in the lysed cells is converted to cDNA, PCR is then performed on this in 
the presence of a fluorescent DNA dye. The fluorescence level is measured during every PCR 
cycle which allows precise quantification of the target. A value is assigned to the sample 
based on the number of cycles it takes for the fluorescence to reach a particular level. This is 
known as the Ct value. qPCR can be used to assess the absolute or relative quantity of the 
target miRNA, in absolute quantification the Ct value is measured against a serial dilution of 
RNA of a known quantity and in relative quantification the Ct values of two samples are 
compared using a housekeeping small-RNA as an internal control using the ΔΔCT equation:  
ΔΔCt = ΔCt,sample - ΔCt,reference 
When performing qPCR on the mRNA for a gene, reverse transcription to create cDNA is 
performed using random short primers and/or oligo(dT) primers. However miRNA transcripts 
don’t have polyA tails and are much too short for the random oligo hexamers to bind to. The 
first widely used solution found was to create specific primers for reverse transcription of a 
particular target miRNA [10]. In order to work specifically in spite of the short transcript the 
primer is designed to form a stem loop, with the homologous region overhanging (see Figure 
4.1). This solution is effective and allows specific amplification but it requires cDNA to be 
made separately for each miRNA studied.  This means that more sample must be used for 
each test, and reduces accuracy by increasing the chance of pipetting errors as well as being 
more time consuming for the researcher. 
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A more recent innovation [191, 192], allows a polyA tail to be enzymatically conjugated to 
the miRNA before reverse transcription. cDNA can then be made by reverse transcription can 
then be done using an oligo(dT) primer. qPCR remains the most accurate and specific method 
of quantifying the expression of an individual miRNA. 
Other methods for miRNA analysis: In addition to these methods levels of miRNA 
expression can be estimated using in situ hybridisation, which shows localisation in cells and 
tissues. The role of miRNAs in development has been studied using genetic modification to 
tie expression of a specific miRNA to a fluorescent marker, for example and cells which 
constitutively express Luciferase or GFP with 3’ complimentary sequence to miRNA of 
interest and a bioluminescent or fluorescent protein of another colour under the same 
promoter but without the miRNA binding region acting as an internal control [193, 194]. 
These methods are good for information on the localisation of miRNAs but are not 
quantitative. Electrochemical biosensors for detection of miRNA are being developed as well 
[195], but recent advancements in RNA-Seq technology mean that it is now potentially viable 
to replace other methods such as microarray and qPCR [196]. 
Figure 4.1 
                               
Figure 4.1: Schematic showing how the two-step stem-loop Taqman miRNA RT-PCR system 
works. [10] 
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4.2 Microarray analysis comparing hematopoietic progenitors derived from hESCs or 
bone marrow 
Microarray analysis comparing miRNA expression in hematopoietic progenitors to hESC 
derived progenitors was done by Dr David Blesa (CIPF, Valencia, Spain) before the start of 
the project. The cells analysed were two hESC (H9) replicates, day 4 P-HPCs and CD34+ 
human bone marrow cells. This allowed a comparison between the expression of over 800 
miRNAs in bone marrow derived HSCs, P-HPCs, and the pluripotent cells they were derived 
from. The expression of the miRNAs in these cell types can be divided into six broad patterns, 
as shown in Figure 4.2. The expression is plotted in the order hESC1, hESC2, P-HPCs and 
bone marrow, from left to right; so the patterns are named, for example, flat-down for the ones 
which are expressed at similar levels in hESC and P-HPC and at lower levels in bone marrow 
HSCs, or flat-up for the ones which are expressed at similar levels in hESC and P-HPC and at 
higher levels in bone marrow. The number of miRNAs in each group is given under the 
example graph; the miRNAs in each group are shown in appendix table A. Details of the 
analysis and how it was carried out are in methods section 2.2. 
 
Microarray analysis identified mis-expressed miRNAs, which can be grouped by 
expression pattern: The 57 miRNAs in the flat-up group and the 32 miRNAs in the flat-
down group are the most interesting for this project as they are the ones which are 'mis-
expressed' i.e. they are expressed in P-HPCs at a more similar level to hESCs than to real 
HSCs. The intent in this project was to correct the expression of these miRNAs by inhibiting 
those in the flat-down group or ectopically expressing those in the flat-up group in the hope 
that it would result in some functional improvement in the hematopoietic potential of the P-
HPCs. 
During my mRES project I researched the functions of miRNAs in the flat-up and flat-down 
groups using published literature and TargetScan database [118] which computationally 
predicts the potential targets of miRNAs. Software can compare sequences of known 
miRNAs to 3’UTR from the genome sequence and predict likely mRNA targets of miRNAs 
by looking for conservation of binding sites across species. Algorithms predict targets based 
on complimentarity, especially strong base pairing in the 5’ 2-8 nucleotides and on structural 
availability of the surrounding sequence. 
However this method will not necessarily predict all miRNA-mRNA interactions because 
miRNAs can target parts of the mRNA other than the 3’UTR and can target mRNA even 
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when there is imperfect matching.  Target prediction using this kind of software can be very 
useful but different algorithms that are used are shown to give a substantial number of false 
positives and often come up with radically different predictions, so all predicted targets must 
be validated. The results of this research are summarised in Table 4.1 and 4.2.  
Mis-expressed miRNAs fall into several broad functional categories:  Several broad 
patterns emerged from analysis of the microarray data, which are informative about the 
differences between HSC and P-HPC and about the causes of the problems in transplantation 
experiments. In the flat-down group there are miRNAs which control various cellular 
functions, such as pluripotency, cell cycle, EMT and hematopoiesis (see results section 
4.2.2). The flat-up group contains several miRNAs which target genes essential for 
hematopoiesis (see results section 4.2.2). Since microarray data is not reliable enough to be 
considered conclusive several key miRNAs were chosen from the flat-up and flat-down 
groups for further analysis by qPCR. 
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4.2.1 Flat-down group miRNAs are involved in pluripotency, hematopoiesis, EMT and 
the cell cycle:  
 
Pluripotency: One of the most striking results from this microarray data is the high 
expression of the miR-302 cluster (miR-302a, miR-302b, miR-302c, miR-302d and miR-367) 
in P-HPCs. This is surprising because this group of miRNAs has been exclusively associated 
with pluripotency, and ectopic expression is even able to reprogram cells to pluripotency [21, 
197]. The miR-302 cluster is always be down-regulated immediately upon exit from the 
Figure 4.2 
 
Figure 4.2:  Graphs showing representative examples of estimated differential gene 
expression from microarray data in different cell types.  
Left to right: esc1=hESC replica 1, esc2=hESC replica 2, shc4=hESCs differentiated to 
day 4 sorted for CD34+ CD31+KDR+CD45-(haemangioblast markers), 
cd34=CD34+cells from bone marrow.  
The distribution of normalised intensity values for each sample is displayed in the box 
plots, and the relative fluorescence of the individual miRNA is shown as a line graph. 
miRNAs have been sorted according to the shape of the graph e.g. flat-down, flat-up etc. 
For example the flat down group miRNAs are expressed at similar levels in the hESC 
lines and in the day 4 differentiated hESC cells but at a lower level in the CD34+ bone 
marrow cells. 
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pluripotent state [198], so the continued expression of this cluster, which is expressed as a 
polycistronic precursor, is aberrant, and is likely to be disruptive to the function of the P-
HPCs. Expression of the miR-302 cluster in cells after they have left pluripotency is so 
unlikely that it is reasonable to be sceptical of this result but the fact that so many members of 
the group show the same pattern of expression does suggest that the result is real. Several 
members of the miR-302 group (miR-302a, miR-302a*, and miR-367) were selected for 
validation by qPCR. 
 
Hematopoiesis: Unsurprisingly several of the misregulated miRNAs from the flat-down 
group target genes associated with haematopoiesis or hematopoietic differentiation (see Table 
4.1). Although these all target hematopoietic genes they seem to target different ones at 
different stages in the hematopoietic process, so it seems likely that it is an effect rather than a 
cause of the functional deficiencies of P-HPCs. In any case miR-148a, miR-150 and miR-
150*, miR-18b, miR-34a, miR-424 and miR-9 were chosen for analysis by qPCR for their 
roles in hematopoietic differentiation. 
 
EMT: Another unexpected pattern in these results is the very high number of flat-down group 
miRNAs which are associated with suppression of EMT; many of them are described in the 
literature as inhibitors of metastasis and angiogenesis (see Table 4.1). 12 of the 32 miRNAs in 
the flat-down group have some role in suppressing EMT.  EMT is the process which cells lose 
their adherent epithelial phenotype and become mesenchymal, it is characterised by loss of E-
cadherin, cytoskeletal rearrangement, and increased motility. It is heavily involved in both 
normal developmental processes and in malignancy/metastasis. 
 EMT suppressors are expressed at high levels in pluripotent cells, which are epithelial in 
nature and at low levels in hematopoietic cells which are mesodermal. Therefore the pHSCs 
should express low levels of these miRNAs, however they maintain the high expression found 
in pluripotent stem cells. This failure to down-regulate these miRNAs indicates a likely 
problem in the in vitro differentiation. Hematopoietic cells' most important transition is the 
one in which the cells change from an endothelial cell type to a hematopoietic cell type (see 
introduction section 1.3.2). Although this is called the EHT rather than the EMT the 
processes share most molecular and functional characteristics. Inhibitors of EMT are likely 
detrimental to EHT and would almost certainly make the cells less motile. It is plausible that 
this miRNA expression is responsible for the failure (described in introduction section 1.4.4) 
of P-HPCs to home to the bone marrow niche. Although we know that EHT does occur in the 
in vitro system, since endothelial colonies can be seen giving rise to hematopoietic clusters 
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which eventually detach from the basement layer of cells, the microarray results indicate that 
this EHT process may be impaired or incomplete. If the cells retain some of the characteristics 
of the endothelial/adherent phenotype they may have some difficulty attaining the level of 
motility needed for chemotaxis to the bone marrow niche.  miRNAs from the miR-200 family 
(miR-200b, miR-200c and miR-205) were chosen for qPCR validation as they are well known 
EMT inhibitors (see Table 4.1). 
 
Cell cycle: Finally, many of the miRNAs in the flat-down group are involved in regulating the 
cell cycle. PSC and HSC have very different cell cycle protein profiles as HSCs are typically 
quiescent the vast majority of the time but PSC are characterised by their constant 
proliferation. In spite of this, the microarray results show that the p-HPCs express miRNAs 
which target cell cycle genes such as cyclin D, which indicates that the cell cycle of these 
cells may be more similar to that of pluripotent stem cells than HSCs. This could have 
negative effects such as causing any HSCs which do arise in the cultures to differentiate more 
rapidly. However the first HSCs to arise in the foetal aorta and foetal liver are known to be 
more proliferative, and only become quiescent later, in the bone marrow, so it is possible that 
the expression of miRNAs pertaining to the cell cycle merely reflect the foetal characteristics 
typical of pluripotent-derived cells. Nevertheless the expression of miR-148a, miR-200c and 
miR-200b, the miR-302 cluster, miR-34a, miR-424 and miR-9 were analysed by qPCR 
because of their role in cell cycle control. 
 
4.2.2 Flat-up miRNAs regulate pluripotency and hematopoiesis 
 
The flat-up miRNAs also show an interesting pattern, many of the let-7 group are under-
expressed in p-HPCs compared to HSCs from bone marrow, which is consistent with the data 
showing high expression of the miR-302 group (see above, section 4.2.1.), since these two 
groups of miRNAs  reciprocally inhibit each other. However it is cause for concern for the 
same reason; it indicates that the cells are more pluripotent in character than would be 
expected. 
For many miRNAs in the flat-up group the significance in hematopoiesis is not clear, however 
miR-142 is known to be essential for hematopoiesis to occur at all in zebrafish, miR-146 is 
hematopoietic stem cell specific, miR-181 is known to play a critical role in lymphoid cell 
development, which is of particular interest to us due to the difficulty in directing PSCs into 
lymphoid cells, and miR-223 is an important regulator of hematopoietic development (see 
Table 4.2). The relative lack of any one of these miRNAs might be enough to damage the 
79 
 
hematopoietic potential of the cells so their expression was analysed further by qPCR. 
 
miR-150 shows differential expression between strands: miR-150 showed an interesting 
pattern in that the active molecule (miR-150 or miR-150-5p) was in the flat-down group 
whereas miR-150* (mir-150-3p) was in the flat-up group, showing the opposite expression. 
This is unexpected since the two molecules are made from the same transcript, but it is not 
completely unbelievable because miR-150* is highly expressed in ESCs but not processed 
into 150 until the cells differentiate [97]. This means the high miR-150* expression is 
consistent with the general pattern of aberrantly maintained pluripotency associated miRNA 
expression. miR-150 is known to target hematopoietic transcription factor c-MYB [115, 199, 
200] as well as EMT transcription factor ZEB1 [201] and has a role in hematopoietic lineage 
commitment, so both miR-150 and miR-150* were selected for qPCR validation. All of the 
key miRNAs chosen for further analysis are highlighted in bold in Table 4.1.
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Table 
4.1: 
FLAT_
DOWN 
Pluripotency 
associated 
Epithelial-
mesenchymal 
transition 
Hematopoiesis and 
angiogenesis 
associated 
Cell cycle and 
apoptosis Other 
hsa-miR-
151-3p   
Regulates EMT via 
RhoGDIA [202, 203] 
and TWIST1 [204] 
Associated with foetal 
haemoglobin switch 
[205, 206] 
Targets cyclin 
E1[207]   
hsa-miR-
432      
 Promotes 
proliferation 
via WNT 
pathway [208] Biomarker for schizophrenia [209, 210] 
hsa-miR-
598         
Involved in DNA damage response 
pathway[211] 
hsa-miR-
1181         
Possible role as a tumour suppressor [212, 
213] 
hsa-miR-
1224-5p        Possible role in inflammation [214] 
hsa-
miR-134 
Regulates 
pluripotency via 
C-MYC, NANOG, 
OCT4, SOX2, 
LRH1[215, 216] 
Supresses EMT via 
FOXM1[217, 218] 
Enhances erythroid 
differentiation [219]    
Pushes mESCS towards the ectodermal 
lineage [216] 
hsa-
miR-
148a     
Role in innate 
immunity via NF-KB 
pathway [220] 
Targets p53, 
mTOR [221, 
222] 
Mir-148a is a tumour suppressor; 
promotes adipogenesis and 
osteoclastogenesis [223], suppresses 
mesenchymal lineage via EPAS1, 
Targets DNMT1 [224] 
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hsa-
miR-18b   
 Modulates cell 
migration [225]  
Down-regulated 
during erythroid 
differentiation, 
targets STAT3, HIF-
1α, VEGF [226] 
Targets the 
MDM2-p53 
pathway [227]  Promotes epithelial differentiation [228] 
hsa-miR-
193b   
 Suppresses 
metastasis via 
targeting uPA, and 
NF1 [229, 230] 
Targets hematopoietic 
transcription factors C-
KIT [231], c-MYB 
[232] 
Targets Cyclin 
D1 [233, 234]   
hsa-
miR-
200b   
Targets critical 
EMT regulators 
ZEB1, ZEB2, BMI1, 
RND3,  SNAIL, 
ETS1 [201, 235, 236] 
Regulates 
angiogenesis via 
ZEB1 [201], targets 
immune system 
pathways TLR4 and 
NF-KB [237]   
hsa-
miR-
200c 
Used to enhance 
reprogramming 
[21]  
Inhibits EMT via 
BIN1, ZEB1, RND3, 
LHFP, TGFb [237, 
238] 
Targets VEGF [239], 
ETS1 [240] and cMYB  
[241]    
hsa-
miR-205   
Targets ZEB1and 
ZEB2 [235]   
E2F1, PTEN, 
(p73/DNp73-
miR-205) Complex role in tumour formation [242] 
hsa-miR-
210       Key hypoxia associated miRNA [243, 244] 
hsa-miR-
214    Targets VEGF [245] 
Targets p53 
[246] 
Biomarker for cancer [247, 248], role in 
osteoblast formation [249, 250]  
hsa-miR-
218     
Regulates vascular 
patterning via SLIT-
ROBO signalling [251]  Tumour suppressor [229] 
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hsa-miR-
301a   
 Targets E-cadherin 
[252] 
 Regulates NF-κB 
signalling [253, 254]   
hsa-
miR-
302a, b, 
c, d, 
hsa-
miR-367 
Used to enhance 
reprogramming, 
[21, 197, 198]   
Targets cyclin 
E-CDK2 and 
cyclin D-
CDK4/6 
pathways 
[255]   
hsa-
miR-34a   Targets MYC [256] 
NOTCH1, FOXP1(B 
cell differentiation) 
[111],  
Targets CEBPA 
(myeloid 
differentiation [257]   
Very important tumour suppressor [229, 
258] 
hsa-miR-
365    
 Targets 
cyclinD [259] Adipocyte differentiation [260] 
hsa-
miR-424     
Hematopoietic genes 
PU.1 [101], 
CEBPA[261], VEGF,  
VEGFR2, FGF2, 
FGF1, FGFR2[262] 
CyclinE1, 
CDC25A, 
MEK[263] 
Controls myeloid and monocyte 
differentiation [101], inhibits angiogenesis 
[264], cell cycle regulator 
hsa-miR-
455-3p    Targets ZEB1 [265]    
Regulates chondrogenesis [266] and 
adipogenesis [267] 
hsa-miR-
630   
Inhibits EMT via 
SLUG-TGFB 
pathway [268-270]     
hsa-miR-
7   
Inflammation and 
innate immunity 
[271]   
Role in organogenesis, particularly the brain 
[272] 
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hsa-
miR-9 LIN28 [273] E-Cadherin [274] 
Hematopoiesis, 
myeloid 
differentiation via 
FOX01 and FOX03 
[275] 
Cyclin D1, 
ETS1 [276] 
Promotes pluripotency [273], tumour 
suppressor and oncogene, involved in 
inflammatory response. In hematopoietic 
cells it promotes terminal differentiation 
and apoptosis [275] 
      
 
 
Table 4.2: 
FLAT_UP Pluripotency 
Inflammatory 
pathway Hematopoiesis 
Cell cycle and 
proliferation Other 
hsa-let-7b, 
7b*, 7c, 7d, 
7f-1*, 7g, 
miR-98 
Negative 
regulator of 
pluripotency via 
LIN28, C-MYC, 
SALL4 [273]     
Targets Cyclin 
D1, A2, CDK8, 
RAS, 
HGMA2[277]   
mir-7-1* 
Targets KLF4 
[278]   
 
Regulates mTOR, 
PI3K/AKT 
pathway [279]   
hsa-miR-10a*           
hsa-miR-
1225-3p           
hsa-miR-
1237           
hsa-miR-
1238           
hsa-miR-127-
3p           
hsa-miR-138-
2*           
hsa-miR-
142-3p, 5p     
Essential for HSC formation 
by targeting IRF7 , essential     
84 
 
for hematopoiesis in zebrafish, 
controls myeloid 
differentiation [280-282] 
hsa-miR-
146a, 146b-
5p     
Involved in the differentiation 
of primitive HSCs and T 
lymphocytes[93, 280, 283, 284] 
TRAF6, IRAK1, 
CARD10, 
COPS8 (NF-κB 
pathway)[253]   
hsa-miR-
1470           
hsa-miR-150     
MS4A3, AGA, PTPRR 
(erythroid), C-MYB, 
NOTCH3, promotes 
megakaryocyte development at 
the expense of erythrocytes 
Regulates HSC migration 
[285], targets cMYB[286], 
promotes T-lymphoid 
lineage[287] 
Inhibits cell 
division via 
CyclinD1, BCL2, 
MYB [199, 200, 
286] 
 hsa-miR-
1539           
hsa-miR-155   PI3K-AKT, IFN[253] 
SOCS1 (encourages T cell 
differentiation) [288], myeloid 
differentiation [289] 
  hsa-miR-16-
2*           
hsa-miR-
181a*, 181a-
2*, 181b, 
181c   
C-Fos and  
PCAF(supress 
inflammatory 
response)[290] 
Encourages B-lymphoid 
lineage [291], T-cell 
development [98, 292] 
HTR-A1, 
TIMP3, BCL2 
[258, 293] 
 hsa-miR-
191*           
hsa-miR-
1913           
hsa-miR-202           
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hsa-miR-212 
 
IRAK4, 
STAT4(inflammatory) 
[294] 
 Regulates B-cell development 
via SOX4 [295] 
 
Mir-212 is an EMT 
suppressor [296] 
hsa-miR-
221*           
hsa-miR-
223, 223*   
Inflammation 
associated [297, 298] 
Regulates granulopoiesis, 
erythropoiesis and 
hematopoetic proliferation via 
LMO2 and CEBPA [103, 299-
302] 
Regulates the 
cell cycle [303] 
 hsa-miR-23a*           
hsa-miR-338-
3p, 5p     
 
Targets cyclin D1 
[304] 
Contributes to the 
formation of basolateral 
polarity in epithelial cells 
[305] 
hsa-miR-361-
3p       
 
Biomarker for many 
cancers  
hsa-miR-376c     
 
Inhibits 
proliferation by 
targeting BMI1 
and LRH [306, 
307] 
 
hsa-miR-378, 
378* 
 
  
Targets RUNX1 [308], promotes 
macrophage proliferation [309] 
 
Involved in adipogenesis 
and angiogenesis [310, 
311] 
hsa-miR-
431*           
hsa-miR-486-
5p         
Diagnostic for many types 
of cancer 
hsa-miR-564         
 hsa-miR-634           
hsa-miR-650   
 Promotes IL6 
expression [312]   
  
86 
 
hsa-miR-665       
 
EMT suppressor [313] 
hsa-miR-766   
 Upregulated in 
inflamed tissue [314]     
 hsa-miR-767-
3p       
 
DNA methylation via TET1 
[315] 
hsa-miR-770-
5p         
 hsa-miR-933         
 hsa-miR-
1306         
 hsa-miR-324-
5p         
 hsa-miR-
487b     
 Negative regulator of 
macrophage activation [316]   
Promotes angiogenesis 
[317] 
hsa-miR-92b 
 Controls G1/S 
checkpoint in 
ESCs [318] 
  
  EMT promoter [319, 320] 
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Figure 4.3b 
  
  
  
 
Figure 4.3:  Graphs showing microarray data of 
the miRNAs chosen for further analysis  
Left to right: esc1=hESC replica 1, esc2=hESC 
replica 2, shc4=hESCs differentiated to day 4 
sorted for CD34+ CD31+KDR+CD45-
(haemangioblast markers), cd34=CD34+cells 
from bone marrow.  
The distribution of normalised intensity values for 
each sample are displayed in the box plots, and the 
relative fluorescence of the individual miRNA is 
shown as a line graph. 4.3a shows the microarray 
data for chosen miRNAs in the flat-down group, 
4.3b shows chosen miRNAs in the flat-up group. 
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4.3 qPCR validation of miRNA candidates selected from microarray analysis 
The candidates from the microarray analysis must be validated: microarray analysis is not 
considered accurate enough to be conclusive (see results section 4.1), and the protocol used for this 
project is more advanced and produces hematopoietic cells more similar to the HSC cell type than 
the one which was used for the microarray analysis. The method used for qPCR was the Taqman 
two-step system (see methods section 2.5.1), as this was state of the art at the time the project 
started. 
miRNA expression was analysed in several hematopoietic progenitor populations: Expression 
of the chosen miRNAs was analysed at several time-points during development and in various 
subpopulations of cells sorted by FACS using cell surface markers for hematopoietic progenitors. 
PSC derived cultures of hematopoietic stem cells contain many different cell types which arise at 
different time-points. Several hematopoietic populations were sorted and analysed in order to get a 
clearer picture of when the key miRNAs are up or down regulated and in what cell types, in order to 
give an idea of the progression of hematopoietic development in different hematopoietic 
progenitors. The cell types chosen for analysis were hemogenic endothelium at day four 
(CD34+KDR+CD31+ [64, 321]) primitive hematopoietic cells (CD41a+CD235a+ 
CD43+CD34low/- CD45- [8, 65, 322]) which arise in large numbers at day 7 and definitive cells 
which arise in detectable numbers at day 12 (CD43+CD34low/- CD41a-CD235a-CD45+ [8]), as 
well as analysing the primitive cells at the same time-point. Non-hematopoietic populations 
(negative for all hematopoietic markers, referred to as 'negative' in this chapter) were also analysed 
so as to provide a comparison for the expression of miRNAs which are known to be hematopoietic 
specific. Details of the cell sorting process and the markers used are given in methods section 2.4. 
These populations were compared to three other cell types: Undifferentiated pluripotent stem cells, 
bone marrow derived CD34+ cells (as in the microarray data) and cord blood derived CD34+ cells 
as it is thought that pluripotent derived hematopoietic cells have more in common with 
foetal/neonatal cells. 
 
4.3.1 qPCR analysis for flat-up miRNAs 
Expression levels of miRNAs in PSC derived hematopoietic progenitors were compared to bone 
marrow and cord blood CD34+ cells. Several of the miRNAs (miR-142, miR-223) are not 
expressed in the ‘negative’ non-hematopoietic populations, but highly expressed in all of the 
hematopoietic populations, which supports the literature saying they are hematopoietic specific. 
miR-146 on the other hand was shown to be expressed at equivalent or higher levels than bone 
marrow and cord blood in all the differentiated populations, and miR-181 is expressed at high levels 
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in the negative population at day 12, so these miRNAs are probably less useful as markers for 
hematopoiesis in PSC derived cultures (Figure 4.4a). 
The ‘flat-up’ group miRNAs are mostly hematopoietic specific miRNAs and were shown by the 
microarray data to be expressed at too low a level in P-HPCs. The results of the qPCR analysis 
show a different pattern; in definitive hematopoietic progenitors (which are the ones that this project 
is most interested in) the miRNAs are either not expressed at significantly different levels to bone 
marrow and cord blood or in some cases are expressed at significantly higher levels than either bone 
marrow or cord blood progenitors (Figure 4.4a). Although these results contradict the microarray 
data the high expression of hematopoietic-specific miRNAs is encouraging as it suggests that the 
differentiation protocol which was used for the qPCR analysis promotes more effective 
hematopoiesis than the earlier protocol used for the microarray data (see methods section 2.1.2). 
The fact that the expression of some of these miRNAs is higher than that in cord blood or bone 
marrow reflects the more-differentiated nature of the sorted cell population, as these miRNAs are 
expressed in CD34+ progenitors but increase in expression as the cells differentiate towards specific 
blood lineages.  All of these miRNAs can be ruled out as targets for manipulation of expression as 
they seem to be expressed correctly in the definitive population. 
 
qPCR analysis for flat-down miRNAs: The results from the flat-down group can be divided into 
two broad categories as shown in Figure 4.4b; group A, which has miRNAs that eventually down-
regulate to a level not statistically significantly different from cord blood or bone marrow, and 
group B, in which the miRNAs maintain high expression throughout development in all of the 
sorted populations. 
The group A results include all of the miRNAs from the miR-302 cluster as well as miR-18b. This 
data shows that the cells rapidly lose expression of the miR-302 cluster miRNAs upon exit form 
pluripotency, which is what would be expected based on the literature. Where miR-302a and miR-
18b are different from bone marrow and cord blood they are significantly lower in expression, 
indicating that the cells have fully exited the pluripotent state. miR-302a* is expressed at 
significantly higher levels in the definitive population than in bone marrow in both H9 and SB-Ad3 
populations, but it is not significantly different from the expression in cord blood, which may be 
due to the more foetal nature of cord blood. miR-302a* is also the inactive strand, and is present in 
quantities which are at the limits of detection, which reduces the accuracy of the results. 
 It is not clear why so many of the miR-302 cluster fell into the flat-down group in the microarray 
data, it is possible that the early stage that the cells were tested as well as the lesser effectiveness of 
the protocol that was used meant that the cells were still expressing some molecular markers for 
92 
 
pluripotency. Group A miRNAs can be ruled out as candidates for inhibition, as they appear to be 
expressed at the correct level in definitive hematopoietic cells when the Glasgow protocol is used. 
 
The group B miRNAs (miR-9, miR-134, miR-148a, miR-150, miR-150*, miR-200b, miR-200c, 
miR-205, miR-424) are consistently highly expressed throughout development from pluripotent 
stem cells, in all the sorted populations, both hematopoietic and non-hematopoietic. Although for 
the definitive population the expression of some miRNAs such as miR-200b and miR-205 the 
difference is not statistically significant this is due to the large amount of variation and is a technical 
problem caused by the low numbers of this population reducing the accuracy of the results. The 
qPCR data for this group is consistent with the microarray data. Failure to down-regulate all of 
these 9 miRNAs could impair the function of hematopoietic cells. Their expression indicates 
problems in the regulation of the cell cycle, adhesion/motility and hematopoiesis specifically. All 
these miRNAs are therefore possible candidates for inhibition.
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Figure 4.4a 
Flat-up 
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Flat-up 
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Figure 4.4a 
Flat-up 
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Flat-up 
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Figure 4.4b 
Group A 
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Figure 4.4b 
Group A 
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Figure 4.4b 
Group A 
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Figure 4.4b 
Group A 
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Figure 4.4b 
Group B 
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Figure 4.4b 
Group B 
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Figure 4.4b 
Group B 
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Group B 
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Figure 4.4b 
Group B 
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Group B 
 
107 
 
 
Figure 4.4b 
Group B 
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Group B 
 
109 
 
 
 
Figure 4.4b 
Group B 
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Figure 4.4: qPCR data for expression of miRNAs calculated using ΔΔCT method using RNU44 and RNU48 as endogenous controls; all values were 
calculated with respect to a reference value of expression of RNU44 and RNU48 in bone marrow. Data is presented as average +/- SEM. n=3. See 
methods section 2.3.1 for experimental details. 
P values were calculated using unpaired two tailed t-tests comparing the three replicates for each of the cell types for each miRNA against both bone 
marrow and cord blood.  
Figure 4.4a: Flat-up miRNAs Figure 4.4b: Group A micro-RNAs (down regulated by day 12), Group B micro-RNAs (maintained high expression 
throughout differentiation). 
Different time-points are shown in different 
colours: 
 
 
Columns are labelled according to their cell types as sorted in section 
4.3 
Hemogenic endothelium= CD31+ CD34+ KDR+ CD45- 
Primitive= CD34low/-CD41a+CD43+CD235a+CD45- 
Definitive= CD34low/-CD41a-CD43+CD235a-CD45+ 
Negative= negative for all markers used in the sort 
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5. Results: Methods for manipulating miRNA expression 
Methods for miRNA inhibition: Choosing an effective and appropriate means of inhibiting the 
target miRNA was essential for this project. miRNAs can be inhibited by introducing RNA 
molecules which are complimentary to the miRNA of interest; the inhibitor RNA binds to the target 
miRNA and either prevents translation or causes mRNA degradation (see introduction section 
1.4.1). There are several types of miRNA inhibitor and several ways of introducing them into the 
cell.  
Inhibition was one of the first techniques used to study the function of miRNAs [323, 324]. The 
earliest miRNA inhibitors used were based on the design of siRNAs which had been used to inhibit 
gene expression [325]. siRNA are short RNA molecules complimentary to a portion of a mRNA. 
They are introduced into the cell  and  processed by DICER, then they bind to the RISC complex 
and degrade or prevent translation of mRNA using the same mechanism as miRNA [326]. Since 
RNA is unstable, chemically modified RNA nucleotides (reviewed by Zhang et al. 2013 [192]) have 
been used to prevent enzymatic degradation and increase the siRNA’s half-life within the cell. The 
most common chemical alterations are ‘locked nucleic acids’ (LNA) which have a cross link 
between  2’-O and 4’-C [327, 328] and 2’-OMe modified RNA [323] (see Figure 5.1a). These 
modifications can also improve the binding affinity for the target molecule and the stability of the 
RISC complex [329]. 
Lipofection allows RNA inhibitors to be introduced into cells: Introducing the inhibitor RNA to 
the cell is a challenge because nucleic acids are negatively charged and can’t pass through the cell 
membrane. To overcome this, lipofection is used: cationic lipids are allowed to form complexes 
with the RNA, creating a neutral-charge hydrophobic complex which can more easily pass through 
the cell membrane (see Figure 5.1b). The exact chemical formulation of the cationic lipid can vary 
depending on the application, but achieving the correct ratio of lipid to RNA is essential and the 
complexes must be formed in serum free medium [330]. 
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Lipofection is a short-term solution: The most serious limitation of the lipofection 
technique is that the amount of inhibitor introduced to the cells is finite and it is eventually 
degraded, or diluted when the cells divide. Expression of a miRNA inhibitor in a line of 
cultured cells can be achieved by introducing a plasmid with the complimentary miRNA 
inhibitor sequence under a constitutively active promoter. The plasmid can be integrated into 
the genome, allowing long term inhibition, but the promoters on plasmids are usually silenced 
Figure 5.1a 
   
Figure 5.1b  
                                 
Figure 5.1a: Schematic showing chemical structure of RNA, 2’OMe modified RNA, and 
‘Locked nucleic acid’ modified RNA. 
Figure 5.1b: Schematic of Lipofection process [6]. 
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over time. The time can be extended by using antibiotics to select for cells still expressing the 
genes on the plasmid. 
Inhibitor RNAs can be designed with secondary structures to increase effectiveness: The 
inhibitor on the plasmid can be made more robust by introducing a longer RNA strand with  
secondary structure either side of the miRNA binding site, which leaves the inhibitor 
sequence open and able to interact with the RISC complex but protects the inhibitor from 
degradation [331]. The most common secondary structure is a short hairpin loop, which is 
known as a ‘tough decoy’ inhibitor [332]. Insertion of a  1-3 nucleotide region of non-
complimentary RNA between bases 8 and 9 from the 3’ end of the inhibitor sequence allows 
the RISC complex to form but  prevents Ago2 from degrading the inhibitor, increasing the 
efficiency of down-regulation [332]. 
An alternative type of inhibitor is the RNA sponge, which is also cloned into a vector and 
transfected into the cell. miRNA sponges have multiple  miRNA binding sites separated by 
short spacer sequences, allowing them to sequester many miRNA molecules. They can be 
efficiently generated and can be used to inhibit several different types of miRNA from the 
same family [333-335].  
It is also possible to study the effects of loss of miRNA expression by knocking down a gene 
in a cell by using CRISPR [336-341] or TALENs [342, 343], however these methods are 
challenging as all copies of the miRNA-gene must be mutated without causing off site 
mutations, and the short length of these genes limits the possible target sites. 
 
5. 1 Lentiviral transfections 
miR-200c was chosen as the first target for down-regulation as it is a well-studied regulator of 
EMT. The first method chosen for miRNA inhibition was an inhibitor based on the tough 
decoy design, inserted into the cells using a lentiviral vector. Inhibitor plasmids are 
commercially available pre-packaged in lentiviruses with reporter genes and antibiotic 
resistance genes, allowing a rapid start to the experiments and immediate assessments of the 
efficiency of transfection. Initially a lentivirus with a miR-200c inhibitor, a Puromycin 
resistance gene and an mCherry reporter was purchased from Genecopoeia. Unfortunately 
transfection efficiency was low, even at extremely high multiplicity of infection (MOI) (see 
Table 5.1) in both H9 cells and the easier to transfect normal human dermal fibroblasts 
(NHDFs). MOI, polybrene (hexadimethrine bromide) concentration, percentage-confluence 
and time between passages were also altered in an attempt to increase the efficiency but at no 
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point was it possible to achieve a transfection efficiency of greater than 0.4% (see Figures 
5.2b and 5.2c). Cells were expanded after selection with Puromycin but rapidly lost mCherry 
expression. Lentiviral transfection is specifically used for its high efficiency but there are 
several problems which can occur; cells must be healthy to survive infection, the virus itself 
must be competent and the plasmid, once inside the cell must have the opportunity to express 
its genes. Since it was never possible to get this virus to transfect efficiently, trouble-shooting 
was difficult, but it was possible to achieve efficient transfection with another lentivirus (see 
below), and neither the miR-200c inhibitor virus or the scramble control virus were effective, 
so it is more likely that the cause of the low tranfection efficiency was either the virus or the 
plasmid itself, rather than experimental technique or the properties of the cells. Lentiviruses 
are not stable if stored above -80
o
C and are known to be extremely sensitive to freeze-thaw 
cycles [344] so it is possible that the viruses were damaged at some point when they were in 
storage. Alternatively, the cells may have rapidly silenced the promoters, which is known to 
happen in some cases with newly introduced plasmids [345, 346]. Either of these explanations 
is plausible. 
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Figure 5.2a 
 
Figure 5.2b                                                                 Figure 5.2c 
 
Table 5.1: Efficiency of transfection 
Polybrene (ug/ml) MOI % 
mCherry 
 5 100 0.0065 
200 0.0005 
300 0.034 
8 100 0.034 
200 0.0415 
300 0.124 
10 100 0.046 
200 0.0005 
300 0.026 
 
 
 
 
Figure 5.2a: Schematic representation of 
genes and promoters on the Genecopoiea 
lentiviral plasmid (provided by the 
manufacturer) 
Figure 5.2b: Representative image of NHDF 
fibroblasts transduced with lentivirus (MOI 
300, 8μg polybrene/ml) showing mCherry 
reporter 48hr after transduction. Bar = 
200μm 
Figure 5.2c: Flow cytometry data showing 
mCherry expression in hematopoietic 
progenitors 48hr after transduction. MOI = 
460, polybrene concentration = 2μg/ml 
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A second attempt was made with a SigmaAldrich MISSION
TM
 miR-200c tough decoy 
inhibitor lentivirus. This was more successful in that the transfection efficiency was much 
higher, based on Puromycin resistance after transfection. Up to 60% of cells survived, 
enabling qPCR analysis of miR-200c after transfection. However the expression was not 
significantly reduced when analysing expression 48hrs after transfection, even in cells which 
had been selected for with Puromycin (see Figure 5.3a). This means that although the cells 
had taken up the plasmid the inhibitor is either not being expressed or the design is not 
effective. The most likely explanation is that the promoter for the miRNA-inhibitor was 
silenced whereas the Puromycin resistance gene continued to be expressed. Most plasmid 
genes, including antibiotic resistance genes, are expressed under constitutively active, very 
strong RNA polymerase II promoters such as CMV or hPGK. However miRNA-inhibitors, 
due to their small size, are more effectively expressed under RNA polymerase III promoters 
such as U6 or H1 (see Figures 5.2a, 5.3b) [347]. Both types are promoters for constitutively 
expressed housekeeping genes, however genes on vectors introduced into hESCs are silenced 
in unpredictable ways depending on both the cell line transfected  and the promoter which  is 
used to drive gene expression [348]. It is also possible that the design of the inhibitor is 
flawed; the inhibitor is designed based on a proprietary algorithm. 
Although lentiviral introduction of inhibitors is in theory an ideal method of inhibiting a 
miRNA’s expression it did not appear to be effective in inhibiting our target miRNAs for 
technical or biological reasons so this approach was eventually abandoned. 
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5.2 Lipofection 
Lipofection of small chemically modified miRNA inhibitors is one of the most well 
established techniques for studying the effects of miRNA down-regulation. The lipofection 
protocol (see methods section 2.8) was optimised on undifferentiated H9 cells by adjusting 
the ratio of cationic lipofectamine to negatively charged RNA. The half-life of the inhibition 
molecule in vitro is critical in lipofection, so after the ratio was optimised the length of time 
the inhibition lasted was analysed (see Figures 5.4b, 5.4c). In undifferentiated H9 cells the 
inhibition was very effective at reducing the expression of miR-200c for the first 48 hrs, after 
which it becomes less effective over time, and the effect is no longer significant after 96 hrs. 
The brief time-span of the effect meant that careful strategizing about the timing of inhibition 
was necessary. Although it is possible to perform multiple lipofections on the same cells at 
different times, long term exposure to lipofectamine can be toxic to the cells so this was 
avoided. 
The results of the expression analysis of miRNAs suggested that the EHT is the critical period 
in differentiation of p-HSPCs, as so many of the miRNAs mis-regulated control EMT (see 
Figure 5.3a                                             Figure 5.3b 
  
Figure 5.3a: qPCR expression analysis of miR-200c expression in puromycin selected 
day 12 SB-Ad3 cells which were transfected with a lentiviral mir-200c inhibitor at day 
10. Calculated using ΔΔCT method, presented as a mean±SEM, n=3. Results with H9 
cells and undifferentiated cells are comparable. 
Figure 5.3b: Schematic representation of genes and promoters on the MISSION 
lentiviral plasmid, provided by the manufacturer. 
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section 4.2.1). Therefore miR-200c, a critical EMT regulator, was inhibited at a time point 
where the 48hr window of inhibition would have the maximum effect on the EHT process of 
definitive cells. Since definitive cells arise in small numbers starting at day 7 and reach 
maximum numbers at day 12 [8], inhibition was done at day 10 to allow the measurement of 
the effect at day 12. 
 
At days 10-12 there are multiple distinct cell types in the culture, including committed 
endothelial cells, hemogenic endothelial cells, primitive progenitors, definitive progenitors 
and lineage committed hematopoietic progenitors (see flow cytometry results, Section 5.3, 
Figure 5.7). Some of these cells are in suspension, and some are adherent, which can affect 
the efficiency of transfection, and some may be proliferating at different rates, affecting the 
longevity of the effect.  Since the main focus of this project is on the definitive hematopoietic 
lineage it was necessary to ensure that those cells in particular took up the inhibitor and 
maintained an acceptable level of inhibitor at the time-point when the cells were measured. A 
fluorescent-conjugated scramble-control (see methods section 2.8) was transfected into P-
HPCs at day 10 and analysed by flow cytometry. Fortunately the FITC dye was present in 
100% of cells after 24 hours and the effect holds in 96.8% of cells up to 48 hours (see Figure 
5.4a, 5.4b) so we can analyse the effect of inhibition on the whole population of cells up to 48 
hours after lipofection with confidence the inhibitor was introduced into the overwhelming 
majority of cells, including the definitive progenitors.  
The effectiveness of the inhibitor was tested by measurement of miR-200c by qPCR after the 
inhibitor was transfected into undifferentiated pluripotent stem cells (Figure 5.4c). As with 
the fluorescent control, inhibition is strong at 48 hours but grows weaker over time. 
Lipofection of mir-200c inhibitor at day 10 of differentiation was also successful, with qPCR 
analysis showing significant down-regulation in both H9 and SB-Ad3 cells at 48 hours after 
transfection, although most of the effect is lost by 96 hours (Figures 5.4d-5.4g), an effect 
equivalent to that in undifferentiated hESCs. There appears to be more variability between 
experimental repeats which are further from the time of transfection in all the different 
lipofection experiments which were done; it is not clear why this is but it may be due to cells 
in different experimental repeats proliferating at different rates. 
This method was found to be effective and reliable so the rest of the project used the same 
method of lipofection with an inhibitor at day 10 and analysis of the cells 48 hours after. 
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Figure 5.4a                                                                          
 
Figure 5.4b                                                                   Figure 5.4c 
   
Figure 5.4a: Flow cytometry data showing FITC fluorescence in control and FITC transfected H9 
day 12 cells. 5.4b: Flow cytometry data showing % FITC fluorescent H9 cells at different 
timepoints after lipofection with FITC-conjugated control siRNA. Data is shown as mean±SEM, 
n=3. Day = day of differentiation, hour = hours post lipofection. 
5.4c: qPCR expression analysis of mir-200c in undifferentated H9 cells at 24, 48, 72 and 96 hours 
after lipofection. Data is shown as mean±SEM, n=3. 
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5.3 Effects of miRNA inhibition 
Once an effective method for inhibiting miR-200c in hematopoietic progenitors was 
established the same method could also be used for inhibiting other group B miRNAs which 
were chosen as potential targets in results section 4. The miRNAs chosen were miR-148a, 
miR-200b, miR-200c, miR-205 and miR-424. The other candidates for inhibition, miR-9, 
miR-134, miR-150, miR-150* were excluded as these miRNAs are less involved in EHT. The 
main focus of this project was on  EHT-supressing miRNAs because as shown in results 
section 4.2, these miRNAs represent the largest group of mis-regulated miRNAs and 
therefore likely the most important mechanism preventing P-HPCs from functioning 
Figure 5.4d                                                                        Figure 5.4e 
 
Figure 5.4f                                                                      Figure 5.4g 
 
5.4d-5.4g qPCR expression analysis of mir-200c in day 12 and day 16 differentiated H9 and SB 
adult 3 cells which were lipofected with a mir-200c inhibitor at day 10. Data is shown as 
mean±SEM, n=3. 
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effectively, as well as providing a clear mechanistic explanation for their failure to home to 
the niche. 
 The chosen miRNAs all have validated functional roles in the process of EMT, often 
inhibiting some of the same genes, and these overlapping functions mean that it is likely that 
there is some redundancy between these miRNAs, so miRNA inhibitions were carried out 
both individually and in combination with others. miR-200b and miR-200c inhibitors were 
introduced to the cells together due to their high level of sequence homology making them the 
most likely to have functional overlap. Experiments where all 5 miRNA inhibitors were 
introduced to the cells at once were used to determine if the effect of inhibition would be 
greater when all the inhibitors were combined. 
 
miRNA inhibition: The effectiveness of the inhibitor molecules was analysed by measuring 
the quantity of their target miRNAs by qPCR (see Figure 5.5). This was done after both 
individual miRNA inhibition and combined inhibition, as there was some concern that 
attempting to inhibit multiple miRNAs at once would decrease the efficiency of inhibition. 
The inhibitors were all found to be very effective at reliably inhibiting their target miRNAs. 
Interestingly multiplex inhibitions don't down-regulate miRNAs to the same level as the 
individual inhibitions. miR-205 appears to be inhibited less efficiently when combined with 
other inhibitors, but the miR-200 group are even more down-regulated when combined with 
the other inhibitors. This suggests that there is some co-regulation of the inhibitors. Papers on 
the function and regulation of these miRNAs indicate that they are part of a complex 
regulatory network, with multiple feedback loops (see Figure 5.9). As many of these miRNAs 
regulate some of the same genes it appears that inhibiting one can have an impact on the 
expression of the others. Although the effect of an individual miRNAs expression on any one 
gene is usually small, effects of changing the expression levels of more than one can change 
the precise balance of gene and miRNA expression on a larger scale, which is positive in that 
it suggests that manipulation of miRNA expression may be a viable strategy for altering cell 
phenotype/fate/functionality, however it is also concerning as the effects of inhibition on the 
expression of other miRNAs are not immediately predictable.
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Figure 5.5 
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Figure 5.5 
 
 
Figure 5.5: qPCR data showing miRNA expression in hiPSCs and hESCs at day 12, 48hr after inhibition. Data is shown as mean ΔΔCT values ±SEM, n=3. 
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The cells were analysed for changes in hematopoietic potential at day 12, 48 hours after 
inhibition of the selected miRNAs. Their hematopoietic colony forming potential, cell surface 
marker expression and gene expression were assessed. 
 
Colony forming assays and flow cytometry:  The results of the colony forming assays show 
no significant improvement in hematopoietic development (see Figure 5.6). Most of the 
inhibitions show no significant changes, although as would be expected, the largest change 
comes after inhibition of all 5 miRNAs in one population of cells. Few colony types are 
significantly different in cells inhibited with any of the miRNAs, in fact the only significant 
change which occurs in both cell lines is in CFU-GEMM potential, which is significantly 
decreased in both hESCs and hiPSCs. This is the opposite result to what was hoped for as it 
indicates a decrease in the fraction of multi-potent hematopoietic progenitors. 
The results of these experiments have less statistical power than is ideal (see results section 
3.5) so it is possible that the apparently statistically insignificant differences seen in the other 
colony types are real decreases, or that the inhibition of these miRNAs is having an effect on 
CFU-GEMMs in particular. This may be because the inhibited miRNAs are themselves 
inhibitors of hematopoietic differentiation (see section 4.2), causing the earliest progenitors to 
spontaneously differentiate, or it may be that the combined effect is preventing them from 
differentiating at all. 
Flow cytometry shows no significant changes in either the megakaryocyte erythroid 
progenitors, multilineage myeloid progenitors or definitive hematopoietic progenitor 
populations after miRNA inhibition (see Figure 5.7), consistent with the CFU results. 
 
Gene expression: Following miRNA inhibition the expression of known target genes was 
analysed by qPCR. A miRNA can have up to thousands of predicted target genes so several 
criteria were used to choose which genes to analyse: They had to be validated targets of one 
or more of the inhibited miRNAs, and to have known relevance to either EMT or EHT, as this 
is the key cellular process which was identified in results section 4 as being regulated by the 
aberrantly expressed miRNAs. Given the robust down-regulation of the miRNAs you would 
expect to see some up-regulation of their target genes. Many of the genes show an increase 
(see Figure 5.8), but it is small and unfortunately there is considerably more variability 
between repeats of these qPCR experiments than the ones analysing miRNA expression, in 
spite of them both being derived from the same RNA samples in most cases. Few genes show 
an increase that is statistically significant, which explains the lack of dramatic changes in the 
cell surface markers and CFU assays. 
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Figure  5.6a   SB–Ad3 cells 
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Figure  5.6b   H9 cells 
                              
Figure 5.6: Estimated marginal means ±SEM  for CFU made from day 12 pluripotent stem cell derived hematopoietic progenitors a: SB-Ad3 cells, 
b: H9 cells, n=3. See methods section 2.10 for how EMMs are calculated. 
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Figure 5.7 
 
 
Figure 5.7: Graphs showing percentage of live cells expressing MkEP (megakaryocyte erythroid 
progenitors) = CD43+CD34+CD235+CD41a+CD45-; MMp (multilineage myeloid progenitors) = 
CD43+CD34+CD235-CD41a-CD45-; Definitive hematopoietic progenitors = CD43+CD34+/-CD235-
CD41a-CD45+. Data is shown as estimated marginal means ±SEM , n=3. 
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Figure 5.8 
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The robust change in miRNA expression has resulted in very small changes in phenotype and 
gene expression. Large changes in gene expression are not expected after miRNA inhibition 
because miRNAs function as 'buffers' or 'fine tuners' of gene expression, rather than as master 
regulators [349, 350].  It is also important that there were many other mis-regulated miRNA 
with similar functions, (i.e. EMT suppressors, see results section 4.2.1). Stabilising the cells 
in the epithelial or mesenchymal state is one of the best studied and most important functions 
of miRNA, and there are dozens of miRNAs which are known to have a role in preventing 
EMT [351], so inhibiting as few as five may not have been enough to overcome the factors 
stabilising the cells in an adherent endothelial/epithelial phenotype. 
 Redundancy between different miRNAs controlling the same process is common enough that 
miRNA knockdown mice often have no phenotype [352, 353]  and this is recognised as one of 
the principal challenges in the field of miRNA research. Epithelial cells usually benefit from 
maintaining a stable phenotype, EMT is a major factor in oncogenesis and metastasis, and 
EMT suppressing miRNAs may be one of the most important factors in maintaining this 
stability and preventing tumourigenesis. One of the ways that miRNAs are able to do this is 
though auto-regulatory feedback loops, for example the miR-200 group inhibits ZEB1 and 
ZEB2, and these transcription factors inhibit miR-200 expression [354]. Figure 5.9 shows the 
complexity of the genetic network which governs miR-200c expression alone, this network of 
factors means that the change in expression of only one factor may not be enough to affect the 
 
 
Figure 5.8: qPCR data showing gene expression in hiPSCs and hESCs at day 12, 48hr after inhibition. 
Data is shown as mean ΔΔCT values ±SEM, n=3. 
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overall phenotype. 
 
 
 
 
  
Figure 5.9 
                         
Figure 5.9: Schematic of relationships between genes regulating miR-200c 
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6.  Effect of hypoxia on hematopoietic differentiation 
Hypoxia plays a key role in many of the cellular processes involved in this project, including 
HSC maintenance, hematopoietic differentiation, EMT and the regulation of many miRNAs. 
Studying the role of hypoxia in in vitro hematopoietic differentiation may help to improve the 
function of HSCs produced from pluripotent stem cells. 
There are two possible mechanisms by which hypoxia might improve the generation of 
multipotent hematopoietic progenitors. Firstly, hematopoiesis requires VEGF pathway 
activation and although VEGF is a cytokine which is present in the media throughout 
differentiation it is possible that it is more effective to activate this pathway endogenously. 
HIF-1α directly induces endogenous expression of several receptors and ligands in the VEGF 
pathway [355] in addition to multiple other hematopoeisis promoting pathways including 
Notch, EPO and CEBP signalling (reviewed by Liu et al 2012 [356]). 
Secondly hypoxia is a well established promoter of EMT [356, 357], which my miRNA data 
suggests is the primary point-of-failure in in vitro hematopoietic differentiation (results 
section 4). It was hoped that HIF-1α, by acting as a transcription factor for EMT promoting 
factors would indirectly reduce the expression of EMT blocking miRNAs. This might be 
more effective than inhibiting individual miRNAs because hypoxia is known to produce a 
global effect in terms of gene expression so there is less potential for functional redundancy 
between miRNAs reducing the effect of inhibition. HIF-1α is known to have numerous direct 
miRNA targets including miR-200b and miR-424 [398]. 
 
HIF-1α mediates cells’ response to hypoxic conditions: Cells must be able to sense 
hypoxia and respond by making adjustments to their metabolism and gene expression. HIF-1α 
is the master transcription factor responsible for this process. It is constitutively expressed but 
is rapidly broken down if oxygen levels are normal [358, 359]. Under normoxic conditions 
oxygen-dependent proteins hydroxylate prolyl residues on the HIF-1α protein, allowing von 
Hippel Lindau factor to ubiquitinate it [359-361]. In hypoxic conditions HIF-1α is stabilised 
and forms a heterodimer with HIF-1 β, and the complex acts as a transcription factor 
regulating hundreds of genes [358]. HIF-1α  stabilisation has a global effect on both gene and 
miRNA expression, affecting many cellular processes including glucose metabolism [362], 
the cell cycle [363], angiogenesis [364], morphogenesis [365, 366], inflammation [367], and 
hematopoiesis [367].  
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6.1 The role of HIF-1α in HSC biology 
There are several compelling lines of evidence that HIF-1α is critical in the maintenance of 
HSC. The HSC niche is hypoxic, with HSC clustering in the most hypoxic areas of the bone 
marrow, as shown by pimonidazole staining [368, 369], HIF-1α  expression [368], and direct 
measurement of oxygen tension in the bone marrow [370]. HIF-1α expression is important for 
the maintenance of the HSC population; HSC differentiation occurs along an increasing 
gradient of increasing oxygen tension [371] and stabilisation of HIF-1α increases HSC 
quiescence and survival [372]. 
The key effect of HIF-1α is on cellular metabolism: Hypoxia switches metabolism from 
mitochondrial-dependent oxidative phosphorylation to glycolysis, which is less efficient but 
requires less oxygen and produces fewer potentially mutagenic reactive oxygen species. HSC 
have a glycolytic metabolism which aids in maintaining a stable genome and is essential for 
keeping them in an undifferentiated and quiescent state [373-375]. Preventing mitochondrial 
respiration completely blocks HSC differentiation [376, 377]. 
HIF-1α can sometimes be stabilised even under normoxic conditions by cytokine signals such 
as SCF [378] and TPO [379] and this aids in maintaining the stem cell state when HSC leave 
the bone marrow niche [380]. This makes the picture more complex as it shows that HIF-1α is 
controlled by factors other than hypoxia, but it underscores the importance of HIF-1α in HSC 
biology. Danet et al. have shown that hypoxia also helps in maintaining HSC ex vivo [381, 
382].  
Most interesting from the point of view of those trying to produce HSCs from pluripotent 
stem cells is that hypoxia has also been shown to be important in hematopoietic development 
in the embryo: HIF-1α  expression is essential for HSC formation in zebrafish [383] and 
murine [384] embryos. HIF-1α is also an essential factor in HSC mobilisation [355, 385] 
which makes it a potential target for improving the motility of P-HPCs. 
6.2 Hypoxia promotes EHT 
Hypoxia is important for the maintenance and production of HSC in vivo, but it may also be 
helpful in the specific problem of producing HSC in vitro from pluripotent cells because it is 
likely to encourage the process of EHT, which has been identified as the major block in P-
HPC production (see results section 4).   Hypoxia promotes EMT [386, 387], which is much 
like EHT in that it involves dramatic changes; for example cell-cell junctions are removed and 
motility is increased, the cell changes from a flat, polarised cell morphology to a rounder, 
non-polar one and proliferation and resistance to apoptosis are increased. miRNA data from 
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this project shows aberrant high expression of miRNA which are known EMT inhibitors (see 
results section 4) and hypoxia might potentially reduce the expression of these miRNAs. 
EHT is also a similar process to angiogenesis. Angiogenesis is the process by which blood 
vessels expand their reach, primarily in response to signals emitted by hypoxic tissues. 
Endothelial cells become less adhesive and more proliferative and migrate towards the 
hypoxic tissue. Hematopoietic cells and endothelium have a common evolutionary [388] and 
developmental [74] origin and both angiogenesis and hematopoietic development are 
controlled by the same pathways and signalling molecules [389, 390]. For example the VEGF 
pathway, which is activated by HIF-1α is essential for both angiogenesis [391] and 
hematopoietic development [392]. The NF-KB pathway [393-395], EPO [396, 397] and GM-
CSF [390] are also essential for both hematopoietic development and angiogenesis, so it’s 
reasonable to hypothesise that a condition which promotes angiogenesis might also promote 
hematopoiesis. 
Given the connection between hypoxia and EHT it is possible that hypoxia would improve the 
ability of hESC and hiPSC to produce functional hematopoietic progenitors. This might be 
more effective than inhibiting individual miRNAs because hypoxia is known to produce a 
global effect in terms of gene expression so there is less potential for functional redundancy 
between miRNAs reducing the effect of inhibition. HIF-1α is known to have numerous direct 
miRNA targets including miR-200b and miR-424 [398]. 
6.3 Measuring the effect of hypoxia on hematopoiesis 
The effect of hypoxia on hematopoiesis was tested on both the hESC and hiPSC cell lines. 
CoCl2 is commonly used by researchers to mimic the effect of hypoxia [399], and is more 
practical to use for many experiments, as different concentrations can be tested in parallel and 
a specialised hypoxic incubator is not needed. Cobalt mimics hypoxia by binding to HIF-1α 
and preventing its ubiquitination [400] but since hypoxia may affect the P-HPCs by HIF-1α 
independent mechanisms [401] and CoCl2 can potentially affect other cellular pathways [402] 
differentiation was also done in a hypoxic incubator at 5% O2 so as to test the effect of true 
hypoxia. The effect on hematopoietic differentiation was tested using the same techniques 
described in previous chapters: colony forming assays, flow cytometry and qPCR of gene and 
miRNA expression.  
Preliminary tests were done to optimise the concentration of CoCl2 and the time-points at 
which it should be added to the differentiation cultures. These tests found that while CoCl2 
was present in the culture throughout development from day 0 until they were analysed at day 
135 
 
12 strong measurable effects on numbers for hematopoietic progenitors were seen, but there 
was  little effect at all when CoCl2 was added or removed at other time-points during 
development. It was also found that the concentration which had the maximum effect on 
numbers of hematopoietic progenitors was 0.1ug/ml CoCl2 (data not shown). Therefore the 
analysis in this chapter was done on cells which were exposed to either 5% O2 or 0.1 μg/ml 
CoCl2 throughout development. 
The effect of hypoxia on HIF-1α expression was tested by qPCR (Figure 6.1). The 5% O2 
condition shows a slight increase in HIF-1α, a larger increase would not be expected as HIF-
1α  is constitutively expressed and is mostly regulated by oxygen levels in  a post-
transcriptional way, by degradation or stabilisation of the protein [358, 359]. 
 
CFU assays show increases in hematopoietic progenitors after treatment with hypoxia 
or CoCl2: Both cell lines show an overall increase in the number of hematopoietic colonies 
produced by both the hypoxic (5% O2) and hypoxia mimic (CoCl2) conditions (see Figure 
6.2). The increase in the number of colonies is comparable for both lines, the apparent 
Figure 6.1 
                    
Figure 6.1: graph showing relative HIF-1α expression in induced pluripotent stem cells 
differentiated to day 12 in normoxia and hypoxia conditions. Expression calculated using the 
ΔΔCT method. 
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differences shown in the chart are due to the figures being adjusted for passage number (see 
results chapter 3.3). When this data is broken down by colony type the results are more 
interesting, showing different effects for the two different conditions (Figure 6.3). Hypoxia 
produces a greater number of erythroid colonies, both BFU-E and CFU-E. Although the 
increase isn’t statistically significant in all the experiments it appears to be consistent across 
both cell lines. This is completely unsurprising as hypoxia is one of the major drivers for 
erythropoiesis in vivo. Hypoxia also promotes a significant increase in CFU-M across both 
cell lines, which is a less intuitive result. However it is the CoCl2 induced increase in the 
numbers of CFU-GM and especially CFU-GEMM which are the most interesting for this 
project because numbers of multi-potent progenitors can be considered stand-ins for HSCs 
(see results section 3.2.3). Both cell lines show a greater than two-fold average increase in 
CFU-GEMM numbers in cells treated with CoCl2. 
CoCl2 and hypoxia have different effects: CoCl2 appears to have very little effect on 
erythropoiesis, and a much greater effect on the numbers of CFU-GM and CFU-GEMMs, 
whereas the results from the experiments where the cells were treated with hypoxia show the 
opposite. It is possible that this is due to the differences in biological action described above, 
but it would be unlikely to have so different an effect. It is more likely that the concentration 
of CoCl2 used for these experiments corresponds to a different concentration of oxygen than 
the 5% used in the incubator. Blood cells regulate their response to O2 levels very precisely 
and are likely to respond differently to different levels, for example HSC are stable at the 
slightly hypoxic physiological levels of O2 concentration typically found in the bone marrow 
but will respond urgently to unusually O2 low levels by producing large numbers of 
erythrocytes.  
Effect of hypoxia on cell surface marker expression: The results of the flow cytometry 
experiments using the Kennedy 2012 markers are not clear. From the CFU data you would 
expect to see more CD235a+ cells in the hypoxia treated cell population as this is an erythroid 
marker, but this does not appear to be the case for either cell line (see Figure 6.4a).  Nor do 
either hypoxia or CoCl2 treated populations have a higher proportion of hematopoietic cells 
overall. The CoCl2 treated SB-Ad3 cells have a significantly higher proportion of definitive 
progenitors, and the H9 CoCl2 treated cells have a significantly higher proportion of 
megakaryocyte erythroid progenitors and a significantly lower proportion of multi-lineage 
myeloid progenitors, but none of these results are replicated in the other cell line. The cell 
surface markers may not correspond to the colonies formed because the colonies have been 
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cultured in a different cytokine mix for a further 14 days, but overall the results of this 
experiment are inconclusive.  
However, since there was a clear increase in the number of CFU-GEMM colonies in the 
CoCl2 treated cells they were also analysed for the markers described by Notta et al. as being 
specific for LT-HSC [159].  There is a lot of variation in the numbers of this rare cell 
population but the H9 cells showed an increase of over 2-fold in CoCl2 treated cells (see 
Figure 6.4b). The results for the SB-Ad3 cells are skewed by a major outlier, but aside from 
this they also show an increase of a similar amount. Although I have not demonstrated that 
the pluripotent-derived cells expressing this combination of markers are LT-HSCs capable of 
long term engraftment, this is an increase of a similar amount to the increase in CFU-GEMMs 
and supports the colony assay data which suggests that treating cells with CoCl2 during 
hematopoietic differentiation can increase the number of progenitors with multi-potent 
hematopoietic potential. 
miRNA and gene expression during hypoxic hematopoietic differentiation: miRNA 
expression of the key miRNAs which were chosen for inhibition in results chapter 4 was 
analysed, in the hope that hypoxia might bring their expression more into line with the 
expression in cord blood and bone marrow hematopoietic progenitors. Unfortunately the 
effect on most of the miRNA was small, with only miR-148a being significantly affected, 
when exposed to hypoxic conditions (see Figure 6.5). The lack of overall change in miRNA 
expression suggests that the positive effect that CoCl2 and hypoxia have on colony numbers is 
due more to the effect of stabilising progenitors against differentiation rather than enhanced 
EHT. Much like the miRNA expression, hypoxia had much less effect on the expression of 
hematopoietic genes than was expected, none of them were significantly changed (see Figure 
6.6).  
Although these experiments didn’t produce the results that were expected in terms of 
changing gene or miRNA expression the considerable increases in CFU-GM and CFU-
GEMM produced by CoCl2 exposure are a promising result and this technically simple 
method of boosting the numbers of multi-potent progenitors may be helpful in future 
experiments.
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Figure 6.2                       
  
Figure 6.2: Bar charts show a comparison of total CFU numbers under different experimental conditions in two cell lines. Colony numbers are 
counted from a starting population of 30000 cells, the means are normalised for the effect of passage number using the estimated marginal means 
method ±SEM. The cells were differentiated to day 12 according to the protocol given in methods section 2.1.2 and then cultured in methocult 
medium for 14 days before the colonies were scored. Three experimental conditions were tested: a control, 5% O2 throughout differentiation and 
0.1 μg/ml CoCl2 throughout differentiation. n = 3. 
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Figure 6.3a  
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Figure 6.3b 
                          
Figure 6.3: Bar charts show a comparison of individual colony types produced by the experiment shown in figure 6.1. Colony numbers are counted from a 
starting population of 30000 cells, estimated marginal means ±SEM, n = 3. Graphs show a control, 5% O2 throughout differentiation and 0.1 μg/ml CoCl2 
throughout differentiation. a: SB-Ad3 cells, b: H9 cells. 
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Figure 6.4a 
 
Figure 6.4a: Graphs showing percentage of live cells expressing Megakaryocyte erythroid progenitors (MkEP) = CD43+CD34+CD235+CD41a+CD45-; Multi-
lineage myeloid progenitors (MMp) = CD43+CD34+CD235-CD41a-CD45-; Definitive hematopoietic progenitors = CD43+CD34+/-CD235-CD41a-CD45+. 
Cells were generated by differentiating two pluripotent cell lines  until day 12 under three experimental conditions: a control, 5% O2 throughout differentiation 
and 0.1 μg/ml CoCl2 throughout differentiation. Data is shown as estimated marginal means normalised for the effect of passage number ±SEM, n=3. 
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 Figure 6.4b 
 
Figure 6.4b:  Graphs showing fold-change in percentage of live cells expressing markers for LT-HSC 
(CD34+CD38-CD45RA-CD90+CD49f+). Cells were generated by differentiating two pluripotent cell lines 
(SB-Ad3 cells and  H9 cells) until day 12 under either control conditions or treated with 0.1 μg/ml CoCl2 
throughout differentiation. Data is shown as mean fold-change ±SD, n=3. 
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Figure 6.5 
Figure 6.5: qPCR expression analysis of miRNA normalised to RNU48 and RNU44 in SB-Ad3 
and H9 cells after 12 days of differentiation under the effects of 0.1 μg/ml CoCl2 or 5% O2 
throughout differentiation normalised against control conditions. Data is shown as mean±SEM, 
n=3. 
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Figure 6.6 
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Figure 6.6: Gene expression analysis of miRNA normalised to GAPDH in SB-Ad3 and H9 cells 
after 12 days of differentiation under the effects of 0.1 μg/ml CoCl2 or 5% O2 throughout 
differentiation or control conditions. Data is shown as mean±SEM, n=3. 
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7. Discussion 
7.1 Recent progress in the in vitro production of LT-HSCs:  
Manufacturing HSC from pluripotent cells has been a long term goal of stem cell research. A 
great deal of progress has been made in this field in the last few years, allowing long term 
repopulating HSC to be produced from human cells for the first time. Although there is 
progress in elucidating the inductive factors which trigger HSC formation in the embryo, the 
most exciting results have been produced by direct reprogramming induced by the ectopic 
expression of various transcription factors (see below, section 7.1.2). In spite of this progress 
the methods used still require the cells to be co-cultured with animal cells either in vitro or in 
vivo, suggesting there are key factors produced by the hematopoietic niche which have yet to 
be discovered.  
7.1.1 Inductive factors for HSC development 
In vitro hematopoietic development closely follows the development of hematopoietic cells in 
the embryo, and mimicking the signals developing HSCs receive in the embryo should allow 
them to be produced in vitro. An incomplete understanding of hematopoietic ontogeny and 
the signalling pathways and transcription factors involved has hampered the efforts towards 
this but recent developments are building a more complete picture. PSC differentiation 
systems are an excellent model for analysing the factors necessary for differentiation as any 
factor can be easily added or  removed. This kind of experiment has demonstrated the 
importance of stage-specific Activin-nodal signalling and Wnt3 signalling [8, 49], as well as 
other factors such as notch signalling [403], mechanical forces and nitric oxide signalling 
[404, 405] in the specification of definitive hematopoietic cells.  
Other systems such as animal models of embryogenesis can also be helpful in elucidating 
these pathways. More information should eventually make it possible to promote the 
formation of HSC from pluripotent stem cells, and progress has been made on screening small 
molecules which can promote HSC formation [406]. For example evidence showing that 
hypoxia (as mimicked by CoCl2) promotes HSC formation in the zebrafish embryo has been 
shown [383, 407] but it has now been demonstrated to promote hematopoiesis in human cells 
(see results chapter 6). Further progress towards learning all the inductive factors necessary 
for HSC formation will be aided by model systems with reporter genes marking the earliest 
hematopoietic cells [149, 408, 409], but there is still much work to be done, and it is clear that 
producing HSC from pluripotent stem cells will not be as easy as producing other 
hematopoietic cell types. 
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7.1.2 Direct reprogramming towards HSCs 
Recent experiments using direct reprogramming to make HSCs have been more successful 
than the previous approach of using cytokines to direct differentiation. Direct conversion from 
fibroblasts to hematopoietic cells was first achieved by Szabo et al. in 2010 [410], by 
ectopically expressing OCT4 and culturing the cells with hematopoietic cytokines. Direct 
conversion from fibroblasts using various combinations of transcription factors (see Table 
7.1) has allowed multi-potent hematopoietic progenitors to be made [411, 412] but there has 
been more success in reprogramming cells from cell types which are from lineages to more 
closely related HSC such as committed blood progenitors [413] or endothelial cells [414].  
Expressing FOSB, GFI1, RUNX1, and SPI1 in human endothelial cells is the most successful 
attempt at manufacturing human HSC to date, achieving relatively high levels of multi-
lineage engraftment over serial transplantations [414]. The authors suggest that using starting 
cells which are epigenetically and transcriptionally similar to HSC allows them to be more 
easily reprogrammed. Certainly chromatin remodelling plays an important role in the 
development for hematopoietic cells, from controlling the original hematopoietic specification 
of mesoderm by HOXB4 expression [415] to down-regulating endothelial genes and up-
regulating hematopoietic ones during EHT [416-418] and in maintaining HSC in the adult 
[152, 419-421], so reprogramming to HSC would have to not only make sure that the right 
transcription factors  are expressed but also make sure that the enhancers of hematopoietic 
genes had the correct histone modifications.  
Interestingly, although there are several papers showing direct conversion to HPSCs no 
consensus has been formed on which transcription factors are necessary for the conversion. 
Different transcription factors would be expected when using different starting cell types but 
there also appears to be some differences caused by overlapping functions or stochastic 
difference based on cell line. That being said there are some transcription factors which many 
of the papers have in common, which are known key regulatory factors of haematopoiesis and 
particularly EHT, such as GATA2, LMO2, GFI1 and RUNX1 (see results section 3.2.4). 
Table 7.1: Factors used for direct reprogramming 
Starting cell 
type 
Transcription 
factors Other factors Outcome Reference 
mESCs HoxB4 
Co-culture 
with OP9 cells 
and 
hematopoietic 
Long term multi-
lineage hematopoiesis. [50] 
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cytokines. 
Human 
fibroblasts OCT4 
Culture with 
hematopoietic 
cytokines. 
CD45+ cells, low levels 
of mostly myeloid 
engraftment. [410] 
Murine 
fibroblasts 
Gata2, 
Gfi1b, cFos, 
and Etv6 
Co-culture 
with stromal 
cells. 
Definitive 
hematopoiesis (based 
on gene and marker 
expression), mostly 
myeloid cells in CFU 
assays. [412] 
hESCs and 
hiPSCs 
ETV2, 
GATA2; 
TAL1, 
GATA2 
Culture with 
hematopoietic 
cytokines. 
Definitive 
hematopoietic cells 
based on marker 
expression and CFU 
assays, no transplants 
were performed. [422] 
Murine 
fibroblasts 
ERG, 
GATA2, 
LMO2, 
RUNX1c, 
and SCL 
Culture with 
hematopoietic 
cytokines. 
Low levels of short 
term engraftment. [411] 
Murine 
committed 
lymphoid 
and myeloid 
progenitors 
Hlf, Runx1t1, 
Pbx1, Lmo2, 
Zfp37, and 
Prdm5 
Immediate 
transplant after 
transfection. 
Low levels of multi-
lineage engraftment 
after serial 
transplantation. [413] 
HUVECs 
(human 
umbilical 
cord 
vascular 
endothelial 
cells) 
FOSB, GFI1, 
RUNX1, and 
SPI1 
Co-culture 
with E4ECs 
(immortalised 
human 
endothelial 
cells). 
Definitive cells positive 
for LT-HSC markers, 
transplant into NSG 
mice at relatively high 
levels over serial 
transplants, mostly 
myeloid cells. [414] 
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7.1.3 The hematopoietic niche in HSC formation 
Co-culture with stromal cells such as OP9s has long been used to differentiate cells into 
hematopoietic cell types (see introduction section 1.3.2), and recent papers have emphasised 
the importance of the hematopoietic niche in HSC formation. The niche has been replicated in 
several ways, including by teratoma formation, in animal bone marrow and with co-cultures 
of niche derived cells. 
Differentiation of pluripotent cells in vivo: HSC have been made from pluripotent cells 
which were injected directly into animals and allowed to form teratomas. The hESCs in the 
teratomas were directed towards the hematopoietic lineage by co-injection with OP9s [47, 48] 
or with hematopoietic cytokines [48] and the teratomas were shown to contain bone marrow-
like tissues, around which the HSC were clustered. These experiments showed colonisation of 
the animals’ bone marrow and spleen with human hematopoietic cells, which could engraft 
after secondary transplant, although in low numbers and with mostly myeloid lineage 
differentiation. These experiments show that HSC can be made from human pluripotent stem 
cells, but that there are key factors in the in vivo system which are necessary for successful 
differentiation into HSCs.  A similar experiment found that pluripotent stem cells which were 
differentiated towards the hematopoietic lineage could successfully differentiate into HSC 
when transplanted into a mouse [46], but only when the cells were at day 3 of differentiation 
(which corresponds to the early hemogenic endothelium stage). Cells injected after that stage 
were unable to form HSC, suggesting that there are conditions in vivo which are permissive of 
HSC formation which are absent in their in vitro culture system. Riddell et al [413] 
transplanted the committed progenitors they had transformed immediately after transfecting 
them with their transcription factors, possibly allowing the hematopoietic niche to direct the 
reprogramming of the cells. 
HSC using the vascular niche: The vascular niche is especially important in the 
differentiation and maintenance of HSC. Engraftable multi-potent progenitors have been 
made from hiPSCs using co-culture with endothelial cells expressing notch ligands JAG1 and 
DLL4 [423]. Sandler et al. [414] made LT-HSC by directly reprogramming endothelial cells 
but their method requires co-culture with immortalised endothelial cells. 
Although differentiation in vivo or with co-culture of cells from the hematopoietic niche have 
been the most successful attempts at creating HSCs in the lab it is not a clinically viable 
strategy to use animals, animal cells or immortalised cell lines, both because it is risky and 
because the results are less reliable than in feeder free systems. These experiments are 
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promising however, because they will allow the factors which make up the HSC permissive 
niche to be discovered.  
7.2 Is miRNA manipulation a viable technique for HSC induction? 
Work in this project has been equivalent to direct reprogramming from HE cells or 
hematopoietic progenitors using miRNAs rather than transcription factors. Other papers have 
shown that the more similar the cell type to HSC the easier reprogramming is (see above, 
section 7.1) and the success of reprogramming endothelial cells or committed hematopoietic 
progenitors shows that our approach has promise.  Having said that, these successful attempts 
used starting cells which were derived in vivo rather than from pluripotent stem cells so they 
would not have had the same epigenetic profile as endothelial cells and hematopoietic 
progenitors derived in vitro from pluripotent cells [424]. In that sense the experiments in this 
project are more like the experiments where HOXB4 expression was used to make ESC 
derived hematopoietic progenitors into functional HSCs  [50, 425]. 
Reprogramming cell fate with miRNA: It is possible to reprogram cell fate with ectopic 
miRNA expression; in combination with Yamanaka factors SOX2, KLF4, and OCT4, 
expression of the miR-302 cluster is known to enhance the efficiency of reprogramming to a 
pluripotent state [426], and the combination of mir-200c, mir-302 and mir-369 can induce 
pluripotency without the need for any transcription factors [21]. miRNA have also been used 
for direct reprogramming. This is usually done in combination with transcription factors, for 
example fibroblasts can be turned into neurons with the ectopic expression of miR-124, 
MYT1L and BRN2 [427], or fibroblasts into monocytes using miR-125b and SOX2 [428]. In 
these experiments the miRNA function as enhancers of reprogramming which is done by the 
transcription factors, but it is also possible to directly reprogram cells with miRNA alone, for 
example cardiomyocytes can be made from fibroblasts with a combination of miR-1, miR-
133, miR-208, and miR-499 [429]. 
miRNAs are certainly important in the differentiation of hematopoietic cells (see 
introduction section 1.4.4), but although the results of this project show that a number of 
miRNAs are mis-regulated, attempting to fix the problem by manipulating the expression of 
miRNAs may not be the best approach, because miRNA are modulators and have only a small 
effect on any particular gene’s expression (see results chapter 5). miRNA-reprogramming 
without transcription factors typically occurs at very low efficiency. Although the 
experiments in this project should be helped by the fact that the cells are reprogrammed from 
hematopoietic progenitors, reducing the ‘distance’ in gene expression, they may also be 
hindered by low efficiency leading to only a tiny number of cells being transformed, which 
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would lead to a small effect size perhaps undetectable in such a ‘noisy’ experimental system 
with large amounts of variability. Although miRNA can control genes which affect epigenetic 
factors this is unlikely to be a short term effect, so will not help to overcome the epigenetic 
differences between in vitro-generated hematopoietic progenitors and LT-HSC. 
 The majority of experiments where transcription factors were used to reprogram cells to 
hematopoietic cells also used a more systematic approach, screening dozens of transcription 
factors by ectopically expressing all of them at once to create a large effect and then 
eliminating the ones that are unnecessary. If it was possible to eliminate the expression of all 
the candidates flagged by the microarray data a larger effect may have been seen. This was 
not practical using our techniques as large amounts of lipofectamine are toxic to the cell. 
It may also be particularly difficult to change the expression of the genes targeted by the 
miRNAs identified as mis-regulated in this study because the miRNAs are part of a network 
of tumour suppressors, and the cell benefits by having multiple redundant regulators 
regulating the stability of potentially oncogenic genes. The technique that was used for 
miRNA inhibition was transient, and it may not have had a strong enough effect for long 
enough to overcome the barriers to EHT. 
7.3 HSC emergence, tumour suppressors, and EHT 
7.3.1 Tumour suppressors prevent the formation of HSC in vitro 
 The formation of HSCs in the embryo necessitates that at some point cells should lose 
contact with and leave their parent tissue and survive doing so with their self-renewal 
capabilities intact. This process is something that is undesirable under any other 
circumstances as it is equivalent to the metastasis of cancerous cells. It is therefore not 
surprising that HSC formation is so tightly controlled both spatially and temporally (see 
introduction section 1.3.1). It is also not surprising that it is so difficult to produce HSC in 
vitro in comparison to hematopoietic lineages without self-renewal capability such as 
primitive hematopoietic progenitors and lineage restricted definitive progenitors.  
The data on microRNA expression produced in this project bears this out, miRNA with 
functions as tumour suppressors are the largest group which are highly expressed in the in 
vitro cultures in comparison to HSC derived from bone marrow or cord blood. Unfortunately 
this means that attempting to down-regulate these miRNAs engages multiple robust 
anticancer mechanisms, which appear either suppress EHT, preventing the cells from 
acquiring a motile phenotype and homing capabilities, or to allow EHT but remove the cells’ 
self-renewal capacity, allowing them to form hematopoietic colonies in vitro but preventing 
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them from permanently repopulating bone marrow when transplanted. This is supported by 
the evidence that loss of tumour suppressors such as p53 dramatically improves the efficiency 
of direct reprogramming to HSCs [411] and the fact that no tumours have been reported in 
any experiment where P-HPCs have been transplanted into immune-deficient mice. 
7.3.2 HSC form via a multi-step specification process 
The question is how nascent HSC in the embryo can overcome the anti-cancer mechanisms. 
Evidence suggests a multi-step specification process, where HE capable of forming HSC 
(HSC-HE) is specified early in the developmental process, but which only form HSC when a 
variety of conditions are met. The HE is ‘primed’- epigenetic and transcriptional factors are 
put in place which would allow self-renewing cells to undergo EHT, and then ‘triggered’ by a 
selection of factors present in only the dorsal aorta. 
HSC-HE is specified early in embryogenesis:  Haemogenic endothelium is a separate 
lineage from other types of endothelium [61], and it has been shown that HE cells are an 
intermediate stage to becoming hematopoietic cells rather than being bi-potent progenitors as 
was previously believed. However it also seems that there are multiple lineages of HE which 
give rise to different types of hematopoietic progenitors. 
mESC which are differentiated towards the hematopoietic lineage can engraft in a recipient 
animal and form functional HSC, but only if they are transplanted at day 3 of differentiation, 
when they are still in the early hemogenic endothelium stage; if they are transplanted at a later 
stage they will not generate HSC [46], which suggests that the in vitro differentiation protocol 
is missing a factor which must be present at the very earliest stages of hematopoietic 
specification. Experiments in transgenic mice show that the HE which generates EMP and the 
HE which generates HSC are distinct lineages [430] and in vitro experiments on hESCs 
demonstrate that endothelial progenitors for the definitive and primitive hematopoietic 
lineages are determined as early as day 3 of differentiation by the presence or absence of Wnt 
and activin-nodal signalling [8, 49]. The idea that HSC-HE is separate from other HE lineages 
is supported by the direct reprogramming experiments by Elcheva et al [422] which show that 
ETV2 and GATA2 promote conversion to HE which generates definitive cells whereas TAL1 
and GATA2 promote conversion to HE which generates definitive cells. 
It is clear that the specification of HSC-HE occurs early in development, well before the 
emergence of HSC. Unfortunately there are no known markers which can differentiate HSC-
HE from other lineages so although they differentiate early it is difficult to separate them in 
the embryo or in vitro, making the progression from mesoderm to HSC-HE difficult to study.  
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Signalling in the AGM triggers EHT of HSC: HSC-HE once formed is not destined to 
become HSCs, it can only do so when triggered by a combination of mechanical, chemical 
and biological signals found only in the AGM for a short time in embryogenesis. Signalling 
from the sub-aortic mesenchyme is required for HSC formation [431], as are the mechanical 
stresses caused by blood flow in the lumen of the aorta [405]. Signalling by SCF, BMP4, the 
Wnt pathway, retinoic acid and signalling from the sympathetic nervous system (see review 
by Rowe et al for list of all known factors [3]) are either necessary for HSC formation or 
promote it, although this should not be considered a complete list of necessary factors as there 
may be others which are not yet known. This multiple step process for the specification of 
HSC allows very precise control over when and where they can form, protecting the organism 
from the effects of allowing self-renewing cells to undergo EMT. 
7.4 Future work 
Evidence from this project suggests that the major cause of the failure of motility and 
engraftment shown by P-HPCs is due to over-expression of tumour suppressor factors. 
miRNA inhibition may not be the best solution for this problem because the tumour 
suppressor network is more robust  than was initially apparent. Although the P-HPCs 
produced by treating pluripotent cells with cytokines share many common attributes with LT-
HSC in terms of gene and marker expression, in vitro differentiation capacity etc. there are 
powerful mechanisms preventing the production of motile self-renewing cells in culture. 
In order to overcome this problem some groups have turned to direct conversion, which has 
the advantage of being rapid and the possibility of using cells which are epigenetically similar 
to the desired cell type, or even of converting mononuclear blood cells, avoiding the necessity 
of inducing EHT altogether. However there are some potential problems with this approach. 
Most methods have used transcription factors introduced to the cells in integrating viruses, 
opening up the possibility of insertional oncogenesis [432]. Although there are methods to 
introduce genes into cells without integrating them into the genome it remains to be seen if 
they will be efficient and effective enough for reprogramming cells to HSC. There is also a 
problem that many of the reprogramming techniques use pluripotency factors, which are 
potentially oncogenic [433]. 
With or without ectopically expressed transcription factors, it is still necessary to use animals 
or animal cells to complete the transformation into HSC which means there are essential 
factors which are unknown and will have to be elucidated before these techniques can be used 
clinically. Systematically studying embryonic and in vitro hematopoietic differentiation and 
the ways in which they diverge transcriptionally and epigenetically should be the priority in 
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this field. This work is already being done in murine hematopoiesis from mESCs [434] but 
should be continued in human cells. Analysis of miRNA expression should be included in this 
work, but changing miRNA expression alone is not likely to have a sufficient effect, it would 
probably be more effective to analyse the transcription factors which control miRNA 
expression and how they, in turn, are regulated. 
 
 
References 
 
1. Mallanna, S.K. and A. Rizzino, Emerging roles of microRNAs in the control of embryonic stem 
cells and the generation of induced pluripotent stem cells. Dev Biol, 2010. 344(1): p. 16-25. 
2. Olivier, E.N., et al., High-Efficiency Serum-Free Feeder-Free Erythroid Differentiation of 
Human Pluripotent Stem Cells Using Small Molecules. Stem Cells Transl Med, 2016. 
3. Rowe, R.G., et al., Engineering Hematopoietic Stem Cells: Lessons from Development. Cell 
Stem Cell, 2016. 18(6): p. 707-20. 
4. http://www.csa.com/discoveryguides/stemcell/overview.php. 
5. https://www.thermofisher.com/uk/en/home/life-science/stem-cell-research/stem-cell-
culture/stem-cell-research-misc/stempro-ezpassage.html. 
6.     
http://www.ibioexperts.com/index.php?show=services&cat=2&act=details&id=70&PHPSESSI
D=b81dceebf57bcba97c1a14bf93f01611. 
7. Morrison, S.J. and D.T. Scadden, The bone marrow niche for haematopoietic stem cells. 
Nature, 2014. 505(7483): p. 327-34. 
8. Kennedy, M., et al., T lymphocyte potential marks the emergence of definitive hematopoietic 
progenitors in human pluripotent stem cell differentiation cultures. Cell Rep, 2012. 2(6): p. 
1722-35. 
9. Lancrin, C., et al., The haemangioblast generates haematopoietic cells through a haemogenic 
endothelium stage. Nature, 2009. 457(7231): p. 892-5. 
10. Chen, C., et al., Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids 
Res, 2005. 33(20): p. e179. 
11. Passweg, J.R., et al., The EBMT activity survey: 1990-2010. Bone Marrow Transplant, 2012. 
47(7): p. 906-23. 
12. Oran, B. and E. Shpall, Umbilical cord blood transplantation: a maturing technology. 
Hematology Am Soc Hematol Educ Program, 2012. 2012: p. 215-22. 
13. Thomson, J.A., et al., Embryonic stem cell lines derived from human blastocysts. Science, 
1998. 282(5391): p. 1145-7. 
14. Takahashi, K. and S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors. Cell, 2006. 126(4): p. 663-76. 
15. Yu, J., et al., Induced pluripotent stem cell lines derived from human somatic cells. Science, 
2007. 318(5858): p. 1917-20. 
16. Takahashi, K., et al., Induction of pluripotent stem cells from adult human fibroblasts by 
defined factors. Cell, 2007. 131(5): p. 861-72. 
17. Zhou, W. and C.R. Freed, Adenoviral gene delivery can reprogram human fibroblasts to 
induced pluripotent stem cells. Stem Cells, 2009. 27(11): p. 2667-74. 
155 
 
18. Fusaki, N., et al., Efficient induction of transgene-free human pluripotent stem cells using a 
vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc 
Jpn Acad Ser B Phys Biol Sci, 2009. 85(8): p. 348-62. 
19. Okita, K., et al., Generation of mouse induced pluripotent stem cells without viral vectors. 
Science, 2008. 322(5903): p. 949-53. 
20. Woltjen, K., et al., piggyBac transposition reprograms fibroblasts to induced pluripotent stem 
cells. Nature, 2009. 458(7239): p. 766-70. 
21. Miyoshi, N., et al., Reprogramming of mouse and human cells to pluripotency using mature 
microRNAs. Cell Stem Cell, 2011. 8(6): p. 633-8. 
22. Warren, L., et al., Highly efficient reprogramming to pluripotency and directed differentiation 
of human cells with synthetic modified mRNA. Cell Stem Cell, 2010. 7(5): p. 618-30. 
23. Kim, D., et al., Generation of human induced pluripotent stem cells by direct delivery of 
reprogramming proteins. Cell Stem Cell, 2009. 4(6): p. 472-6. 
24. Zhou, H., et al., Generation of induced pluripotent stem cells using recombinant proteins. Cell 
Stem Cell, 2009. 4(5): p. 381-4. 
25. Hou, P., et al., Pluripotent stem cells induced from mouse somatic cells by small-molecule 
compounds. Science, 2013. 341(6146): p. 651-4. 
26. Hyka-Nouspikel, N., et al., Deficient DNA damage response and cell cycle checkpoints lead to 
accumulation of point mutations in human embryonic stem cells. Stem Cells, 2012. 30(9): p. 
1901-10. 
27. Allegrucci, C., et al., Restriction landmark genome scanning identifies culture-induced DNA 
methylation instability in the human embryonic stem cell epigenome. Hum Mol Genet, 2007. 
16(10): p. 1253-68. 
28. Baker, D.E., et al., Adaptation to culture of human embryonic stem cells and oncogenesis in 
vivo. Nat Biotechnol, 2007. 25(2): p. 207-15. 
29. Ji, J., et al., Elevated coding mutation rate during the reprogramming of human somatic cells 
into induced pluripotent stem cells. Stem Cells, 2012. 30(3): p. 435-40. 
30. Hanna, J.H., K. Saha, and R. Jaenisch, Pluripotency and cellular reprogramming: facts, 
hypotheses, unresolved issues. Cell, 2010. 143(4): p. 508-25. 
31. Tobin, S.C. and K. Kim, Generating pluripotent stem cells: differential epigenetic changes 
during cellular reprogramming. FEBS Lett, 2012. 586(18): p. 2874-81. 
32. http://www.geron.com/media/pressview.aspx?id=1188. 
33. Ilic, D., et al., Human embryonic and induced pluripotent stem cells in clinical trials. Br Med 
Bull, 2015. 116: p. 19-27. 
34. Schwartz, S.D., et al., Human embryonic stem cell-derived retinal pigment epithelium in 
patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-
up of two open-label phase 1/2 studies. Lancet, 2015. 385(9967): p. 509-16. 
35. Sayed, N., C. Liu, and J.C. Wu, Translation of Human-Induced Pluripotent Stem Cells: From 
Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol, 2016. 67(18): p. 2161-76. 
36. Menasche, P., et al., Human embryonic stem cell-derived cardiac progenitors for severe heart 
failure treatment: first clinical case report. Eur Heart J, 2015. 36(30): p. 2011-7. 
37. Risueno, R.M., et al., Inability of human induced pluripotent stem cell-hematopoietic 
derivatives to downregulate microRNAs in vivo reveals a block in xenograft hematopoietic 
regeneration. Stem Cells, 2012. 30(2): p. 131-9. 
38. Wang, L., et al., Generation of hematopoietic repopulating cells from human embryonic stem 
cells independent of ectopic HOXB4 expression. J Exp Med, 2005. 201(10): p. 1603-14. 
39. Ledran, M.H., et al., Efficient hematopoietic differentiation of human embryonic stem cells on 
stromal cells derived from hematopoietic niches. Cell Stem Cell, 2008. 3(1): p. 85-98. 
40. Woods, N.B., et al., Brief report: efficient generation of hematopoietic precursors and 
progenitors from human pluripotent stem cell lines. Stem Cells, 2011. 29(7): p. 1158-64. 
41. Tian, X., et al., Bioluminescent imaging demonstrates that transplanted human embryonic 
stem cell-derived CD34(+) cells preferentially develop into endothelial cells. Stem Cells, 2009. 
27(11): p. 2675-85. 
156 
 
42. Lu, M., et al., Enhanced generation of hematopoietic cells from human hepatocarcinoma cell-
stimulated human embryonic and induced pluripotent stem cells. Exp Hematol, 2009. 37(8): 
p. 924-36. 
43. Tian, X., et al., Hematopoietic engraftment of human embryonic stem cell-derived cells is 
regulated by recipient innate immunity. Stem Cells, 2006. 24(5): p. 1370-80. 
44. Takeuchi, M., et al., Cultivation of aorta-gonad-mesonephros-derived hematopoietic stem 
cells in the fetal liver microenvironment amplifies long-term repopulating activity and 
enhances engraftment to the bone marrow. Blood, 2002. 99(4): p. 1190-6. 
45. Narayan, A.D., et al., Human embryonic stem cell-derived hematopoietic cells are capable of 
engrafting primary as well as secondary fetal sheep recipients. Blood, 2006. 107(5): p. 2180-
3. 
46. Pearson, S., et al., In Vivo Repopulating Activity Emerges at the Onset of Hematopoietic 
Specification during Embryonic Stem Cell Differentiation. Stem Cell Reports, 2015. 4(3): p. 
431-44. 
47. Suzuki, N., et al., Generation of engraftable hematopoietic stem cells from induced 
pluripotent stem cells by way of teratoma formation. Mol Ther, 2013. 21(7): p. 1424-31. 
48. Amabile, G., et al., In vivo generation of transplantable human hematopoietic cells from 
induced pluripotent stem cells. Blood, 2013. 121(8): p. 1255-64. 
49. Sturgeon, C.M., et al., Wnt signaling controls the specification of definitive and primitive 
hematopoiesis from human pluripotent stem cells. Nat Biotechnol, 2014. 
50. Kyba, M., R.C. Perlingeiro, and G.Q. Daley, HoxB4 confers definitive lymphoid-myeloid 
engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell, 
2002. 109(1): p. 29-37. 
51. Xiong, J.W., Molecular and developmental biology of the hemangioblast. Dev Dyn, 2008. 
237(5): p. 1218-31. 
52. Huber, T.L., et al., Haemangioblast commitment is initiated in the primitive streak of the 
mouse embryo. Nature, 2004. 432(7017): p. 625-30. 
53. Choi, K., Hemangioblast development and regulation. Biochem Cell Biol, 1998. 76(6): p. 947-
56. 
54. Slukvin, II, Deciphering the hierarchy of angiohematopoietic progenitors from human 
pluripotent stem cells. Cell Cycle, 2013. 12(5): p. 720-7. 
55. Choi, K., et al., A common precursor for hematopoietic and endothelial cells. Development, 
1998. 125(4): p. 725-32. 
56. Zambidis, E.T., et al., Expression of angiotensin-converting enzyme (CD143) identifies and 
regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood, 2008. 
112(9): p. 3601-14. 
57. Kissa, K. and P. Herbomel, Blood stem cells emerge from aortic endothelium by a novel type 
of cell transition. Nature, 2010. 464(7285): p. 112-5. 
58. Boisset, J.C., et al., In vivo imaging of haematopoietic cells emerging from the mouse aortic 
endothelium. Nature, 2010. 464(7285): p. 116-20. 
59. Wang, C., et al., TGFbeta inhibition enhances the generation of hematopoietic progenitors 
from human ES cell-derived hemogenic endothelial cells using a stepwise strategy. Cell Res, 
2012. 22(1): p. 194-207. 
60. Swiers, G., et al., A short history of hemogenic endothelium. Blood Cells Mol Dis, 2013. 51(4): 
p. 206-12. 
61. Ditadi, A., et al., Human definitive haemogenic endothelium and arterial vascular 
endothelium represent distinct lineages. Nat Cell Biol, 2015. 17(5): p. 580-91. 
62. Golub, R. and A. Cumano, Embryonic hematopoiesis. Blood Cells Mol Dis, 2013. 51(4): p. 226-
31. 
63. Tober, J., K.E. McGrath, and J. Palis, Primitive erythropoiesis and megakaryopoiesis in the yolk 
sac are independent of c-myb. Blood, 2008. 111(5): p. 2636-9. 
64. Kennedy, M., et al., Development of the hemangioblast defines the onset of hematopoiesis in 
human ES cell differentiation cultures. Blood, 2007. 109(7): p. 2679-87. 
157 
 
65. Vodyanik, M.A., J.A. Thomson, and Slukvin, II, Leukosialin (CD43) defines hematopoietic 
progenitors in human embryonic stem cell differentiation cultures. Blood, 2006. 108(6): p. 
2095-105. 
66. Palis, J., et al., Spatial and temporal emergence of high proliferative potential hematopoietic 
precursors during murine embryogenesis. Proc Natl Acad Sci U S A, 2001. 98(8): p. 4528-33. 
67. Bertrand, J.Y., et al., Definitive hematopoiesis initiates through a committed erythromyeloid 
progenitor in the zebrafish embryo. Development, 2007. 134(23): p. 4147-56. 
68. Frame, J.M., K.E. McGrath, and J. Palis, Erythro-myeloid progenitors: "definitive" 
hematopoiesis in the conceptus prior to the emergence of hematopoietic stem cells. Blood 
Cells Mol Dis, 2013. 51(4): p. 220-5. 
69. Muller, A.M., et al., Development of hematopoietic stem cell activity in the mouse embryo. 
Immunity, 1994. 1(4): p. 291-301. 
70. Medvinsky, A. and E. Dzierzak, Definitive hematopoiesis is autonomously initiated by the 
AGM region. Cell, 1996. 86(6): p. 897-906. 
71. Ivanovs, A., et al., Identification of the niche and phenotype of the first human hematopoietic 
stem cells. Stem Cell Reports, 2014. 2(4): p. 449-56. 
72. Taoudi, S. and A. Medvinsky, Functional identification of the hematopoietic stem cell niche in 
the ventral domain of the embryonic dorsal aorta. Proc Natl Acad Sci U S A, 2007. 104(22): p. 
9399-403. 
73. Kumaravelu, P., et al., Quantitative developmental anatomy of definitive haematopoietic 
stem cells/long-term repopulating units (HSC/RUs): role of the aorta-gonad-mesonephros 
(AGM) region and the yolk sac in colonisation of the mouse embryonic liver. Development, 
2002. 129(21): p. 4891-9. 
74. Zovein, A.C., et al., Fate tracing reveals the endothelial origin of hematopoietic stem cells. Cell 
Stem Cell, 2008. 3(6): p. 625-36. 
75. Samokhvalov, I.M., N.I. Samokhvalova, and S. Nishikawa, Cell tracing shows the contribution 
of the yolk sac to adult haematopoiesis. Nature, 2007. 446(7139): p. 1056-61. 
76. Kieusseian, A., et al., Immature hematopoietic stem cells undergo maturation in the fetal 
liver. Development, 2012. 139(19): p. 3521-30. 
77. Taoudi, S., et al., Extensive hematopoietic stem cell generation in the AGM region via 
maturation of VE-cadherin+CD45+ pre-definitive HSCs. Cell Stem Cell, 2008. 3(1): p. 99-108. 
78. Rybtsov, S., et al., Hierarchical organization and early hematopoietic specification of the 
developing HSC lineage in the AGM region. The Journal of Experimental Medicine, 2011. 
208(6): p. 1305-1315. 
79. Boiers, C., et al., Lymphomyeloid contribution of an immune-restricted progenitor emerging 
prior to definitive hematopoietic stem cells. Cell Stem Cell, 2013. 13(5): p. 535-48. 
80. Bueno, M.J., I. Perez de Castro, and M. Malumbres, Control of cell proliferation pathways by 
microRNAs. Cell Cycle, 2008. 7(20): p. 3143-8. 
81. Eulalio, A., E. Huntzinger, and E. Izaurralde, Getting to the root of miRNA-mediated gene 
silencing. Cell, 2008. 132(1): p. 9-14. 
82. http://www.mirbase.org/. 
83. Ha, M. and V.N. Kim, Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol, 2014. 15(8): 
p. 509-24. 
84. Ambros, V., et al., A uniform system for microRNA annotation. Rna, 2003. 9(3): p. 277-9. 
85. Subramanyam, D. and R. Blelloch, From microRNAs to targets: pathway discovery in cell fate 
transitions. Curr Opin Genet Dev, 2011. 21(4): p. 498-503. 
86. Barta, T., et al., Brief Report: Inhibition of miR-145 Enhances Reprogramming of Human 
Dermal Fibroblasts to Induced Pluripotent Stem Cells. Stem Cells, 2016. 34(1): p. 246-51. 
87. Huo, J.S. and E.T. Zambidis, Pivots of pluripotency: the roles of non-coding RNA in regulating 
embryonic and induced pluripotent stem cells. Biochim Biophys Acta, 2013. 1830(2): p. 2385-
94. 
88. Buza-Vidas, N., et al., Dicer is selectively important for the earliest stages of erythroid 
development. Blood, 2012. 120(12): p. 2412-6. 
158 
 
89. Bissels, U., A. Bosio, and W. Wagner, MicroRNAs are shaping the hematopoietic landscape. 
Haematologica, 2012. 97(2): p. 160-7. 
90. Votavova, H., et al., Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J 
Hematol Oncol, 2011. 4: p. 1. 
91. Lechman, E.R., et al., Attenuation of miR-126 activity expands HSC in vivo without exhaustion. 
Cell Stem Cell, 2012. 11(6): p. 799-811. 
92. Han, Y.C., et al., microRNA-29a induces aberrant self-renewal capacity in hematopoietic 
progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med, 2010. 
207(3): p. 475-89. 
93. Merkerova, M., et al., MicroRNA expression profiles in umbilical cord blood cell lineages. 
Stem Cells Dev, 2010. 19(1): p. 17-26. 
94. Hussein, K., et al., Aberrant microRNA expression pattern in myelodysplastic bone marrow 
cells. Leuk Res, 2010. 34(9): p. 1169-74. 
95. Dostalova Merkerova, M., et al., Distinctive microRNA expression profiles in CD34+ bone 
marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet, 2011. 19(3): p. 
313-9. 
96. Sokol, L., et al., Identification of a risk dependent microRNA expression signature in 
myelodysplastic syndromes. Br J Haematol, 2011. 153(1): p. 24-32. 
97. Kuchen, S., et al., Regulation of microRNA expression and abundance during lymphopoiesis. 
Immunity, 2010. 32(6): p. 828-39. 
98. Liu, G., et al., Pre-miRNA loop nucleotides control the distinct activities of mir-181a-1 and mir-
181c in early T cell development. PLoS One, 2008. 3(10): p. e3592. 
99. Kong, K.Y., et al., MIR-23A microRNA cluster inhibits B-cell development. Exp Hematol, 2010. 
38(8): p. 629-640.e1. 
100. Tenedini, E., et al., Integrated analysis of microRNA and mRNA expression profiles in 
physiological myelopoiesis: role of hsa-mir-299-5p in CD34+ progenitor cells commitment. 
Cell Death Dis, 2010. 1: p. e28. 
101. Rosa, A., et al., The interplay between the master transcription factor PU.1 and miR-424 
regulates human monocyte/macrophage differentiation. Proc Natl Acad Sci U S A, 2007. 
104(50): p. 19849-54. 
102. Lu, J., et al., MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte 
progenitors. Dev Cell, 2008. 14(6): p. 843-53. 
103. Yuan, J.Y., et al., MicroRNA-223 reversibly regulates erythroid and megakaryocytic 
differentiation of K562 cells. J Cell Mol Med, 2009. 13(11-12): p. 4551-9. 
104. Larsen, M.T., et al., MicroRNA profiling in human neutrophils during bone marrow 
granulopoiesis and in vivo exudation. PLoS One, 2013. 8(3): p. e58454. 
105. Choong, M.L., H.H. Yang, and I. McNiece, MicroRNA expression profiling during human cord 
blood-derived CD34 cell erythropoiesis. Exp Hematol, 2007. 35(4): p. 551-64. 
106. Masaki, S., et al., Expression patterns of microRNAs 155 and 451 during normal human 
erythropoiesis. Biochem Biophys Res Commun, 2007. 364(3): p. 509-14. 
107. Bruchova, H., et al., Regulated expression of microRNAs in normal and polycythemia vera 
erythropoiesis. Exp Hematol, 2007. 35(11): p. 1657-67. 
108. Barde, I., et al., A KRAB/KAP1-miRNA cascade regulates erythropoiesis through stage-specific 
control of mitophagy. Science, 2013. 340(6130): p. 350-3. 
109. Dore, L.C., et al., A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl 
Acad Sci U S A, 2008. 105(9): p. 3333-8. 
110. Velu, C.S., A.M. Baktula, and H.L. Grimes, Gfi1 regulates miR-21 and miR-196b to control 
myelopoiesis. Blood, 2009. 113(19): p. 4720-8. 
111. Rao, D.S., et al., MicroRNA-34a perturbs B lymphocyte development by repressing the 
forkhead box transcription factor Foxp1. Immunity, 2010. 33(1): p. 48-59. 
112. Fu, Y.F., et al., Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during 
primitive erythropoiesis. Blood, 2009. 113(6): p. 1340-9. 
159 
 
113. Du, T.T., et al., Experimental validation and complexity of miRNA-mRNA target interaction 
during zebrafish primitive erythropoiesis. Biochem Biophys Res Commun, 2009. 381(4): p. 
688-93. 
114. Gabbianelli, M., et al., Mechanism of human Hb switching: a possible role of the kit 
receptor/miR 221-222 complex. Haematologica, 2010. 95(8): p. 1253-60. 
115. Grabher, C., et al., Zebrafish microRNA-126 determines hematopoietic cell fate through c-
Myb. Leukemia, 2011. 25(3): p. 506-14. 
116. Bolstad, B.M., et al., A comparison of normalization methods for high density oligonucleotide 
array data based on variance and bias. Bioinformatics, 2003. 19(2): p. 185-93. 
117. Smyth, G.K., Linear models and empirical bayes methods for assessing differential expression 
in microarray experiments. Stat Appl Genet Mol Biol, 2004. 3: p. Article3. 
118. http://www.targetscan.org/. 
119.
 www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldoc
uments/cms_044972.pdf. 
120. Wotschofsky, Z., et al., Reference genes for the relative quantification of microRNAs in renal 
cell carcinomas and their metastases. Anal Biochem, 2011. 417(2): p. 233-41. 
121. Torres, A., et al., Selection and validation of endogenous controls for microRNA expression 
studies in endometrioid endometrial cancer tissues. Gynecol Oncol, 2013. 130(3): p. 588-94. 
122. http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome. 
123. https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/molecular-
biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-
scientific-web-tools/multiple-primer-analyzer.html. 
124. Bosma, G.C., R.P. Custer, and M.J. Bosma, A severe combined immunodeficiency mutation in 
the mouse. Nature, 1983. 301(5900): p. 527-30. 
125. Araki, R., et al., Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase 
catalytic subunit of severe combined immune deficiency mice. Proc Natl Acad Sci U S A, 1997. 
94(6): p. 2438-43. 
126. Lapidot, T., et al., Cytokine stimulation of multilineage hematopoiesis from immature human 
cells engrafted in SCID mice. Science, 1992. 255(5048): p. 1137-41. 
127. Hesselton, R.M., et al., High levels of human peripheral blood mononuclear cell engraftment 
and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-
scid/scid mice. J Infect Dis, 1995. 172(4): p. 974-82. 
128. Greiner, D.L., R.A. Hesselton, and L.D. Shultz, SCID mouse models of human stem cell 
engraftment. Stem Cells, 1998. 16(3): p. 166-77. 
129. Shultz, L.D., et al., Multiple defects in innate and adaptive immunologic function in NOD/LtSz-
scid mice. J Immunol, 1995. 154(1): p. 180-91. 
130. Bosma, G.C., et al., Evidence of functional lymphocytes in some (leaky) scid mice. J Exp Med, 
1988. 167(3): p. 1016-33. 
131. Ito, M., et al., NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for 
engraftment of human cells. Blood, 2002. 100(9): p. 3175-82. 
132. McDermott, S.P., et al., Comparison of human cord blood engraftment between 
immunocompromised mouse strains. Blood, 2010. 116(2): p. 193-200. 
133. van Os, R.P., B. Dethmers-Ausema, and G. de Haan, In vitro assays for cobblestone area-
forming cells, LTC-IC, and CFU-C. Methods Mol Biol, 2008. 430: p. 143-57. 
134. Ploemacher, R.E., et al., Use of limiting-dilution type long-term marrow cultures in frequency 
analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the 
mouse. Blood, 1991. 78(10): p. 2527-33. 
135. Nakano, T., H. Kodama, and T. Honjo, Generation of lymphohematopoietic cells from 
embryonic stem cells in culture. Science, 1994. 265(5175): p. 1098-101. 
136. Maillard, I., T. Fang, and W.S. Pear, Regulation of lymphoid development, differentiation, and 
function by the Notch pathway. Annu Rev Immunol, 2005. 23: p. 945-74. 
160 
 
137. Schmitt, T.M., et al., Induction of T cell development and establishment of T cell competence 
from embryonic stem cells differentiated in vitro. Nat Immunol, 2004. 5(4): p. 410-7. 
138. Ohler, L., K. Geissler, and W. Hinterberger, Diagnostic and prognostic value of colony 
formation of hematopoietic progenitor cells in myeloid malignancies. Wien Klin Wochenschr, 
2003. 115(13-14): p. 537-46. 
139. Zhou, F., et al., Tracing haematopoietic stem cell formation at single-cell resolution. Nature, 
2016. 533(7604): p. 487-92. 
140. Technau, U., Brachyury, the blastopore and the evolution of the mesoderm. Bioessays, 2001. 
23(9): p. 788-94. 
141. Lacaud, G., et al., Regulation of hemangioblast development. Ann N Y Acad Sci, 2001. 938: p. 
96-107; discussion 108. 
142. Toscano, M.G., et al., SCL/TAL1-mediated transcriptional network enhances megakaryocytic 
specification of human embryonic stem cells. Mol Ther, 2015. 23(1): p. 158-70. 
143. Real, P.J., et al., SCL/TAL1 regulates hematopoietic specification from human embryonic stem 
cells. Mol Ther, 2012. 20(7): p. 1443-53. 
144. Yung, S., et al., Large-scale transcriptional profiling and functional assays reveal important 
roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human 
embryonic stem cells. Hum Mol Genet, 2011. 20(24): p. 4932-46. 
145. Monteiro, R., et al., Transforming Growth Factor beta Drives Hemogenic Endothelium 
Programming and the Transition to Hematopoietic Stem Cells. Dev Cell, 2016. 38(4): p. 358-
70. 
146. Chen, M.J., et al., Runx1 is required for the endothelial to haematopoietic cell transition but 
not thereafter. Nature, 2009. 457(7231): p. 887-91. 
147. Tanaka, Y., et al., Circulation-independent differentiation pathway from extraembryonic 
mesoderm toward hematopoietic stem cells via hemogenic angioblasts. Cell Rep, 2014. 8(1): 
p. 31-9. 
148. Mikkola, H.K., et al., Expression of CD41 marks the initiation of definitive hematopoiesis in the 
mouse embryo. Blood, 2003. 101(2): p. 508-16. 
149. Chen, J.Y., et al., Hoxb5 marks long-term haematopoietic stem cells and reveals a 
homogenous perivascular niche. Nature, 2016. 530(7589): p. 223-7. 
150. Ramos-Mejia, V., et al., HOXA9 promotes hematopoietic commitment of human embryonic 
stem cells. Blood, 2014. 124(20): p. 3065-75. 
151. Hills, D., et al., Hoxb4-YFP reporter mouse model: a novel tool for tracking HSC development 
and studying the role of Hoxb4 in hematopoiesis. Blood, 2011. 117(13): p. 3521-8. 
152. Xu, J., et al., Combinatorial assembly of developmental stage-specific enhancers controls gene 
expression programs during human erythropoiesis. Dev Cell, 2012. 23(4): p. 796-811. 
153. Ma, O., et al., Granulopoiesis requires increased C/EBPalpha compared to monopoiesis, 
correlated with elevated Cebpa in immature G-CSF receptor versus M-CSF receptor expressing 
cells. PLoS One, 2014. 9(4): p. e95784. 
154. Imperato, M.R., et al., The RUNX1-PU.1 axis in the control of hematopoiesis. Int J Hematol, 
2015. 101(4): p. 319-29. 
155. Lansdorp, P.M., H.J. Sutherland, and C.J. Eaves, Selective expression of CD45 isoforms on 
functional subpopulations of CD34+ hemopoietic cells from human bone marrow. J Exp Med, 
1990. 172(1): p. 363-6. 
156. Craig, W., et al., CD45 isoform expression on human haemopoietic cells at different stages of 
development. Br J Haematol, 1994. 88(1): p. 24-30. 
157. Bhatia, M., et al., Purification of primitive human hematopoietic cells capable of repopulating 
immune-deficient mice. Proc Natl Acad Sci U S A, 1997. 94(10): p. 5320-5. 
158. Majeti, R., C.Y. Park, and I.L. Weissman, Identification of a hierarchy of multipotent 
hematopoietic progenitors in human cord blood. Cell Stem Cell, 2007. 1(6): p. 635-45. 
159. Notta, F., et al., Isolation of single human hematopoietic stem cells capable of long-term 
multilineage engraftment. Science, 2011. 333(6039): p. 218-21. 
161 
 
160. Oguro, H., L. Ding, and S.J. Morrison, SLAM family markers resolve functionally distinct 
subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell, 
2013. 13(1): p. 102-16. 
161. Larochelle, A., et al., Human and rhesus macaque hematopoietic stem cells cannot be purified 
based only on SLAM family markers. Blood, 2011. 117(5): p. 1550-4. 
162. Remold-O'Donnell, E., et al., Expression on blood cells of sialophorin, the surface glycoprotein 
that is defective in Wiskott-Aldrich syndrome. Blood, 1987. 70(1): p. 104-9. 
163. Dahlke, M.H., et al., The biology of CD45 and its use as a therapeutic target. Leuk Lymphoma, 
2004. 45(2): p. 229-36. 
164. Slukvin, II, Hematopoietic specification from human pluripotent stem cells: current advances 
and challenges toward de novo generation of hematopoietic stem cells. Blood, 2013. 122(25): 
p. 4035-46. 
165. Oberlin, E., et al., Blood-forming potential of vascular endothelium in the human embryo. 
Development, 2002. 129(17): p. 4147-57. 
166. Ferkowicz, M.J., et al., CD41 expression defines the onset of primitive and definitive 
hematopoiesis in the murine embryo. Development, 2003. 130(18): p. 4393-403. 
167. Lan, Y., et al., Endothelial Smad4 restrains the transition to hematopoietic progenitors via 
suppression of ERK activation. Blood, 2014. 123(14): p. 2161-71. 
168. Mizuochi, C., et al., Intra-aortic clusters undergo endothelial to hematopoietic phenotypic 
transition during early embryogenesis. PLoS One, 2012. 7(4): p. e35763. 
169. Ng, E.S., et al., Forced aggregation of defined numbers of human embryonic stem cells into 
embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood, 2005. 
106(5): p. 1601-3. 
170. Watanabe, K., et al., A ROCK inhibitor permits survival of dissociated human embryonic stem 
cells. Nat Biotechnol, 2007. 25(6): p. 681-6. 
171. Cheng, Y.T., et al., Rho-associated kinase inhibitors promote the cardiac differentiation of 
embryonic and induced pluripotent stem cells. Int J Cardiol, 2015. 201: p. 441-8. 
172. Vodyanik, M.A., et al., A mesoderm-derived precursor for mesenchymal stem and endothelial 
cells. Cell Stem Cell, 2010. 7(6): p. 718-29. 
173. Gerlach, J.C., et al., Role of transcription factor CCAAT/enhancer-binding protein alpha in 
human fetal liver cell types in vitro. Hepatol Res, 2015. 45(8): p. 919-32. 
174. Rouhani, F.J., et al., Mutational History of a Human Cell Lineage from Somatic to Induced 
Pluripotent Stem Cells. PLoS Genet, 2016. 12(4): p. e1005932. 
175. Catalina, P., et al., Human ESCs predisposition to karyotypic instability: Is a matter of culture 
adaptation or differential vulnerability among hESC lines due to inherent properties? Mol 
Cancer, 2008. 7: p. 76. 
176. Cowan, C.A., et al., Derivation of embryonic stem-cell lines from human blastocysts. N Engl J 
Med, 2004. 350(13): p. 1353-6. 
177. Imreh, M.P., et al., In vitro culture conditions favoring selection of chromosomal 
abnormalities in human ES cells. J Cell Biochem, 2006. 99(2): p. 508-16. 
178. Young, M.A., et al., Background mutations in parental cells account for most of the genetic 
heterogeneity of induced pluripotent stem cells. Cell Stem Cell, 2012. 10(5): p. 570-82. 
179. Abyzov, A., et al., Somatic copy number mosaicism in human skin revealed by induced 
pluripotent stem cells. Nature, 2012. 492(7429): p. 438-42. 
180. Fung, H. and D.M. Weinstock, Repair at single targeted DNA double-strand breaks in 
pluripotent and differentiated human cells. PLoS One, 2011. 6(5): p. e20514. 
181. Barta, T., et al., Human embryonic stem cells are capable of executing G1/S checkpoint 
activation. Stem Cells, 2010. 28(7): p. 1143-52. 
182. Laurent, L.C., et al., Dynamic changes in the copy number of pluripotency and cell 
proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell 
Stem Cell, 2011. 8(1): p. 106-18. 
162 
 
183. Garitaonandia, I., et al., Increased risk of genetic and epigenetic instability in human 
embryonic stem cells associated with specific culture conditions. PLoS One, 2015. 10(2): p. 
e0118307. 
184. Werbowetski-Ogilvie, T.E., et al., Evidence for the transmission of neoplastic properties from 
transformed to normal human stem cells. Oncogene, 2011. 30(46): p. 4632-44. 
185. Yang, S., et al., Differences between karyotypically normal and abnormal human embryonic 
stem cells. Cell Prolif, 2010. 43(3): p. 195-206. 
186. Mitalipova, M.M., et al., Preserving the genetic integrity of human embryonic stem cells. Nat 
Biotechnol, 2005. 23(1): p. 19-20. 
187. Lee, R.C. and V. Ambros, An extensive class of small RNAs in Caenorhabditis elegans. Science, 
2001. 294(5543): p. 862-4. 
188. Michael, M.Z., et al., Reduced accumulation of specific microRNAs in colorectal neoplasia. 
Mol Cancer Res, 2003. 1(12): p. 882-91. 
189. Baskerville, S. and D.P. Bartel, Microarray profiling of microRNAs reveals frequent 
coexpression with neighboring miRNAs and host genes. Rna, 2005. 11(3): p. 241-7. 
190. Castoldi, M., et al., A sensitive array for microRNA expression profiling (miChip) based on 
locked nucleic acids (LNA). Rna, 2006. 12(5): p. 913-20. 
191. Luo, X., et al., PolyA RT-PCR-based quantification of microRNA by using universal TaqMan 
probe. Biotechnol Lett, 2012. 34(4): p. 627-33. 
192. Zhang, Y., Z. Wang, and R.A. Gemeinhart, Progress in microRNA delivery. J Control Release, 
2013. 172(3): p. 962-74. 
193. Ko, M.H., et al., Bioimaging of the unbalanced expression of microRNA9 and microRNA9* 
during the neuronal differentiation of P19 cells. Febs j, 2008. 275(10): p. 2605-16. 
194. Lee, J.Y., et al., Development of a dual-luciferase reporter system for in vivo visualization of 
MicroRNA biogenesis and posttranscriptional regulation. J Nucl Med, 2008. 49(2): p. 285-94. 
195. Hamidi-Asl, E., et al., A review on the electrochemical biosensors for determination of 
microRNAs. Talanta, 2013. 115: p. 74-83. 
196. Khatoon, Z., et al., Introduction to RNA-Seq and its applications to drug discovery and 
development. Drug Dev Res, 2014. 75(5): p. 324-30. 
197. Lin, S.L., et al., Regulation of somatic cell reprogramming through inducible mir-302 
expression. Nucleic Acids Res, 2011. 39(3): p. 1054-65. 
198. Barroso-del Jesus, A., G. Lucena-Aguilar, and P. Menendez, The miR-302-367 cluster as a 
potential stemness regulator in ESCs. Cell Cycle, 2009. 8(3): p. 394-8. 
199. Guillon-Munos, A., et al., The chicken miR-150 targets the avian orthologue of the functional 
zebrafish MYB 3'UTR target site. BMC Mol Biol, 2010. 11: p. 67. 
200. Bousquet, M., et al., miR-150 blocks MLL-AF9-associated leukemia through oncogene 
repression. Mol Cancer Res, 2013. 11(8): p. 912-22. 
201. Luo, Z., et al., MicroRNA-200C and -150 play an important role in endothelial cell 
differentiation and vasculogenesis by targeting transcription repressor ZEB1. Stem Cells, 
2013. 31(9): p. 1749-62. 
202. Ding, J., et al., Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and 
spreading through downregulating RhoGDIA. Nat Cell Biol, 2010. 12(4): p. 390-9. 
203. Luedde, T., MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor 
cell migration and spreading of hepatocellular carcinoma. Hepatology, 2010. 52(3): p. 1164-
6. 
204. Nairismagi, M.L., et al., The proto-oncogene TWIST1 is regulated by microRNAs. PLoS One, 
2013. 8(5): p. e66070. 
205. Pule, G.D., et al., Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-
mediated actions to induce gamma-globin expression: implications for new therapeutic 
approaches of sickle cell disease. Clin Transl Med, 2016. 5(1): p. 15. 
206. Walker, A.L., et al., Epigenetic and molecular profiles of erythroid cells after hydroxyurea 
treatment in sickle cell anemia. Blood, 2011. 118(20): p. 5664-70. 
163 
 
207. Liu, Y., et al., A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin 
E1 gene associated with nasopharyngeal carcinoma. Biochem Biophys Res Commun, 2013. 
432(4): p. 660-5. 
208. Jiang, N., et al., Downregulation of miR-432 activates Wnt/beta-catenin signaling and 
promotes human hepatocellular carcinoma proliferation. Oncotarget, 2015. 6(10): p. 7866-
79. 
209. Lai, C.Y., et al., MicroRNA expression aberration as potential peripheral blood biomarkers for 
schizophrenia. PLoS One, 2011. 6(6): p. e21635. 
210. Yu, H.C., et al., Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of 
schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry, 2015. 63: p. 23-9. 
211. Girardi, C., et al., Analysis of miRNA and mRNA expression profiles highlights alterations in 
ionizing radiation response of human lymphocytes under modeled microgravity. PLoS One, 
2012. 7(2): p. e31293. 
212. Zhang, H.Y., et al., Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-
mesenchymal transition in ovarian cancer. Oncol Rep, 2015. 34(3): p. 1193-202. 
213. Jiang, J., et al., MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in 
human pancreatic cancer. Cancer Lett, 2015. 356(2 Pt B): p. 962-70. 
214. Niu, Y., et al., Lipopolysaccharide-induced miR-1224 negatively regulates tumour necrosis 
factor-alpha gene expression by modulating Sp1. Immunology, 2011. 133(1): p. 8-20. 
215. Zhang, L., et al., MiR-134-Mbd3 axis regulates the induction of pluripotency. J Cell Mol Med, 
2016. 20(6): p. 1150-8. 
216. Tay, Y.M., et al., MicroRNA-134 modulates the differentiation of mouse embryonic stem cells, 
where it causes post-transcriptional attenuation of Nanog and LRH1. Stem Cells, 2008. 26(1): 
p. 17-29. 
217. Liu, Y., et al., miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-
mesenchymal Transition by targeting KRAS in renal cell carcinoma cells. DNA Cell Biol, 2015. 
34(6): p. 429-36. 
218. Li, J., et al., miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-
small cell lung cancer cells. FEBS Lett, 2012. 586(20): p. 3761-5. 
219. Chae, H.D., M.R. Lee, and H.E. Broxmeyer, 5-Aminoimidazole-4-carboxyamide ribonucleoside 
induces G(1)/S arrest and Nanog downregulation via p53 and enhances erythroid 
differentiation. Stem Cells, 2012. 30(2): p. 140-9. 
220. Patel, V., et al., The stretch responsive microRNA miR-148a-3p is a novel repressor of IKBKB, 
NF-kappaB signaling, and inflammatory gene expression in human aortic valve cells. Faseb j, 
2015. 29(5): p. 1859-68. 
221. Xu, X., et al., Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J 
Clin Invest, 2013. 123(2): p. 630-45. 
222. Gao, J., et al., MicroRNA expression during osteogenic differentiation of human multipotent 
mesenchymal stromal cells from bone marrow. J Cell Biochem, 2011. 112(7): p. 1844-56. 
223. Shi, C., et al., Adipogenic miRNA and meta-signature miRNAs involved in human adipocyte 
differentiation and obesity. Oncotarget, 2016. 
224. Hsiao, K.Y., et al., Coordination of AUF1 and miR-148a destabilizes DNA methyltransferase 1 
mRNA under hypoxia in endometriosis. Mol Hum Reprod, 2015. 21(12): p. 894-904. 
225. Fonseca-Sanchez, M.A., et al., microRNA-18b is upregulated in breast cancer and modulates 
genes involved in cell migration. Oncol Rep, 2013. 30(5): p. 2399-410. 
226. Yang, G.H., et al., MicroRNAs are involved in erythroid differentiation control. J Cell Biochem, 
2009. 107(3): p. 548-56. 
227. Jazirehi, A.R., A.X. Torres-Collado, and R. Nazarian, Role of miR-18b/MDM2/p53 circuitry in 
melanoma progression. Epigenomics, 2013. 5(3): p. 254. 
228. Kushwaha, R., et al., miR-18b and miR-518b Target FOXN1 during epithelial lineage 
differentiation in pluripotent cells. Stem Cells Dev, 2014. 23(10): p. 1149-56. 
164 
 
229. Jamali, Z., et al., MicroRNAs as prognostic molecular signatures in human head and neck 
squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol, 2015. 51(4): p. 
321-31. 
230. Li, J., et al., miR-193b directly targets STMN1 and uPA genes and suppresses tumor growth 
and metastasis in pancreatic cancer. Mol Med Rep, 2014. 10(5): p. 2613-20. 
231. Gao, X.N., et al., MicroRNA-193b regulates c-Kit proto-oncogene and represses cell 
proliferation in acute myeloid leukemia. Leuk Res, 2011. 35(9): p. 1226-32. 
232. Mets, E., et al., MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB 
oncogene in T-cell acute lymphoblastic leukemia. Leukemia, 2015. 29(4): p. 798-806. 
233. Wang, L., et al., MicroRNA-193b inhibits the proliferation, migration and invasion of gastric 
cancer cells via targeting cyclin D1. Acta Histochem, 2016. 
234. Chen, J., et al., MicroRNA-193b represses cell proliferation and regulates cyclin D1 in 
melanoma. Am J Pathol, 2010. 176(5): p. 2520-9. 
235. Gregory, P.A., et al., The miR-200 family and miR-205 regulate epithelial to mesenchymal 
transition by targeting ZEB1 and SIP1. Nat Cell Biol, 2008. 10(5): p. 593-601. 
236. Hur, K., et al., MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in 
human colorectal cancer metastasis. Gut, 2013. 62(9): p. 1315-26. 
237. Wendlandt, E.B., et al., The role of microRNAs miR-200b and miR-200c in TLR4 signaling and 
NF-kappaB activation. Innate Immun, 2012. 18(6): p. 846-55. 
238. Gregory, P.A., et al., An autocrine TGF-beta/ZEB/miR-200 signaling network regulates 
establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell, 2011. 
22(10): p. 1686-98. 
239. Choi, Y.C., et al., Regulation of vascular endothelial growth factor signaling by miR-200b. Mol 
Cells, 2011. 32(1): p. 77-82. 
240. Chan, Y.C., et al., miR-200b targets Ets-1 and is down-regulated by hypoxia to induce 
angiogenic response of endothelial cells. J Biol Chem, 2011. 286(3): p. 2047-56. 
241. Cesi, V., et al., TGFbeta-induced c-Myb affects the expression of EMT-associated genes and 
promotes invasion of ER+ breast cancer cells. Cell Cycle, 2011. 10(23): p. 4149-61. 
242. Tian, L., et al., MicroRNA-205 suppresses proliferation and promotes apoptosis in laryngeal 
squamous cell carcinoma. Med Oncol, 2014. 31(1): p. 785. 
243. Chan, Y.C., et al., miR-210: the master hypoxamir. Microcirculation, 2012. 19(3): p. 215-23. 
244. Sarakul, O., et al., Enhanced erythroid cell differentiation in hypoxic condition is in part 
contributed by miR-210. Blood Cells Mol Dis, 2013. 51(2): p. 98-103. 
245. Jin, Y., et al., MiR-214 regulates the pathogenesis of patients with coronary artery disease by 
targeting VEGF. Mol Cell Biochem, 2015. 402(1-2): p. 111-22. 
246. Wang, F., et al., microRNA-214 enhances the invasion ability of breast cancer cells by 
targeting p53. Int J Mol Med, 2015. 35(5): p. 1395-402. 
247. Nagata, M., S. Muto, and S. Horie, Molecular Biomarkers in Bladder Cancer: Novel Potential 
Indicators of Prognosis and Treatment Outcomes. 2016. 2016: p. 8205836. 
248. Sharma, T., R. Hamilton, and C.C. Mandal, miR-214: a potential biomarker and therapeutic for 
different cancers. Future Oncol, 2015. 11(2): p. 349-63. 
249. Yang, L., et al., MiR-214 Attenuates Osteogenic Differentiation of Mesenchymal Stem Cells via 
Targeting FGFR1. Cell Physiol Biochem, 2016. 38(2): p. 809-20. 
250. Zhao, C., et al., miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway. 
RNA Biol, 2015. 12(3): p. 343-53. 
251. Kong, Y., et al., Slit-miR-218-Robo axis regulates retinal neovascularization. Int J Mol Med, 
2016. 37(4): p. 1139-45. 
252. Nam, R.K., et al., MiR-301a regulates E-cadherin expression and is predictive of prostate 
cancer recurrence. Prostate, 2016. 76(10): p. 869-84. 
253. Ma, X., et al., MicroRNAs in NF-kappaB signaling. J Mol Cell Biol, 2011. 3(3): p. 159-66. 
254. Yang, Y. and J.K. Wang, The functional analysis of MicroRNAs involved in NF-kappaB 
signaling. Eur Rev Med Pharmacol Sci, 2016. 20(9): p. 1764-74. 
165 
 
255. Wang, Y., et al., miR-294/miR-302 promotes proliferation, suppresses G1-S restriction point, 
and inhibits ESC differentiation through separable mechanisms. Cell Rep, 2013. 4(1): p. 99-
109. 
256. Sun, M., et al., MicroRNA-34a inhibits human trophoblast cell invasion by targeting MYC. 
BMC Cell Biol, 2015. 16: p. 21. 
257. Pulikkan, J.A., et al., C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis 
and is down-regulated in AML with CEBPA mutations. Blood, 2010. 116(25): p. 5638-49. 
258. Zanette, D.L., et al., miRNA expression profiles in chronic lymphocytic and acute lymphocytic 
leukemia. Braz J Med Biol Res, 2007. 40(11): p. 1435-40. 
259. Kim, M.H., et al., MicroRNA-365 inhibits the proliferation of vascular smooth muscle cells by 
targeting cyclin D1. J Cell Biochem, 2014. 115(10): p. 1752-61. 
260. Vienberg, S., et al., MicroRNAs in Metabolism. Acta Physiol (Oxf), 2016. 
261. Shen, X., et al., MiR-424 regulates monocytic differentiation of human leukemia U937 cells by 
directly targeting CDX2. Biotechnol Lett, 2013. 35(11): p. 1799-806. 
262. Chamorro-Jorganes, A., et al., MicroRNA-16 and microRNA-424 regulate cell-autonomous 
angiogenic functions in endothelial cells via targeting vascular endothelial growth factor 
receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol, 2011. 
31(11): p. 2595-606. 
263. Nakashima, T., et al., Down-regulation of mir-424 contributes to the abnormal angiogenesis 
via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One, 2010. 
5(12): p. e14334. 
264. Ghosh, G., et al., Hypoxia-induced microRNA-424 expression in human endothelial cells 
regulates HIF-alpha isoforms and promotes angiogenesis. J Clin Invest, 2010. 120(11): p. 
4141-54. 
265. Li, Y.J., et al., MicroRNA-455 suppresses non-small cell lung cancer through targeting ZEB1. 
Cell Biol Int, 2016. 40(6): p. 621-8. 
266. Zhang, Z., et al., MiR-455-3p regulates early chondrogenic differentiation via inhibiting Runx2. 
FEBS Lett, 2015. 589(23): p. 3671-8. 
267. Zhang, H., et al., MicroRNA-455 regulates brown adipogenesis via a novel HIF1an-AMPK-
PGC1alpha signaling network. EMBO Rep, 2015. 16(10): p. 1378-93. 
268. Chen, W.X., et al., MicroRNA-630 suppresses tumor metastasis through the TGF-beta- miR-
630-Slug signaling pathway and correlates inversely with poor prognosis in hepatocellular 
carcinoma. Oncotarget, 2016. 
269. Li, X., et al., Long noncoding RNA H19 regulates EZH2 expression by interacting with miR-630 
and promotes cell invasion in nasopharyngeal carcinoma. Biochem Biophys Res Commun, 
2016. 473(4): p. 913-9. 
270. Sun, Y., et al., MiR-630 Inhibits Endothelial-Mesenchymal Transition by Targeting Slug in 
Traumatic Heterotopic Ossification. Sci Rep, 2016. 6: p. 22729. 
271. Giles, K.M., et al., microRNA-7-5p inhibits melanoma cell proliferation and metastasis by 
suppressing RelA/NF-kappaB. Oncotarget, 2016. 
272. Horsham, J.L., et al., MicroRNA-7: A miRNA with expanding roles in development and disease. 
Int J Biochem Cell Biol, 2015. 69: p. 215-24. 
273. Zhong, X., et al., Identification of microRNAs regulating reprogramming factor LIN28 in 
embryonic stem cells and cancer cells. J Biol Chem, 2010. 285(53): p. 41961-71. 
274. Liu, M., et al., c-Myc suppressed E-cadherin through miR-9 at the post-transcriptional level. 
Cell Biol Int, 2013. 37(3): p. 197-202. 
275. Senyuk, V., et al., Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis. 
Proc Natl Acad Sci U S A, 2013. 110(14): p. 5594-9. 
276. Zheng, L., et al., microRNA-9 suppresses the proliferation, invasion and metastasis of gastric 
cancer cells through targeting cyclin D1 and Ets1. PLoS One, 2013. 8(1): p. e55719. 
277. Shyh-Chang, N. and G.Q. Daley, Lin28: primal regulator of growth and metabolism in stem 
cells. Cell Stem Cell, 2013. 12(4): p. 395-406. 
166 
 
278. Meza-Sosa, K.F., et al., MiR-7 promotes epithelial cell transformation by targeting the tumor 
suppressor KLF4. PLoS One, 2014. 9(9): p. e103987. 
279. Wang, Y., et al., MicroRNA-7 regulates the mTOR pathway and proliferation in adult 
pancreatic beta-cells. Diabetes, 2013. 62(3): p. 887-95. 
280. Bellon, M., et al., Deregulation of microRNA involved in hematopoiesis and the immune 
response in HTLV-I adult T-cell leukemia. Blood, 2009. 113(20): p. 4914-7. 
281. Nishiyama, T., et al., miR-142-3p is essential for hematopoiesis and affects cardiac cell fate in 
zebrafish. Biochem Biophys Res Commun, 2012. 425(4): p. 755-61. 
282. Wang, X.S., et al., MicroRNA-29a and microRNA-142-3p are regulators of myeloid 
differentiation and acute myeloid leukemia. Blood, 2012. 119(21): p. 4992-5004. 
283. Fallah, P., et al., miR-146a and miR-150 promote the differentiation of CD133+ cells into T-
lymphoid lineage. Mol Biol Rep, 2013. 40(8): p. 4713-9. 
284. Zhao, J.L., et al., MicroRNA-146a acts as a guardian of the quality and longevity of 
hematopoietic stem cells in mice. Elife (Cambridge), 2013. 2: p. e00537. 
285. Tano, N., H.W. Kim, and M. Ashraf, microRNA-150 regulates mobilization and migration of 
bone marrow-derived mononuclear cells by targeting Cxcr4. PLoS One, 2011. 6(10): p. 
e23114. 
286. Barroga, C.F., H. Pham, and K. Kaushansky, Thrombopoietin regulates c-Myb expression by 
modulating micro RNA 150 expression. Exp Hematol, 2008. 36(12): p. 1585-92. 
287. Adams, B.D., et al., An in vivo functional screen uncovers miR-150-mediated regulation of 
hematopoietic injury response. Cell Rep, 2012. 2(4): p. 1048-60. 
288. Salaun, B., et al., Differentiation associated regulation of microRNA expression in vivo in 
human CD8+ T cell subsets. J Transl Med, 2011. 9: p. 44. 
289. O'Connell, R.M., et al., Sustained expression of microRNA-155 in hematopoietic stem cells 
causes a myeloproliferative disorder. J Exp Med, 2008. 205(3): p. 585-94. 
290. Rio, P., et al., Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: 
implications in TNFalpha regulation and proliferation of hematopoietic progenitor cells. 
Blood, 2012. 119(13): p. 3042-9. 
291. Tan, L.P., et al., miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B 
cells with variation between centroblasts and centrocytes. Lab Invest, 2009. 89(6): p. 708-16. 
292. Henao-Mejia, J., et al., The microRNA miR-181 is a critical cellular metabolic rheostat 
essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity, 
2013. 38(5): p. 984-97. 
293. Yu, J., et al., Human microRNA clusters: genomic organization and expression profile in 
leukemia cell lines. Biochem Biophys Res Commun, 2006. 349(1): p. 59-68. 
294. Lei, Z., et al., MicroRNA-132/212 family enhances arteriogenesis after hindlimb ischaemia 
through modulation of the Ras-MAPK pathway. J Cell Mol Med, 2015. 19(8): p. 1994-2005. 
295. Mehta, A., et al., The microRNA-212/132 cluster regulates B cell development by targeting 
Sox4. J Exp Med, 2015. 212(10): p. 1679-92. 
296. Fu, W., et al., MicroRNA-132/212 Upregulation Inhibits TGF-beta-Mediated Epithelial-
Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4. Prostate, 2016. 
297. Fulci, V., et al., miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid 
arthritis. Hum Immunol, 2010. 71(2): p. 206-11. 
298. Haneklaus, M., et al., miR-223: infection, inflammation and cancer. J Intern Med, 2013. 
274(3): p. 215-26. 
299. Fazi, F., et al., A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and 
C/EBPalpha regulates human granulopoiesis. Cell, 2005. 123(5): p. 819-31. 
300. Zardo, G., et al., Polycombs and microRNA-223 regulate human granulopoiesis by 
transcriptional control of target gene expression. Blood, 2012. 119(17): p. 4034-46. 
301. Felli, N., et al., MicroRNA 223-dependent expression of LMO2 regulates normal 
erythropoiesis. Haematologica, 2009. 94(4): p. 479-86. 
167 
 
302. Sun, W., et al., miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 
positively regulates miR-142 through LMO2 isoforms and CEBP-beta. Cell Res, 2010. 20(10): 
p. 1158-69. 
303. Pulikkan, J.A., et al., Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory 
negative feedback loop in acute myeloid leukemia. Blood, 2010. 115(9): p. 1768-78. 
304. Fu, X., et al., miR-338-3p is down-regulated by hepatitis B virus X and inhibits cell proliferation 
by targeting the 3'-UTR region of CyclinD1. Int J Mol Sci, 2012. 13(7): p. 8514-39. 
305. Tsuchiya, S., et al., MicroRNA-338-3p and microRNA-451 contribute to the formation of 
basolateral polarity in epithelial cells. Nucleic Acids Res, 2009. 37(11): p. 3821-7. 
306. Deng, Y., Y. Xiong, and Y. Liu, miR-376c inhibits cervical cancer cell proliferation and invasion 
by targeting BMI1. Int J Exp Pathol, 2016. 97(3): p. 257-65. 
307. Jiang, W., et al., MicroRNA-376c suppresses non-small-cell lung cancer cell growth and 
invasion by targeting LRH-1-mediated Wnt signaling pathway. Biochem Biophys Res 
Commun, 2016. 473(4): p. 980-6. 
308. Browne, G., et al., MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive 
phenotype of triple-negative MDA-MB-231 human breast cancer cells. Tumour Biol, 2016. 
37(7): p. 8825-39. 
309. Ruckerl, D., et al., Induction of IL-4Ralpha-dependent microRNAs identifies PI3K/Akt signaling 
as essential for IL-4-driven murine macrophage proliferation in vivo. Blood, 2012. 120(11): p. 
2307-16. 
310. Sacco, J. and K. Adeli, MicroRNAs: emerging roles in lipid and lipoprotein metabolism. Curr 
Opin Lipidol, 2012. 23(3): p. 220-5. 
311. Krist, B., et al., The Role of miR-378a in Metabolism, Angiogenesis, and Muscle Biology. Int J 
Endocrinol, 2015. 2015: p. 281756. 
312. Yun, J.H., et al., MicroRNA-650 in a copy number-variable region regulates the production of 
interleukin 6 in human osteosarcoma cells. Oncol Lett, 2015. 10(4): p. 2603-2609. 
313. Harazono, Y., et al., miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. 
PLoS One, 2013. 8(5): p. e62757. 
314. Zhong, S., et al., Differential expression of microRNAs in normal and inflamed human pulps. J 
Endod, 2012. 38(6): p. 746-52. 
315. Loriot, A., et al., A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-
targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics, 2014. 9(8): p. 
1163-71. 
316. Xiang, Y., et al., MicroRNA-487b Is a Negative Regulator of Macrophage Activation by 
Targeting IL-33 Production. J Immunol, 2016. 196(8): p. 3421-8. 
317. Feng, N., et al., miR-487b promotes human umbilical vein endothelial cell proliferation, 
migration, invasion and tube formation through regulating THBS1. Neurosci Lett, 2015. 591: 
p. 1-7. 
318. Sengupta, S., et al., MicroRNA 92b controls the G1/S checkpoint gene p57 in human 
embryonic stem cells. Stem Cells, 2009. 27(7): p. 1524-8. 
319. Huang, J., et al., miR-92b targets DAB2IP to promote EMT in bladder cancer migration and 
invasion. Oncol Rep, 2016. 36(3): p. 1693-701. 
320. Zhou, Z., et al., Promotion of tumour proliferation, migration and invasion by miR-92b in 
targeting RECK in osteosarcoma. Clin Sci (Lond), 2016. 130(11): p. 921-30. 
321. Vodyanik, M.A., et al., Human embryonic stem cell-derived CD34+ cells: efficient production in 
the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood, 
2005. 105(2): p. 617-26. 
322. Klimchenko, O., et al., A common bipotent progenitor generates the erythroid and 
megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood, 2009. 
114(8): p. 1506-17. 
323. Hutvagner, G., et al., Sequence-specific inhibition of small RNA function. PLoS Biol, 2004. 2(4): 
p. E98. 
168 
 
324. Meister, G., et al., Sequence-specific inhibition of microRNA- and siRNA-induced RNA 
silencing. Rna, 2004. 10(3): p. 544-50. 
325. Nasevicius, A. and S.C. Ekker, Effective targeted gene 'knockdown' in zebrafish. Nat Genet, 
2000. 26(2): p. 216-20. 
326. Filipowicz, W., et al., Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin 
Struct Biol, 2005. 15(3): p. 331-41. 
327. Krutzfeldt, J., et al., Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005. 
438(7068): p. 685-9. 
328. Wahlestedt, C., et al., Potent and nontoxic antisense oligonucleotides containing locked 
nucleic acids. Proc Natl Acad Sci U S A, 2000. 97(10): p. 5633-8. 
329. Yoo, B.H., et al., 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have 
reduced non-specific effects in vitro. Nucleic Acids Res, 2004. 32(6): p. 2008-16. 
330. Koynova, R. and B. Tenchov, Recent patents in cationic lipid carriers for delivery of nucleic 
acids. Recent Pat DNA Gene Seq, 2011. 5(1): p. 8-27. 
331. Vermeulen, A., et al., Double-stranded regions are essential design components of potent 
inhibitors of RISC function. Rna, 2007. 13(5): p. 723-30. 
332. Haraguchi, T., Y. Ozaki, and H. Iba, Vectors expressing efficient RNA decoys achieve the long-
term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res, 2009. 
37(6): p. e43. 
333. Ebert, M.S., J.R. Neilson, and P.A. Sharp, MicroRNA sponges: competitive inhibitors of small 
RNAs in mammalian cells. Nat Methods, 2007. 4(9): p. 721-6. 
334. Kluiver, J., et al., Rapid generation of microRNA sponges for microRNA inhibition. PLoS One, 
2012. 7(1): p. e29275. 
335. Kluiver, J., et al., Generation of miRNA sponge constructs. Methods, 2012. 58(2): p. 113-7. 
336. Zhao, Y., et al., Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system. Sci Rep, 
2014. 4: p. 3943. 
337. Narayanan, A., et al., In vivo mutagenesis of miRNA gene families using a scalable multiplexed 
CRISPR/Cas9 nuclease system. Sci Rep, 2016. 6: p. 32386. 
338. Chang, H., et al., CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in 
vivo. Sci Rep, 2016. 6: p. 22312. 
339. Jing, W., et al., CRISPR/CAS9-Mediated Genome Editing of miRNA-155 Inhibits 
Proinflammatory Cytokine Production by RAW264.7 Cells. Biomed Res Int, 2015. 2015: p. 
326042. 
340. Ho, T.T., et al., Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. 
Nucleic Acids Res, 2015. 43(3): p. e17. 
341. Xiao, A., et al., Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in 
zebrafish. Nucleic Acids Res, 2013. 41(14): p. e141. 
342. Hu, R., et al., Targeting human microRNA genes using engineered Tal-effector nucleases 
(TALENs). PLoS One, 2013. 8(5): p. e63074. 
343. Wang, X., et al., Precise gene modification mediated by TALEN and single-stranded 
oligodeoxynucleotides in human cells. PLoS One, 2014. 9(4): p. e93575. 
344. Jiang, W., et al., An optimized method for high-titer lentivirus preparations without 
ultracentrifugation. Sci Rep, 2015. 5: p. 13875. 
345. Ellis, J., Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther, 
2005. 16(11): p. 1241-6. 
346. Ellis, J. and S. Yao, Retrovirus silencing and vector design: relevance to normal and cancer 
stem cells? Curr Gene Ther, 2005. 5(4): p. 367-73. 
347. Arimbasseri, A.G., K. Rijal, and R.J. Maraia, Comparative overview of RNA polymerase II and III 
transcription cycles, with focus on RNA polymerase III termination and reinitiation. 
Transcription, 2014. 5(1): p. e27639. 
348. Liew, C.G., et al., Transient and stable transgene expression in human embryonic stem cells. 
Stem Cells, 2007. 25(6): p. 1521-8. 
169 
 
349. Ning, M.S. and T. Andl, Concise review: custodians of the transcriptome: how microRNAs 
guard stemness in squamous epithelia. Stem Cells, 2015. 33(4): p. 1047-54. 
350. Ning, M.S. and T. Andl, Control by a hair's breadth: the role of microRNAs in the skin. Cell Mol 
Life Sci, 2013. 70(7): p. 1149-69. 
351. Abba, M.L., et al., MicroRNA Regulation of Epithelial to Mesenchymal Transition. J Clin Med, 
2016. 5(1). 
352. Park, C.Y., et al., A resource for the conditional ablation of microRNAs in the mouse. Cell Rep, 
2012. 1(4): p. 385-91. 
353. Concepcion, C.P., et al., Intact p53-dependent responses in miR-34-deficient mice. PLoS 
Genet, 2012. 8(7): p. e1002797. 
354. Burk, U., et al., A reciprocal repression between ZEB1 and members of the miR-200 family 
promotes EMT and invasion in cancer cells. EMBO Rep, 2008. 9(6): p. 582-9. 
355. Levesque, J.P., et al., Hematopoietic progenitor cell mobilization results in hypoxia with 
increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth 
factor A in bone marrow. Stem Cells, 2007. 25(8): p. 1954-65. 
356. Liu, W., et al., Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J 
Biochem Mol Biol, 2012. 3(2): p. 165-78. 
357. Dengler, V.L., M.D. Galbraith, and J.M. Espinosa, Transcriptional regulation by hypoxia 
inducible factors. Crit Rev Biochem Mol Biol, 2014. 49(1): p. 1-15. 
358. Wang, G.L., et al., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer 
regulated by cellular O2 tension. Proc Natl Acad Sci U S A, 1995. 92(12): p. 5510-4. 
359. Huang, L.E., et al., Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-
dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S 
A, 1998. 95(14): p. 7987-92. 
360. Kaelin, W.G., Jr. and P.J. Ratcliffe, Oxygen sensing by metazoans: the central role of the HIF 
hydroxylase pathway. Mol Cell, 2008. 30(4): p. 393-402. 
361. Ortmann, B., J. Druker, and S. Rocha, Cell cycle progression in response to oxygen levels. Cell 
Mol Life Sci, 2014. 71(18): p. 3569-82. 
362. Liu, L. and M.C. Simon, Regulation of transcription and translation by hypoxia. Cancer Biol 
Ther, 2004. 3(6): p. 492-7. 
363. Semenza, G.L., Hypoxia. Cross talk between oxygen sensing and the cell cycle machinery. Am J 
Physiol Cell Physiol, 2011. 301(3): p. C550-2. 
364. Zimna, A. and M. Kurpisz, Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological 
Angiogenesis: Applications and Therapies. Biomed Res Int, 2015. 2015: p. 549412. 
365. Maes, C., G. Carmeliet, and E. Schipani, Hypoxia-driven pathways in bone development, 
regeneration and disease. Nat Rev Rheumatol, 2012. 8(6): p. 358-66. 
366. Crossin, K.L., Oxygen levels and the regulation of cell adhesion in the nervous system: a 
control point for morphogenesis in development, disease and evolution? Cell Adh Migr, 2012. 
6(1): p. 49-58. 
367. Palazon, A., et al., HIF transcription factors, inflammation, and immunity. Immunity, 2014. 
41(4): p. 518-28. 
368. Takubo, K., et al., Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. 
Cell Stem Cell, 2010. 7(3): p. 391-402. 
369. Parmar, K., et al., Distribution of hematopoietic stem cells in the bone marrow according to 
regional hypoxia. Proc Natl Acad Sci U S A, 2007. 104(13): p. 5431-6. 
370. Spencer, J.A., et al., Direct measurement of local oxygen concentration in the bone marrow of 
live animals. Nature, 2014. 508(7495): p. 269-73. 
371. Nombela-Arrieta, C. and L.E. Silberstein, The science behind the hypoxic niche of 
hematopoietic stem and progenitors. Hematology Am Soc Hematol Educ Program, 2014. 
2014(1): p. 542-7. 
372. Forristal, C.E., et al., Pharmacologic stabilization of HIF-1alpha increases hematopoietic stem 
cell quiescence in vivo and accelerates blood recovery after severe irradiation. Blood, 2013. 
121(5): p. 759-69. 
170 
 
373. Kohli, L. and E. Passegue, Surviving change: the metabolic journey of hematopoietic stem 
cells. Trends Cell Biol, 2014. 24(8): p. 479-87. 
374. Takubo, K., et al., Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell 
cycle quiescence in hematopoietic stem cells. Cell Stem Cell, 2013. 12(1): p. 49-61. 
375. Kocabas, F., et al., Hypoxic metabolism in human hematopoietic stem cells. Cell Biosci, 2015. 
5: p. 39. 
376. Yu, W.M., et al., Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required 
for hematopoietic stem cell differentiation. Cell Stem Cell, 2013. 12(1): p. 62-74. 
377. Liu, X., et al., Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming 
cellular metabolism. Blood, 2015. 125(10): p. 1562-5. 
378. Pedersen, M., et al., Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells. 
Biochem Biophys Res Commun, 2008. 377(1): p. 98-103. 
379. Kirito, K., et al., Thrombopoietin enhances expression of vascular endothelial growth factor 
(VEGF) in primitive hematopoietic cells through induction of HIF-1alpha. Blood, 2005. 
105(11): p. 4258-63. 
380. Piccoli, C., et al., The hypoxia-inducible factor is stabilized in circulating hematopoietic stem 
cells under normoxic conditions. FEBS Lett, 2007. 581(16): p. 3111-9. 
381. Danet, G.H., et al., Expansion of human SCID-repopulating cells under hypoxic conditions. J 
Clin Invest, 2003. 112(1): p. 126-35. 
382. Roy, S., et al., Hypoxia improves expansion potential of human cord blood-derived 
hematopoietic stem cells and marrow repopulation efficiency. Eur J Haematol, 2012. 88(5): p. 
396-405. 
383. Harris, J.M., et al., Glucose metabolism impacts the spatiotemporal onset and magnitude of 
HSC induction in vivo. Blood, 2013. 121(13): p. 2483-93. 
384. Imanirad, P., et al., HIF1alpha is a regulator of hematopoietic progenitor and stem cell 
development in hypoxic sites of the mouse embryo. Stem Cell Res, 2014. 12(1): p. 24-35. 
385. Forristal, C.E., et al., HIF-1alpha is required for hematopoietic stem cell mobilization and 4-
prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1alpha. Leukemia, 2015. 
29(6): p. 1366-78. 
386. Haase, V.H., Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular 
mechanisms and relevance to disease. Kidney Int, 2009. 76(5): p. 492-9. 
387. Kao, S.H., K.J. Wu, and W.H. Lee, Hypoxia, Epithelial-Mesenchymal Transition, and TET-
Mediated Epigenetic Changes. J Clin Med, 2016. 5(2). 
388. Pascual-Anaya, J., et al., The evolutionary origins of chordate hematopoiesis and vertebrate 
endothelia. Dev Biol, 2013. 375(2): p. 182-92. 
389. Bikfalvi, A. and Z.C. Han, Angiogenic factors are hematopoietic growth factors and vice versa. 
Leukemia, 1994. 8(3): p. 523-9. 
390. Ribatti, D., Angiogenic activity of classical hematopoietic cytokines. Leuk Res, 2012. 36(5): p. 
537-43. 
391. Ribatti, D., The crucial role of vascular permeability factor/vascular endothelial growth factor 
in angiogenesis: a historical review. Br J Haematol, 2005. 128(3): p. 303-9. 
392. Imanirad, P. and E. Dzierzak, Hypoxia and HIFs in regulating the development of the 
hematopoietic system. Blood Cells Mol Dis, 2013. 51(4): p. 256-63. 
393. Kim, Y.W., X.Z. West, and T.V. Byzova, Inflammation and oxidative stress in angiogenesis and 
vascular disease. J Mol Med (Berl), 2013. 91(3): p. 323-8. 
394. Szade, A., et al., Cellular and molecular mechanisms of inflammation-induced angiogenesis. 
IUBMB Life, 2015. 67(3): p. 145-59. 
395. Gerondakis, S., et al., NF-kappaB subunit specificity in hemopoiesis. Immunol Rev, 2012. 
246(1): p. 272-85. 
396. Carlini, R.G., A.A. Reyes, and M. Rothstein, Recombinant human erythropoietin stimulates 
angiogenesis in vitro. Kidney Int, 1995. 47(3): p. 740-5. 
397. Wang, L., et al., Derivation and characterization of hematopoietic cells from human 
embryonic stem cells. Methods Mol Biol, 2006. 331: p. 179-200. 
171 
 
398. Shen, G., et al., Hypoxia-regulated microRNAs in human cancer. Acta Pharmacol Sin, 2013. 
34(3): p. 336-41. 
399. Maxwell, P. and K. Salnikow, HIF-1: an oxygen and metal responsive transcription factor. 
Cancer Biol Ther, 2004. 3(1): p. 29-35. 
400. Yuan, Y., et al., Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and 
von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem, 
2003. 278(18): p. 15911-6. 
401. Fujisaka, S., et al., Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages 
in an HIF-1alpha-dependent and HIF-1alpha-independent manner in obese mice. 
Diabetologia, 2013. 56(6): p. 1403-12. 
402. Triantafyllou, A., et al., Cobalt induces hypoxia-inducible factor-1alpha (HIF-1alpha) in HeLa 
cells by an iron-independent, but ROS-, PI-3K- and MAPK-dependent mechanism. Free Radic 
Res, 2006. 40(8): p. 847-56. 
403. Guiu, J., et al., Identification of Cdca7 as a novel Notch transcriptional target involved in 
hematopoietic stem cell emergence. J Exp Med, 2014. 211(12): p. 2411-23. 
404. North, T.E., et al., Hematopoietic stem cell development is dependent on blood flow. Cell, 
2009. 137(4): p. 736-48. 
405. Adamo, L., et al., Biomechanical forces promote embryonic haematopoiesis. Nature, 2009. 
459(7250): p. 1131-5. 
406. MacRae, C.A. and R.T. Peterson, Zebrafish as tools for drug discovery. Nat Rev Drug Discov, 
2015. 14(10): p. 721-31. 
407. Ciau-Uitz, A., et al., Developmental hematopoiesis: ontogeny, genetic programming and 
conservation. Exp Hematol, 2014. 42(8): p. 669-83. 
408. Gazit, R., et al., Fgd5 identifies hematopoietic stem cells in the murine bone marrow. J Exp 
Med, 2014. 211(7): p. 1315-31. 
409. Munoz, P., et al., Specific marking of hESCs-derived hematopoietic lineage by WAS-promoter 
driven lentiviral vectors. PLoS One, 2012. 7(6): p. e39091. 
410. Szabo, E., et al., Direct conversion of human fibroblasts to multilineage blood progenitors. 
Nature, 2010. 468(7323): p. 521-6. 
411. Batta, K., et al., Direct reprogramming of murine fibroblasts to hematopoietic progenitor 
cells. Cell Rep, 2014. 9(5): p. 1871-84. 
412. Pereira, C.F., et al., Induction of a hemogenic program in mouse fibroblasts. Cell Stem Cell, 
2013. 13(2): p. 205-18. 
413. Riddell, J., et al., Reprogramming committed murine blood cells to induced hematopoietic 
stem cells with defined factors. Cell, 2014. 157(3): p. 549-64. 
414. Sandler, V.M., et al., Reprogramming human endothelial cells to haematopoietic cells 
requires vascular induction. Nature, 2014. 511(7509): p. 312-8. 
415. Deng, C., et al., USF1 and hSET1A mediated epigenetic modifications regulate lineage 
differentiation and HoxB4 transcription. PLoS Genet, 2013. 9(6): p. e1003524. 
416. Majumder, A., et al., Histone Chaperone HIRA in Regulation of Transcription Factor RUNX1. J 
Biol Chem, 2015. 290(21): p. 13053-63. 
417. Zhang, C., et al., Inhibition of endothelial ERK signalling by Smad1/5 is essential for 
haematopoietic stem cell emergence. Nat Commun, 2014. 5: p. 3431. 
418. Thambyrajah, R., et al., GFI1 proteins orchestrate the emergence of haematopoietic stem cells 
through recruitment of LSD1. 2016. 18(1): p. 21-32. 
419. Xie, H., et al., Polycomb repressive complex 2 regulates normal hematopoietic stem cell 
function in a developmental-stage-specific manner. Cell Stem Cell, 2014. 14(1): p. 68-80. 
420. Hidalgo, I., et al., Ezh1 is required for hematopoietic stem cell maintenance and prevents 
senescence-like cell cycle arrest. Cell Stem Cell, 2012. 11(5): p. 649-62. 
421. Park, I.K., et al., Bmi-1 is required for maintenance of adult self-renewing haematopoietic 
stem cells. Nature, 2003. 423(6937): p. 302-5. 
422. Elcheva, I., et al., Direct induction of haematoendothelial programs in human pluripotent 
stem cells by transcriptional regulators. Nat Commun, 2014. 5: p. 4372. 
172 
 
423. Gori, J.L., et al., Vascular niche promotes hematopoietic multipotent progenitor formation 
from pluripotent stem cells. J Clin Invest, 2015. 125(3): p. 1243-54. 
424. Schnerch, A., et al., Human embryonic stem cell-derived hematopoietic cells maintain core 
epigenetic machinery of the polycomb group/Trithorax Group complexes distinctly from 
functional adult hematopoietic stem cells. Stem Cells Dev, 2013. 22(1): p. 73-89. 
425. Tashiro, K., et al., Promotion of hematopoietic differentiation from mouse induced pluripotent 
stem cells by transient HoxB4 transduction. Stem Cell Res, 2012. 8(2): p. 300-11. 
426. Liao, B., et al., MicroRNA cluster 302-367 enhances somatic cell reprogramming by 
accelerating a mesenchymal-to-epithelial transition. J Biol Chem, 2011. 286(19): p. 17359-64. 
427. Ambasudhan, R., et al., Direct reprogramming of adult human fibroblasts to functional 
neurons under defined conditions. Cell Stem Cell, 2011. 9(2): p. 113-8. 
428. Pulecio, J., et al., Conversion of human fibroblasts into monocyte-like progenitor cells. Stem 
Cells, 2014. 32(11): p. 2923-38. 
429. Jayawardena, T.M., et al., MicroRNA-mediated in vitro and in vivo direct reprogramming of 
cardiac fibroblasts to cardiomyocytes. Circ Res, 2012. 110(11): p. 1465-73. 
430. Chen, M.J., et al., Erythroid/myeloid progenitors and hematopoietic stem cells originate from 
distinct populations of endothelial cells. Cell Stem Cell, 2011. 9(6): p. 541-52. 
431. Richard, C., et al., Endothelio-mesenchymal interaction controls runx1 expression and 
modulates the notch pathway to initiate aortic hematopoiesis. Dev Cell, 2013. 24(6): p. 600-
11. 
432. Sadelain, M., Insertional oncogenesis in gene therapy: how much of a risk? Gene Ther, 2004. 
11(7): p. 569-73. 
433. Garcia-Alegria, E., et al., Emerging concepts for the in vitro derivation of murine 
hematopoietic stem and progenitor cells. FEBS Lett, 2016. 
434. http://www.bioinformatics.leeds.ac.uk/labpages/hematopoiesis/. 
 
